Dear Colleagues,

For the first time in the history of the UEGW Meetings, the 13th UEGW has been arranged as a joint effort of two countries, and it is a pleasure for the Danish and Swedish Societies of Gastroenterology to bring a special welcome to the participants of the 13th UEGW to be held in Copenhagen.

With great scientific traditions of our two Societies we are proud to hold this Meeting under the auspices of ours and we wish that this work will extend into further excellent scientific cooperation between all European countries.

Danish Society of Gastroenterology

Swedish Society of Gastroenterology
The 13th United European Gastroenterology Week is arranged as a joint project between the Danish and Swedish Societies of Gastroenterology to take place in Copenhagen at the Copenhagen Congress Center - Bella Center
WELCOME ADDRESS

...given by the Local Organizing Committee Chairman

On behalf of the UEGF and the Gastroenterological Societies in Denmark and Sweden, it is our great pleasure to invite you and all your fellow European gastroenterologists and digestive surgeons to participate in the 13th UEGW (United European Gastroenterology Week) to be held in Copenhagen, 15 - 19 October 2005.

The UEGF Scientific Committee has planned a comprehensive scientific programme with the common theme “Translational Biology in Gastroenterology and Liver Disease”. The Core programme, with appeal to practising physicians as well as researchers, is divided into equal parts to represent upper and lower GI diseases, liver diseases, endoscopy and surgery. The Core programme is composed of 45 multidiciplinary symposia, each of which covers breaking new experience from “bench to bedside”, including relevant surgical aspects, in addition to original contributions in chaired, free paper sessions, postgraduate courses and lunch meetings.

The Copenhagen-Malmoe area, now connected by the Öresund bridge, is a rapidly expanding region and one of the most dynamic business and science growth centres in Northern Europe. Copenhagen, the capital of Denmark, which is the oldest kingdom in the world, is the largest city in Scandinavia and Malmoe is the commercial centre of Southern Sweden.

The core meeting, postgraduate courses, satellite symposia and breakfast meetings will take place in the modern congress and exhibition centre - BC Copenhagen Congress Center, Bella Center - offering optimal facilities for the participants of the Meeting. The Congress Centre is located only 10 minutes by Metro from the old city of Copenhagen with its 17th century canals, medieval streets, copper-roofed town houses, atmospheric cobble-stoned squares and modern architecture.

The UEGF and the Local Organizing Committee are grateful for the support of the biomedical industry and the Scandinavian and European scientific Societies and Institutions that will make the Copenhagen meeting possible.

We look forward to meeting you in Wonderful Copenhagen October 2005 and wish you a happy stay.

Prof. Jørgen Rask-Madsen
Chairman
Local Organizing Committee
As Chairman of the Scientific Committee I would like to extend a very warm welcome to all of you for the United European Gastroenterology Week 2005 which takes place in Copenhagen from Saturday 15 October until Wednesday 19 October 2005.

The over arching theme of the Copenhagen meeting is ‘Translational biology in Gastroenterology and Liver disease’. We will aim to showcase this translational theme in the opening plenary session and throughout the core programme and in the free paper sessions.

The Scientific Committee has planned the non-original core programme which has a similar format to the Madrid and Prague meetings with topic based research and clinical symposia, lunchtime clinical practice sessions and a plenary session which will consist of a ‘smorgasbord’ presentations on current challenges for gastroenterology and hepatology and some of our best original research presentations. A presentation from one of our younger rising star investigators will be introduced as well.

The core programme includes symposia on novel approaches to the management of GERD, pancreatic cystic lesions and necrotising acute pancreatitis and many other beside. Several symposia cover the interface between endoscopic and minimally invasive surgical therapy, including the use of endoscopic ultrasound to guide endotherapy. The screening for Barrett’s oesophagus and colorectal cancer will also be debated. Liver symposia include important topical issues such as NAFLD and NASH, viral hepatitis and alcohol mediated liver toxicity. A novel symposium on herbal medicine and the liver is also taking place. Updates on the pathogenesis and treatment of IBS and IBD are featuring as well. We have made a special effort to ensure that surgical topics are appropriately represented in the programme; in some instances these sessions are integrated with imaging and endoscopy to underscore the importance of multidisciplinary working.

Our target for 2005 is to ensure that 50% of the core programme is original research presentations. Our aim is to link the topic-based symposia with appropriate basic and clinical research sessions. Therefore, plan well so that you optimise your chances of finding a place in UEGW Copenhagen 2005.

Prof. Michael J. G. Farthing
Chairman
UEGF Scientific Committee
VENUE

BC Bella Center
Copenhagen Congress Center, Steen Enemark

Center Boulevard, DK-2300 Copenhagen S, Denmark
Phone: + 45 325 28 811, Fax: + 45 325 29 636
E-mail: bc@bellacentre.dk, www.bellacentre.dk

WEBSITE

For updated information about the Congress, please see the official Congress website: www.uegw-2005.dk

CONTACT TO ORGANISERS

UEGF Core PCO
CPO HANSER SERVICE GmbH, Inge Hanser
Paulsborner Strasse 44, 14193 Berlin, Germany
Phone: + 49 30 300 66 90, Fax: + 49 30 305 73 91
E-mail: uegw@cpo-hanser.de

Congress Administration
Symposion International A/S, Karsten Højholdt - Managing Director
Tranekaer Slot, Slotsgade 86, DK-5953 Tranekaer, Denmark
Phone: + 45 983 32 155, Fax: + 45 983 32 828
E-mail: kh@symposion-int.dk

Congress Secretariat: Registration, Hotel Accommodation
DIS Congress Service Copenhagen A/S, Henrik Dyhr
Herlev Ringvej 2c, DK-2730 Herlev, Denmark
Phone: + 45 449 24 492, Fax: + 45 449 25 050
E-mail: uegw@discongress.com
Company Requirements: Exhibition, Sponsorship, Breakfast Meetings, Business Meetings, Common Interest Groups, Offices

GUARANT International, Ingrid Vojtekoaa, Jana Rechlikova

Opletalova 22, 110 00 Prague 1, Czech Republic
Phone: + 420 284 001 444, Fax: + 420 284 001 448
E-mail: uegw2005copenhagen@guarant.cz

ORGANIZING COMMITTEES

LOCAL ORGANIZING COMMITTEE

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman (DK)</td>
<td>Jørgen Rask-Madsen</td>
</tr>
<tr>
<td>Deputy Chairman (DK)</td>
<td>Karsten Lauritsen</td>
</tr>
<tr>
<td>Vice Chairman (SE)</td>
<td>Rolf Hultcrantz</td>
</tr>
<tr>
<td>General Secretary (SE)</td>
<td>Bengt Jeppsson</td>
</tr>
<tr>
<td>General Secretary (DK)</td>
<td>Ole Østergaard Thomsen</td>
</tr>
<tr>
<td>Scientific Coordinator (SE)</td>
<td>Stefan Lindgren</td>
</tr>
</tbody>
</table>

COMMITTEE MEMBERS

<table>
<thead>
<tr>
<th>Reputation</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olaf Bonnevie (DK)</td>
<td>Henrik Kehlet (DK)</td>
</tr>
<tr>
<td>Ulrika Bromée (SE)</td>
<td>Preben Kirkegaard (DK)</td>
</tr>
<tr>
<td>Flemming Burcharth (DK)</td>
<td>Robert Låfberg (SE)</td>
</tr>
<tr>
<td>Åke Danielsson (SE)</td>
<td>Flemming Moesgaard (DK)</td>
</tr>
<tr>
<td>Curt Einarsson (SE)</td>
<td>Ove Schaffalitzky de Muckadell (DK)</td>
</tr>
<tr>
<td>Anders Fischer (DK)</td>
<td>Ole Haagen Nielsen (DK)</td>
</tr>
<tr>
<td>Claës-Henrik Florén (SE)</td>
<td>Henrik Sjövall (SE)</td>
</tr>
<tr>
<td>Ulf Haglund (SE)</td>
<td>Curt Tysk (SE)</td>
</tr>
<tr>
<td>Christer Stäel von Holstein (SE)</td>
<td>Hendryk Vilstrup (DK)</td>
</tr>
</tbody>
</table>

STEERING COMMITTEE

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman (DK)</td>
<td>Jørgen Rask-Madsen</td>
</tr>
<tr>
<td>Deputy Chairman (DK)</td>
<td>Karsten Lauritsen</td>
</tr>
<tr>
<td>Managing Director (DK)</td>
<td>Karsten Højholdt</td>
</tr>
</tbody>
</table>

UEGF SCIENTIFIC COMMITTEE

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman</td>
<td>Michael Farthing</td>
</tr>
<tr>
<td>ASNEMGE</td>
<td>Nadir Arber</td>
</tr>
<tr>
<td>INDEPENDENT</td>
<td>John Atherton</td>
</tr>
<tr>
<td>ISDS</td>
<td>Antonio Basoli</td>
</tr>
<tr>
<td>INDEPENDENT</td>
<td>Christoph Beglinger</td>
</tr>
<tr>
<td>ESGE</td>
<td>Guido Costamagna</td>
</tr>
</tbody>
</table>
2005 UEGF COUNCIL EXECUTIVES

UEGF Chairman  
UEGF Treasurer  
UEGF Scientific Committee Chairman  
UEGF Education Committee Chairman  
UEGF Public Affairs Committee Chairman  
UEGF Secretary General

Peter Ferenci  
Peter Milla  
Michael Farthing  
Peter Malferttheiner  
Michael Keighley  
Juan-R. Malagelada

UNITED EUROPEAN GASTROENTEROLOGY FEDERATION

AIMS

The UEGF is a non-profit making organisation with the following aims:

- To promote and organise an annual scientific meeting devoted to all aspects of gastroenterology and its affiliated and related disciplines.
- To promote scientific, epidemiological and clinical research into the prevention, diagnosis and therapy of gastrointestinal, including hepato-biliary and pancreatic diseases. Preference will be given to co-operative projects.
- To establish scholarships and promote postgraduate education and training.
- To prepare and maintain a code of practice designed to control relationship between the Federation and the biomedical industry. This is designed to ensure appropriate collaboration with the industry and to obtain their financial support for scientific and educational goals in gastroenterology and its affiliated and related disciplines.
- To disseminate information about the Federation’s activities and publish such educational matter as the UEGF Council may consider desirable.
FOUNDING MEMBERS

ASNEMGE  Association of National European and Mediterranean Societies of Gastroenterology
EAGE    European Association for Gastroenterology and Endoscopy
EASL    European Association for the Study of the Liver
EPC    European Pancreatic Club
ESGE  European Society of Gastrointestinal Endoscopy
ESPGHAN  European Society for Pediatric Gastroenterology, Hepatology and Nutrition
ISDS  International Society of Digestive Surgery (European Federation)

ASSOCIATE MEMBERS

EACP    European Association of Coloproctology
EAES    European Association for Endoscopic Surgery
EHSG    European Helicobacter Study Group
ECCO    European Crohn’s and Colitis Organization
EDS    European Digestive Surgery
ESGAR  European Society of Gastrointestinal and Abdominal Radiology
ESNM    European Society of Neurogastroenterology and Motility
ESPCG    European Society for Primary Care Gastroenterology

2005 UEGF COUNCIL MEMBERS

ASNEMGE  Christopher Hawkey
ASNEMGE  Peter Ferenci
EAGE    Michael Farthing
EAGE    Peter Malfertheiner
EASL    Jordi Bruix
EASL    Massimo Leorero
EPC    Christoph Beglinger
EPC    Markus Lerch
ESGE    Jean F. Rey
ESGE    Anthony Axon
ESGE    Michael Lentze
ESPGHAN    Peter Milla
ESPGHAN    Antonio Basoli
ISDS  Michael R. B. Keighley
ISDS  Renzo Caprilli
Associate Member Representatives    Dirk Gouma
Associate Member Representatives    Juan-R. Malagelada
Ad-hoc Councillors    Alberto Montori
2005 UEGF COUNCIL EXECUTIVES

UEGF Chairman
Peter Ferenci

UEGF Treasurer
Peter Milla

UEGF Scientific Committee Chairman
Michael Farthing

UEGF Education Committee Chairman
Peter Malfertheiner

UEGF Public Affairs Committee Chairman
Michael Keighley

UEGF Secretary General
Juan-R. Malagelada

UEGF SECRETARIAT

UEGF Secretariat
Jaume Bolta jr
Avda de Rome, 13-15, Entlo. 2a, esc. B, 08029 Barcelona, Spain
Phone: + 34 933 631 397, Fax: + 34 933 631 398
E-mail: secretariat@secretariatuegf.org
www.secretariatuegf.org

UEGF SCIENTIFIC & EDUCATION SECRETARIAT

UEGF Scientific & Education Secretariat
Doris Möstl
Hollandstrasse 14/Mezzanine, A-1020, Vienna, Austria
Phone: + 43 1 219 91 80, Fax: + 43 1 219 91 80 29
E-mail: uegw-scientific@vereint.com

2005 UEGF PUBLIC AFFAIRS COMMITTEE (PAC)

Chairman: Michael Keighley
E-mail: keighleycolo@uk-consultants.co.uk
Public relations adviser: Jola Gore-Booth
E-mail: jola@gore-booth.fsnet.co.uk

Mission statement
To raise awareness of gastrointestinal disease by research, prevention, early diagnosis and treatment, thereby contributing to the development of an effective health policy for the citizens of Europe.
2005 BMI BOARD

Altana Pharma
AstraZeneca
Boston Scientific International
Fujinon
GlaxoSmithKline
Janssen Cilag
Novartis Pharma
Olympus
Takeda

STATUTES

UEGF Statutes are subject to a deeply review process that will finalise in UEGW Copenhagen 2005

UEGF ON THE INTERNET

Information about UEGF and relevant documents are available at the following Internet address: www.uegf.org

ASSOCIATED MEETING - 9th ESGENA CONFERENCE

9th Conference of the European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) will be held as the UEGW associated meeting from 15-17 October 2005 in Copenhagen. The conference will be hosted by the Society of Gastroenterology Nurses in Denmark.

FORTHCOMING UEGWS

16th UEGW 2008 Vienna, October 2008
17th UEGW 2009 London, not yet specified
<table>
<thead>
<tr>
<th>Time</th>
<th>Room 18</th>
<th>Room 19</th>
<th>Room 20</th>
<th>Room 26-27</th>
<th>10, 11, 12 Auditorium</th>
<th>15 Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 - 7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 - 8:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 - 9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 - 9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 - 10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ESGE Postgraduate Course</td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ESGE Postgraduate Course</td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 - 19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Programme at a Glance**

**Saturday, 15 October 2005**

**ESGENA Scientific Programme**

**Room 18**

**Room 19**

**Room 20**

**Room 26-27**

**10, 11, 12 Auditorium**

**15 Auditorium**
<table>
<thead>
<tr>
<th>Time</th>
<th>A1 Congress Hall</th>
<th>A2+A3 Congress Hall</th>
<th>10 Auditorium</th>
<th>11-12 Auditorium</th>
<th>15 Auditorium</th>
<th>Room 19</th>
<th>Room 26</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 - 7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 - 8:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 - 9:00</td>
<td><strong>ESGENA</strong></td>
<td><strong>ESGENA</strong></td>
<td></td>
<td><strong>EASL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 - 9:30</td>
<td><strong>CONFERENCE</strong></td>
<td><strong>CONFERENCE</strong></td>
<td></td>
<td><strong>POSTGRADUATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 - 10:00</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td></td>
<td></td>
<td></td>
<td><strong>ESGENA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td><strong>CONFERENCE</strong></td>
<td><strong>CONFERENCE</strong></td>
<td></td>
<td><strong>POSTGRADUATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td><strong>LUNCH &amp; POSTER SESSION</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td><strong>SOCIETY INFORMATION DESKS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td><strong>ESGENA</strong></td>
<td><strong>ESGENA</strong></td>
<td></td>
<td><strong>EASL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td><strong>CONFERENCE</strong></td>
<td><strong>CONFERENCE</strong></td>
<td></td>
<td><strong>POSTGRADUATE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td><strong>ESGENA</strong></td>
<td><strong>ESGENA</strong></td>
<td></td>
<td><strong>NOVARTIS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td><strong>CONFERENCE</strong></td>
<td><strong>CONFERENCE</strong></td>
<td></td>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td><strong>ALTANA PHARMA</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td><strong>SATELLITE</strong></td>
<td><strong>SATELLITE</strong></td>
<td></td>
<td><strong>ESGENA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 - 19:30</td>
<td><strong>SYMPOSIUM</strong></td>
<td><strong>SYMPOSIUM</strong></td>
<td></td>
<td><strong>GENERAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Programme at a Glance*
<table>
<thead>
<tr>
<th>Time</th>
<th>A1 CONGRESS HALL</th>
<th>A2-A3 CONGRESS HALL</th>
<th>10, 11, 12 AUDITORIUM</th>
<th>15 AUDITORIUM</th>
<th>ROOM M1 IN HALL C</th>
<th>ROOM M2 IN HALL C</th>
<th>ROOM M3 IN HALL C</th>
<th>ROOM M4 IN HALL C</th>
<th>ROOM M5 IN HALL C</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 - 7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FERRING BREAKFAST MEETING</td>
<td>SCHERING AG BREAKFAST MEETING</td>
<td></td>
<td>ABBOTT BREAKFAST MEETING</td>
<td></td>
</tr>
<tr>
<td>7:30 - 8:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 - 8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30 - 9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 - 9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 - 10:00</td>
<td>BETTER INSIGHTS INTO THE NATURAL HISTORY OF IBD - 10 YEARS FOLLOW UP OF THE EC-IBD</td>
<td>MAASTRICHT - 3 GUIDELINES FOR HELICOBACTER PYLORI INFECTION</td>
<td>HEALTH TECHNOLOGY ASSESSMENT IN GASTRO-INTESTINAL ENDOSCOPY</td>
<td>PREVENTION OF OESOPHAGEAL ADENOCARCINOMA</td>
<td>FREE PAPER SESSION: ENDOSCOPIC MUCOSAL RESECTION</td>
<td>FREE PAPER SESSION: VIRAL HEPATITIS</td>
<td>FREE PAPER SESSION: HELICOBACTER PYLORI PATHOGENESIS</td>
<td>INTESTINAL PSEUDO-OBSTURATION</td>
<td>FREE PAPER SESSION: SCREENING AND SURVEILLANCE IN COLORECTAL CANCER</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FREE PAPER SESSION: COLORECTAL NEOPLASIA: PROGNOSIS AND TREATMENT</td>
<td>ELIS GUIDED ENDOThERAPY</td>
<td>NEW MODELS AND MECHANISMS FOR ALCOHOL-MEDIATED LIVER TOXICITY</td>
<td>PANCREATIC CANCER FROM GENE TO THERAPY</td>
<td>FREE PAPER SESSION: HEREDITARY COLON CANCER SYNDROMES</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>RECENT ADVANCE IN THE PATHOGENESIS IN IBD</td>
<td>HCV HEPATITIS IN SPECIAL PATIENT GROUPS</td>
<td>COMMUNITY APPROACH TO DYSPEPSIA</td>
<td>PATHOGENESIS AND TREATMENT OF OBESITY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>MANAGEMENT OF HCV / HBV HEPATITIS</td>
<td>TREATMENT OF CANCER AT THE OESOPHAGO-GASTRIC JUNCTION</td>
<td>HIGHLIGHTS OF AGA / DDW CHICAGO 2005</td>
<td>HORMONES, HELICOBACTER PYLORI AND INFLAMMATION</td>
<td>MOLECULAR PORTRAIT OF COLORECTAL CANCER</td>
<td>FREE PAPER SESSION: NEW DIAGNOSTICS AND TREATMENT OF COLORECTAL CANCER</td>
<td>FREE PAPER SESSION: CONTROVERSIES IN PANCREATITIS</td>
<td>FREE PAPER SESSION: PORTAL HYPERTENSION</td>
<td>FREE PAPER SESSION: UPPER GI MALIGNANCY: SCREENING, DIAGNOSIS AND FOLLOW-UP</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>SCREENING FOR CRC</td>
<td>FREE PAPER SESSION: HOT TOPICS IN UPPER GI INTERVENTION</td>
<td>FREE PAPER SESSION: LATE BREAKING NEWS</td>
<td>LIVER DISEASE IN THE POST-GENOMIC ERA</td>
<td>FREE PAPER SESSION: NEW DIAGNOSTICS AND TREATMENT OF COLORECTAL CANCER</td>
<td>MOLECULAR BASIS OF PANCREATITIS</td>
<td>FOOD ALLERGY: FROM INFANCY TO ADULTHOOD</td>
<td>FREE PAPER SESSION: WHAT’S NEW IN DIAGNOSING IBD?</td>
<td>FREE PAPER SESSION: NEW TOOLS FOR DIAGNOSIS AND ASSESSMENT OF GORD</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00 - 19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30 - 20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00 - 20:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30 - 21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00 - 21:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**WEDNESDAY, 19 OCTOBER 2005**

**PROGRAMME AT A GLANCE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Session/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 7:50</td>
<td>Room 1</td>
<td>Video Case Marathon</td>
</tr>
<tr>
<td>8:00 - 10:30</td>
<td>Room 2</td>
<td>Free Paper Session: Conventional and Emerging Therapies in Ulcerative Colitis</td>
</tr>
<tr>
<td>9:30 - 10:30</td>
<td>Room 3</td>
<td>Future Therapy for Crohn’s Disease and the Liver</td>
</tr>
<tr>
<td>10:30 - 11:30</td>
<td>Room 4</td>
<td>Hepatic Medicine When Crohn’s Goes Wrong</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Room 5</td>
<td>Novel Approaches to the Management of Gastrointestinal Emergencies</td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td>Room 6</td>
<td>Innovative Imaging for Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td>Room 7</td>
<td>Free Paper Session: Ash and NASH in BD</td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td>Room 8</td>
<td>Novel Approaches to the Management of Gastrointestinal Emergencies</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>Room 9</td>
<td>Free Paper Session: Genetics of Gastroesophageal Manifestations</td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td>Room 10</td>
<td>Free Paper Session: Gastrointestinal Pathogenesis and Extra-Oesophageal Manifestations</td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Room 11</td>
<td>Free Paper Session: Pancreatic Cystic Lesions</td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>Room 12</td>
<td>Management of Pancreatic Cystic Lesions</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td>Room 13</td>
<td>The Liver and Sepsis Symposium</td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td>Room 14</td>
<td>UCB Celltech Satellite Symposium</td>
</tr>
</tbody>
</table>
CORE PROGRAMME

A1 CONGRESS HALL

08:15-08:30 OPENING OF THE MEETING - INTRODUCTION
General Secretary UEGF: Juan R. Malagelada (Barcelona, Spain)
Chair LOC: Jørgen Rask-Madsen (Copenhagen, Denmark)
Chair UEGF: Peter Ferenci (Vienna, Austria)

08:30-10:30 PLENARY SESSION: TRANSLATIONAL BIOLOGY IN GASTROINTESTINAL AND LIVER DISEASE
Chair: Michael Farthing (London, UK)
Peter Ferenci (Vienna, Austria)

STATE-OF-THE-ART-LECTURE (30 minutes):
NOVEL TRANSLATIONAL RESEARCH IN LIVER DISEASE
(Massimo Pinzani, Florence, Italy)

BEST ABSTRACTS PLENARY (12 minutes plus 3 minutes discussion):
EFFICIENT HEPATOCYTES ENGRAFTMENT IN A NON-HUMAN PRIMATE AFTER PARTIAL PORTAL EMBOLISATION
(Ibrahim Dagher, Clamart, France)
MUCOSAL DELIVERY OF OVALBUMIN BY THE GENETICALLY MODIFIED L. LACTIS SUPPRESSES INFLAMMATORY T-CELL RESPONSES IN DO11.10 MICE
(Inge Huibregtse, Amsterdam, The Netherlands)
HIGH RESOLUTION ENDOSCOPY PLUS INDIGO CARMINE CHROMOENDOSCOPY OR NARROW BAND IMAGING: A RANDOMIZED CROSS-OVER STUDY IN BARRETT ESOPHAGUS
(Jacques Bergman, Amsterdam, The Netherlands)
CRITICAL ROLE OF MAP KINASES IN GOVERNING LYMPHOCYTE ADHESION TO AND MIGRATION ACROSS MICROVASCULATURE IN INFLAMMATORY BOWEL DISEASE
(Silvio Danese, Rome, Italy)

STATE-OF-THE-ART-LECTURE (30 minutes):
NORMALIZATION OF TUMOR VASCULATURE BY ANTIANGIOGENIC THERAPY: AN EMERGING CONCEPT IN CANCER TREATMENT
(Rakesh Jain, Boston, USA)
11:00-12:30 **NOVEL TREATMENTS OF GORD: AN EVIDENCE BASED APPROACH**

Chair: Jan Tack (Leuven, Belgium)
       Peter Funch-Jensen (Aarhus, Denmark)

20 minutes presentation including discussion

**STRETTA**
(Jan Tack, Leuven, Belgium)

**ENTERYX**
(Horst Neuhaus, Duesseldorf, Germany)

**GATEKEEPER**
(Paul Fockens, Amsterdam, The Netherlands)

**LAPAROSCOPIC ANTI-REFLUX SURGERY**
(Marco Catarci, Rome, Italy)

---

12:15-14:00 **POSTER SESSIONS - HALL C**

12:45-13:35 **LUNCH SESSION - L1 IN HALL B: EMR VERSUS ESD**

Jacques Bergman (Amsterdam, The Netherlands), Horst Neuhaus (Düsseldorf, Germany)

---

14:00-15:30 **CHEMOPREVENTION OF COLORECTAL CANCER**

Chair: Bernard Levin (Houston, USA)
       Reinhold Stockbrügger (Maastricht, The Netherlands)

20 minutes presentation including discussion

**CHEMOPREVENTION: THE CALCIUM STORY**
(Robert Benamouzig, Bobigny, France)

**CURRENT STRATEGIES FOR CHEMOPREVENTION OF COLORECTAL NEOPLASIA**
(Bernard Levin, Houston, USA)

**TARGETING CHEMOPREVENTION TO THOSE MOST LIKELY TO BENEFIT**
(Reinhold Stockbrügger, Maastricht, The Netherlands)

**COX 2 INHIBITORS: A FRIEND OR AN ENEMY?**
(Nadir Arber, Tel Aviv, Israel)

---

15:45-17:15 **NAFLD AND NASH**

Chair: Giulio Marchesini (Bologna, Italy)
       Helena Cortez-Pinto (Lisbon, Portugal)

20 minutes presentation including discussion

**NAFLD/NASH AND THE METABOLIC SYNDROME**
(Giulio Marchesini, Bologna, Italy)

**GENETIC FACTORS IN THE DEVELOPMENT OF NASH**
(Helena Cortez-Pinto, Lisbon, Portugal)

**MOLECULAR MECHANISMS OF INFLAMMATION/FIBROSIS IN NASH**
(Fabio Marra, Florence, Italy)

**TREATMENTS FOR NASH: WHERE ARE WE?**
(Vlad Ratziu, Paris, France)
A2+A3 CONGRESS HALL

11:00-12:30  MANAGEMENT OF NECROTIZING ACUTE PANCREATITIS
Chair: Christos Dervenis (Athens, Greece)
       Flemming Burcharth (Copenhagen, Denmark)

20 minutes presentation including discussion
NEW INSIGHTS INTO ANTIBIOTICS PROPHYLAXIS
(Rainer Isenmann, Ulm, Germany)
ENDOTHERAPY
(Thomas Roesch, Muenchen, Germany)
MINIMAL INVASIVE SURGICAL TREATMENT
(Ross Carter, Glasgow, UK)
OPEN NECROSECTOMY
(Helmut Friess, Heidelberg, Germany)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L2 IN HALL B: MANAGEMENT OF PANCREATIC STONES
M. Delhaye (Brussels, Belgium), Dirk Gouma (Amsterdam, The Netherlands)

14:00-15:30  COMBINED ENDOSCOPIC AND LAPAROSCOPIC PROCEDURES
Chair: Alberto Montori (Rome, Italy)
       Willem Bemelman (Amsterdam, The Netherlands)

20 minutes presentation including discussion
INTEGRATED LAPAROSCOPIC AND ENDOSCOPIC IMAGING IN THE OPERATING ROOM
(Anton Jansen, Haarlem, The Netherlands)
OESOPHAGEAL DIVERTICULA AND CARDIOMIOTOMY
(Ricardo Rosati, Milan, Italy)
GASTRO-INTESTINAL SUB-MUCOSAL TUMORS (GIST)
(Bryan Warren, Oxford, UK)
LAPAROSCOPY AND COLOSCOPY ASSISTED RESECTION OF POLYPOID COLONIC TUMORS
(Willem Bemelman, Amsterdam, The Netherlands)
15:45-17:15  GORD: PATHOGENESIS AND NATURAL HISTORY
Chair: Daniel Sifrim (Leuven, Belgium)
Jean-Paul Galmiche (Nantes, France)

20 minutes presentation including discussion

DOES NERD PROGRESS TO EROSI贞 OESOPHAGITIS?
(F. Pace, Milano, Italy)

THE ‘ACID POCKET’: EVIDENCE AND RELEVANCE
(Jonathan Fletcher, Melrose, UK)

NON-ACID REFLUX: DOES IT MATTER?
(Daniel Sifrim, Leuven, Belgium)

GORD IN ASTHMA AND LARYNGEAL DISEASE: CHICKEN OR EGG?
(Frank Zerbib, Bordeaux, France)

AUDITORIUM 10,11,12

11:00-12:30  FREE PAPER SESSION: NEW INSIGHTS IN IRRITABLE BOWEL SYNDROME
Chair: Michael Delvaux (Nancy, France)
Niek J. de Witt (Utrecht, The Netherlands)

10 minutes presentation including 2 minutes discussion

OP-G-5  IDENTIFICATION AND DIAGNOSIS OF PATIENTS WITH IRRITABLE BOWEL SYNDROME IN PRIMARY CARE: NOMINAL GROUP TECHNIQUE
(Greg Rubin, Sunderland, UK)
Co-authors: N. De Wit, V. Meineche-Schmidt, B. Seifert, N. Hall, P. Hungin

OP-G-6  CLINICAL EVALUATION OF THE ROME II QUESTIONNAIRE FOR THE DIAGNOSIS OF FUNCTIONAL GASTROINTESTINAL DISORDERS (FGID), AS COMPARED WITH THE DIAGNOSTIC OF THE CLINICIAN, IN PATIENTS CONSULTING IN GASTROENTEROLOGY. RESULTS OF A MULTICENTRE RUSSIAN TRIAL
(Vladimir Ivashkin, Moscow, Russian Federation)

OP-G-7  IS THERE A GRADIENT OF COMORBIDITY RELATED TO CONSULTATION BEHAVIOUR IN IRRITABLE BOWEL SYNDROME (IBS)?
(Per Vandvik, Gjøvik, Norway)
Co-authors: P. G. Farup

OP-G-8  ABDOMINAL ADAPTATION TO INTESTINAL VOLUME LOADS
(Alberto Villoria, Barcelona, Spain)
Co-authors: F. Azpiroz, J. R. Malagelada

OP-G-9  ANTICIPATION AND ENDOGENOUS MODULATION OF VISCERAL PAIN ASSESSED BY FUNCTIONAL MRI (FMRI) IN IRRITABLE BOWEL SYNDROME PATIENTS (IBS) AND CONTROLS
(Clive Wilder-Smith, Bern, Switzerland)
Co-authors: G. Song, V. Venkatraman, K. Ho, M. Chee, K. Yeoh
OP-G-10  VISCEROTOPIC ORGANISATION OF THE BRAIN RESPONSE TO ELECTRICAL STIMULATION OF THE GASTROINTESTINAL TRACT
(Georg Dimcevski, Aalborg, Denmark)
Co-authors: S.A.K. Sami, P. Funch-Jensen, P. Rössel, L. Arendt-Nielsen, A. Mohr Drewes

OP-G-11  DIETARY MODIFICATIONS IN SUBJECTS WITH IRritable BOWErl SYNDROME: CAUSE OR CONSEQUENCE?
(Solveig C. Ligaarden, Gjøvik, Norway)
Co-authors: P. G. Farup

OP-G-12  PLACEBO EFFECTS IN FUNCTIONAL BOWEL DISORDER TRIALS
(Sibylle Klosterhalfen, Tuebingen, Germany)
Co-authors: P. Enck

OP-G-13  HPA AXIS RESPONSE TO TRYPTOPHAN DEPLETION STUDY IN IRRITABLE BOWEL SYNDROME
(Jonathan Q. Shufflebotham, Bristol, UK)
Co-authors: S. Hood, C.S. Probert, J. Potokar

12:15-14:00  POSTER SESSIONS - HALL C

12:45-13:35  LUNCH SESSION - L3 IN HALL B: MANAGEMENT OF OESOPHAGEAL MOTILITY DISORDERS
Andrew Smout (Utrecht, The Netherlands), P. Pouderoux (Nimes, Franche)

14:00-15:30  IBS-ROME III DIAGNOSTIC CRITERIA FOR FUNCTIONAL GASTRO-INTESTINAL DISORDERS
Chair: Juan R. Malagelada (Barcelona, Spain)
Gabriele Moser (Vienna, Austria)

20 minutes presentation including discussion
THE ROME PROCESS, THE BASIC PRINCIPLES
(Michael Delvaux, Nancy, France)
ARE THERE ALTERNATIVES TO SYMPTOM-BASED DIAGNOSIS?
(Robin Spiller, Nottingham, UK)
DESIGNING TREATMENT TRIALS IN IBS
(Enrico Corazziari, Rome, Italy)
ROME III CRITERIA FOR IBS PATIENT SELECTION IN THE GENERAL SETTING
(Greg Rubin, Sunderland, UK)
15:45-17:15  FREE PAPER SESSION: FRONTIERS IN THE TREATMENT OF CROHN’S DISEASE

Chair:  Ole Østergaard-Thomsen (Copenhagen, Denmark)
       Daan Hommes (Amsterdam, The Netherlands)

10 minutes presentation including 2 minutes discussion

OP-G-74  BETTER OUTCOME WITH POTENT TOP-DOWN INDUCTION THERAPY IN RECENT ONSET CROHN’S DISEASE
(Geert R. D’Haens, Bonheiden, Belgium)

OP-G-75  INFLIXIMAB MAINTENANCE THERAPY INDUCES AND MAINTAINS ENDOSCOPIC HEALING AND PREVENTS SURGERY IN PATIENTS WITH ACTIVE CROHN’S DISEASE. A LONG-TERM RETROSPECTIVE ANALYSIS
(Paul Rutgeerts, Leuven, Belgium)
Co-authors: G. Van Assche, S. Vermeire

OP-G-76  SUPERIOR ENDOSCOPIC HEALING WITH AN INDUCTION REGIMEN OF INFLIXIMAB AND AZATHIOPRINE VERSUS CLASSIC STEP-UP THERAPY IN NEWLY DIAGNOSED CROHN’S DISEASE
(Geert R. D’Haens, Bonheiden, Belgium)
Co-authors: F. Baert, M. De Vos, F. Caenepeel, G. Van Assche, G. Lambrecht, J. Coche, S. Vermeire, D. Hommes

OP-G-77  THE EFFECT OF CONCOMITANT USE OF IMMUNOSUPPRESSIVE (IMM) THERAPIES AND THE FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY ADAлимУМAB IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE CLASSIC STUDY
(Remo Panaccione, Calgary, Canada)

OP-G-78  CLINICAL REMISSION AND RESPONSE IN PATIENTS WITH CROHN’S DISEASE TREATED OPEN-LABEL FOR 6-MONTHS WITH FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY ADAлимУМAB
(William J. Sandborn, Rochester, USA)

OP-G-79  MAINTENANCE NATALIZUMAB RESULTS IN GREATER QUALITY OF LIFE IN CROHN’S DISEASE PATIENTS
(Brian G. Feagan, London, UK)

OP-G-80  FONTOLIZUMAB (HUZAFTM), A HUMANIZED ANTI-IFN-GAMMA ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD), IS ACTIVE AND WELL TOLERATED IN A MULTI-DOSE STUDY
(Iskren Kotsev, Varna, Bulgaria)
Co-authors: W.J.S. de Villiers, S. Katz, B. Salzberg, N. Kostova, T. Pearce

OP-G-81  SARGRAMOSTIM IMPROVES QUALITY OF LIFE INDICATORS IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
(Suzanne Laplante, Berlin, Germany)
Co-authors: B. Dieckgraefe, J. Korzenik
OP-G-82 TRAFICET-EN™, A SPECIFIC CCR9 ANTAGONIST, IS A NOVEL APPROACH TO THE TREATMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Satish Keshav, Mountain View, USA)

AUDITORIUM 15

11:00-12:30 HEPATIC ENCEPHALOPATHY
Chair: Dieter Häussinger (Düsseldorf, Germany)
       Juan Cordoba (Barcelona, Spain)

20 minutes presentation including discussion
LOW-GRADE HEPATIC ENCEPHALOPATHY: DIAGNOSIS AND CLINICAL RELEVANCE
(Gerald Kircheis, Düsseldorf, Germany)
DIETARY TREATMENT OF HEPATIC ENCEPHALOPATHY
(Manuela Merli, Rome, Italy)
MEDICAL TREATMENT OF HEPATIC ENCEPHALOPATHY IN CIRRHOTIC PATIENTS
(Juan Cordoba, Barcelona, Spain)
MANAGEMENT OF HEPATIC ENCEPHALOPATHY IN ACUTE LIVER FAILURE
(Rajiv Jalan, London, UK)

12:15-14:00 POSTER SESSIONS - HALL C
12:45-13:35 LUNCH SESSION - L4 IN HALL B: SUBCLASSIFICATION OF FUNCTIONAL DYSEPSIA - HELPFUL FOR TREATMENT?
Fermin Mearin (Barcelona, Spain), Guy Boeckxstaens (Amsterdam, The Netherlands)

14:00-15:30 CHALLENGES IN THE MANAGEMENT OF CHOLANGIOCARCINOMA
Chair: Ulrika Bromeé (Stockholm, Sweden)
       Dirk Gouma (Amsterdam, The Netherlands)

20 minutes presentation including discussion
DIAGNOSTIC WORK-UP OF HILAR BILIARY LESIONS
(T. M. Van Gulik, Amsterdam, The Netherlands)
EXTENDED LIVER RESECTIONS FOR HILAR CHOLANGIOCARCINOMA
(Peter Neuhaus, Berlin, Germany)
ENDOSCOPIC PALLIATIVE TREATMENT
(Massimiliano Mutignani, Rome, Italy)
THE ROLE OF ADJUVANT THERAPIES (ILBT, ERBT, PDT)
(Marianne Ortner, Lausanne, Switzerland)
15:45-17:15  FREE PAPER SESSION: VIDEO DRAMA – ENDOSCOPIC RESECTION

Chair:  Guido Costamagna (Rome, Italy)
Thomas Roesch (Munich, Germany)

10 minutes presentation including 2 minutes discussion

VID-E-1  INVENTION OF WATER JET SHORT NEEDLE KNIVES FOR ENDOSCOPIC SUBMUCOSAL DISSECTION
(Takashi Toyonaga, Kishiwada, Japan)
Co-authors: E. Nishino, T. Hirooka, A. Hayashibe

VID-E-2  IMPROVED ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) USING A NEW DEVICE (MUCOSECTOME)
(Yoshiro Kawahara, Tsuyama, Japan)
Co-authors: A. Imagawa, R. Takenaka, S. Fujiki, Y. Shiratori

VID-E-3  ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) METHOD USING A NEW DEVICE (MUCOSECTOME) FOR LARGE COLORECTAL TUMORS
(Yoshiro Kawahara, Tsuyama, Japan)
Co-authors: A. Imagawa, S. Fujiki, Y. Shiratori

VID-G-4  SAFE TECHNIC OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR COLORECTAL TUMORS
(Yoshiro Tamegai, Shinjukuku, Japan)
Co-authors: N. Nagata, Y. Yago, N. Uemura, T. Koike, E. Kogure, Y. Saito

VID-G-5  THE DIFFICULTY OF ESD FOR GASTRIC NEOPLASM
(Atsushi Imagawa, Okayama, Japan)

VID-G-6  WIDE SPREAD ENDOSCOPIC MUCOSAL RESECTION WITH INSULATION-TIPPED KNIFE FOR LARGE EARLY GASTRIC CANCER
(Yoji Takeuchi, Osaka, Japan)
Co-authors: N. Uedo, H. Iishi, R. Ishihara, K. Higashino, M. Tatsuta

VID-G-7  ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY ESOPHAGEAL CANCER
(Tsuneo Oyama, Saku, Japan)

VID-G-8  EFFECTIVENESS AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION USING HOOK KNIFE FOR EARLY GASTRIC CANCER
(Tsuneo Oyama, Saku, Japan)

VID-G-9  ENDOSCOPIC SUBMUCOSAL DISSECTION USING SODIUM HYALURONATE, A NEW TECHNIQUE FOR EN BLOC RESECTION OF A LARGE SUPERFICIAL TUMOR IN THE COLON AND RECTUM
(Hiroto Kita, Tochigi, Japan)
ROOM M1 IN HALL C

11:00-12:30  FREE PAPER SESSION: EPIDEMIOLOGY IN IBD

Chair:  Pia Munkholm (Copenhagen, Denmark)
        Reinhold Stockbrügger (Maastricht, The Netherlands)

10 minutes presentation including 2 minutes discussion

OP-G-14  PAEDIATRIC INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN COPENHAGEN
         2003-2004: A PROSPECTIVE POPULATION BASED COHORT STUDY
         (Ida Vind, Copenhagen, Denmark)
         Co-authors: T. Jess, A. Berggreen, P. Skytt Andersen, B. Weile, P. Munkholm,
                     A. Paerregaard, V. Wewer

OP-G-15  DECREASING FREQUENCY OF IBD RELATED SURGERY IN COPENHAGEN COUNTY
         AND CITY. AN INCIDENCE COHORT STUDY FROM 2003 - 2005
         (Ida Vind, Copenhagen, Denmark)
         Co-authors: N. Petersen, E. Langholz, F. Moesgaard, P. Munkholm

OP-G-16  HIGH INCIDENCE OF IBD IN MULTIPLE AFFECTED FAMILIES IS NOT ASSOCIATED
         WITH KNOWN ENVIRONMENTAL AND GENETIC RISK FACTORS:
         RESULTS FROM A PROSPECTIVE STUDY
         (Marie Joossens, Leuven, Belgium)
         Co-authors: H.J. Van Kruiningen, S. Joossens, N. Van Schuerbeek, K. Claes, P. Rutgeerts,
                     S. Vermeire

OP-G-17  DISEASE OUTCOME IN CROHN’S DISEASE: A PROSPECTIVE POPULATION BASED
         STUDY IN SOUTH EASTERN NORWAY FROM JANUARY 1990 TO DECEMBER 2004
         (Camilla Solberg, Oslo, Norway)
         Co-authors: J. Jahnsen, M. Vatn, B. Moum, I. Lygren

OP-G-18  MORTALITY IN CROHN’S DISEASE IN THE NORTH JUTLAND COUNTY.
         A POPULATION BASED 26 YEARS FOLLOW-UP STUDY
         (Bent A. Jacobsen, Aalborg, Denmark)
         Co-authors: E. Puho, J. Fallingborg, H.H. Rasmussen, A.M. Drewes, H.T. Soerensen

OP-G-19  MORTALITY IN ULCERATIVE COLITIS IN THE NORTH JUTLAND COUNTY.
         A POPULATION BASED 26 YEARS FOLLOW-UP STUDY
         (Bent A. Jacobsen, Aalborg, Denmark)
         Co-authors: E. Puho, J. Fallingborg, H.H. Rasmussen, A.M. Drewes, H.T. Soerensen

OP-G-20  NO INCREASED MORTALITY 10 YEARS AFTER DIAGNOSIS IN A EUROPE-WIDE
         POPULATION BASED COHORT OF ULCERATIVE COLITIS PATIENTS
         (EC-IBD STUDY GROUP)
         (Ole Høie, Arendal, Norway)
         Co-authors: L. Schouten, F. Wolters, E. Langholz, V. Ochoa, Y. Mouzas, R. Stockbrugger,
                     M. Vatn, B. Moum

OP-G-21  CANCER RISK OF LOW-GRADE DYSPLASIA IN CHRONIC ULCERATIVE COLITIS:
         A META-ANALYSIS
         (Titus Thomas, Leicester, UK)
         Co-authors: K.R. Abrams, R.J. Robinson, J.F. Mayberry

OP-G-22  TIME TRENDS OF COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE
         (Sverre Söderlund, Stockholm, Sweden)
         Co-authors: A. Lapidus, P. Karlén, O. Broström, R. Löfberg, A. Ekborn, J. Askling
12:15-14:00  POSTER SESSIONS - HALL C

12:45-13:35  LUNCH SESSION - L5 IN HALL B: ANTIFIBROTIC THERAPY
Massimo Pinzani (Florence, Italy), Norifumi Kawada (Osaka, Japan)

14:00-15:30  FREE PAPER SESSION: CHOLESTATIS

Chair: Ulrich Beuers (Munich, Germany)
Dieter Häussinger (Duesseldorf, Germany)

INTRODUCTION (10 minutes)
(Ulrich Beuers, Munich, Germany)

10 minutes presentation including 2 minutes discussion

OP-G-48  EVOLUTION OF INFLAMMATORY BOWEL DISEASES AFTER LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS IN A FRENCH COHORT
(Laure Lamare, Creteil, France)
Co-authors: J. Duclos Vallée, F. Durand, O. Chazouillères, G. Pageaux, F. Roudot Thoraval, C. Duvoux

OP-G-49  INTRAHEPATIC CHOLESTASIS OF PREGNANCY (ICP): THREE NOVEL MUTATIONS IN MDR3 GENE
(Isabella Carderi, Padova, Italy)
Co-authors: D. Paternoster, G. Soardo, F. Azzaroli, G. Mazzella, W. Esposito, F. Ferrara, A. Floreani

OP-G-50  LIPOTEICHOIC ACID MAY AFFECT THE PATHOGENESIS OF BILE DUCT DAMAGE IN PRIMARY BILIARY CIRRHOSIS
(Ikuko Haruta, Tokyo, Japan)
Co-authors: E. Hashimoto, Y. Kato, M. Kobayashi, K. Shiratori

OP-G-51  ANTI-CHOLESTEROL ANTIBODIES IN PRIMARY BILIARY CIRRHOSIS AND WILSON DISEASE
(Timea Csak, Budapest, Hungary)

OP-G-52  BILE DUCT LIGATION CIRRHOSIS AND ENDOTOXEMIA BOTH DECREASE IN VIVO UREA SYNTHESIS AND UREA CYCLE ENZYME GENETIC ACTIVITY IN RATS
(Susanne Schouw Nielsen, Aarhus, Denmark)
Co-authors: N. Tygstrup, T. Grofte, H. Vilstrup

OP-G-53  CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE MUTATIONS AND VARIANTS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS
(Liesbet Henckaerts, Leuven, Belgium)

OP-G-54  THE CCR5-DELTA 32 MUTATION MIGHT PROTECT AGAINST PRIMARY SCLEROSING CHOLANGITIS
(Liesbet Henckaerts, Leuven, Belgium)
Co-authors: J. Fevery, W. Van Steenbergen, C. Verslype, P. Yap, F. Nevens, P. Rutgeerts, S. Vermeire
OP-G-55  SERUM 7ALPHA -HYDROXYCHOLESTENONE IN PATIENTS WITH IDIOPATHIC BILE SALT MALABSORPTION – A DETAILED COMPARISON WITH CONVENTIONAL SEHCAT TESTING
(Simon Campbell, Liverpool, UK)
Co-authors: N. Chandra, L. Gladman, A. Mee

15:45-17:15  FREE PAPER SESSION: H. PYLORI ASSOCIATED GASTRIC MALIGNANCY

Chair: John Atherton (Nottingham, UK)
Ernst Kuipers (Rotterdam, The Netherlands)

INTRODUCTION (10 minutes)
Ernst Kuipers (Rotterdam, The Netherlands)

10 minutes presentation including 2 minutes discussion
Ernst Kuipers (Rotterdam, The Netherlands)

OP-G-83  INTERFERON GAMMA INFUSION IN SUSCEPTIBLE HOST INDUCES GASTRIC PRECANCEROUS LESIONS IN THE ABSENCE OF HELICOBACTER INFECTION
(Guanglin Cui, Tromso, Norway)
Co-authors: J. Houghton, N. Finkel, J. Carlson, T.C. Wang

OP-G-84  THE ROLE OF METALLOTHIONEIN IN HELICOBACTER PYLORI POSITIVE GASTRIC MUCOSA WITH OR WITHOUT EARLY GASTRIC CANCER AND THE EFFECT ON ITS EXPRESSION AFTER ERADICATION THERAPY
(Toshifumi Mitani, Kobe, Japan)

OP-G-85  MDR1 P-GLYCOPROTEIN EXPRESSION IN HUMAN GASTRIC TISSUE: NOT ONLY MULTI-DRUG RESISTANCE
(Gerardo Nardone, Naples, Italy)
Co-authors: M. D’Armiento, D. Compare, P. De Colibus, G. Budillon, A. Rocco

OP-G-86  EPIDERMAL GROWTH FACTOR - RECEPTOR ENHANCED EXPRESSION IN HELICOBACTER PYLORI - INDUCED GASTRITIS IS CORRELATED WITH INFLAMMATORY ACTIVITY BUT NOT WITH CHRONIC INFLAMMATION
 Justiça Kotynia, Lodz, Poland
Co-authors: R. Kordek, A. Kozlowska, E. Malecka-Panas

OP-G-87  FRAGILE HISTIDINE TRIAD PROTEIN EXPRESSION IN THE GASTRIC MUCOSA OF CIGARETTE-SMOKING PATIENTS INFECTED WITH HELICOBACTER PYLORI
(Jan Chojnacki, Poland)
Co-authors: A. Krakowiak, L. Peczek, G. Klupinska, K. Stec-Michalska, B. Michalski, B. Nawrot

OP-G-88  GLOBAL METHYLATION OF CPG SITES IN GASTRIC CANCER AND IN ADVANCED STAGES OF H. PYLORI GASTRITIS - IS HYPOMETHYLATION AN EARLY EVENT IN GASTRIC CANCEROGENESIS?
(Andreas Leodolter, La Jolla, United States)
Co-authors: S. Alonso, M. Ebert, C. Roecken, T. Wex, U. Peitz, P. Malfertheiner, M. Perucho

OP-G-89  THE CORRELATION BETWEEN INTERLEUKIN-1B GENE POLYMORPHISMS AND GASTRIC MUCOSAL LEVEL OF INTERLEUKIN-1 BETA BEFORE AND AFTER HELICOBACTER PYLORI ERADICATION
(Young W. Chang, Seoul, South Korea)
OP-G-90  GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: RAPID PROGRESSION TO DIFFUSE LARGE B-CELL LYMPHOMA AFTER ERADICATION OF HELICOBACTER PYLORI
(Masahiro Iwano, Kyoto, Japan)
Co-authors: K. Okazaki, Y. Matsushima, T. Sakurai, A. Nishio, A. Fukumoto, K. Oki, H. Inagaki, T. Chiba

ROOM M2 IN HALL C

11:00-12:30  BASIC SCIENCE IN GI CANCER: GENETIC TESTING
Chair: Ari Ristimäki (Helsinki, Finland)
       Jan Björk (Stockholm, Sweden)

20 minutes presentation including discussion
PROGNOSTIC SIGNIFICANCE OF COX-2 IN HUMAN CARCINOGENESIS;
FROM MOLECULES TO HUMANS
(Ari Ristimäki, Helsinki, Finland)
INVOLVEMENT OF MYH IN COLORECTAL POLYPOSIS: WHERE ARE WE?
(Guglielmina Nadia Ranzani, Pavia, Italy)
JUVENILE POLYPOSIS ASSOCIATED WITH MUTATIONS IN SMAD4
(Sabine Tejpar, Leuven, Belgium)
MOLECULAR CHANGES DURING COLORECTAL CARCINOGENESIS
(Lauri Aaltonen, Helsinki, Finland)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L6 IN HALL B: MANAGEMENT OF NASH
Elisabetta Bugianesi (Bologna, Italy), Helena Cortez-Pinto (Lisabon, Portugal)

14:00-15:30  LESSONS FROM HELICOBACTER PYLORI GENOMIC AND POST-GENOMICS
Chair: Francis Megraud (Bordeaux, France)
       Torkel Wadström (Lund, Sweden)

20 minutes presentation including discussion
HELCOBACTER PYLORI COMPARATIVE GENOMICS: WHAT HAS IT TAUGHT US?
(P. O`Toole, Cork, Ireland)
HOW MICROARRAYS CAN HELP UNDERSTANDING THE PERSISTENCE STRATEGIES OF
HELCOBACTER PYLORI
(Hilde De Reuse, Paris, France)
HELCOBACTER PYLORI PROTEOMICS
(Torkel Wadström, Lund, Sweden)
VACCINE DEVELOPMENT
(Pierre Michetti, Lausanne, Switzerland)
ROOM M3 IN HALL C

11:00-12:30 FREE PAPER SESSION: LIVER REGENERATION, INFLAMMATION AND FIBROSIS

Chair: Fabio Marra (Florence, Italy)
Vlad Ratziu (Paris, France)

INTRODUCTION (10 minutes)
(Fabio Marra, Florence, Italy)

10 minutes presentation including 2 minutes discussion

OP-G-23 MIGRATION OF HUMAN ACTIVATED HEPATIC STELLATE CELLS INDUCED BY SUPEROXIDE ANION: A RAS/ERK-DEPENDENT EVENT THAT DOES NOT AFFECT PROLIFERATION
(Errica Novo, Torino, Italy)
Co-authors: E. Zamara, L. Valfrè di Bonzo, A. Caligiuri, S. Cannito, S. Colombatto,
F. Marra, M. Pinzani, M. Parola

OP-G-24 GENETIC POLYMORPHISMS OF MMP-1, -3, -9 AND IL-1BETA AND THE PROGRESSION OF LIVER FIBROSIS IN CHRONIC HEPATITIS C
(Mari Mandai, Yonago, Japan)
Co-authors: K. Okamoto, K. Mimura, Y. Murawaki

OP-G-25 SIMPLE NONINVASIVE MARKERS OF LIVER FIBROSIS AND INFLAMMATION IN CHRONIC CARRIERS OF HEPATITIS B VIRUS (HBV)
(Mehdi Mohamadnejad, Tehran, Islamic Republic of Iran)
Co-authors: G. Montazeri, F. Zamani, J. Nasiri, H. Nobakht, A. Mohamadkhani,
S. Tavangar, M. Forouzanfar, S. Abedian, M. Farzadi, Fazlollahi, A. Estakhri, N. Noori,
R. Malekzadeh

OP-G-27 DIFFERENT RESPONSE OF HEPATIC STELLATE CELLS AND HEPATIC MYOFIBROBLASTS TO TGFβ1 EXPOSURE
(Gabor Firniesz, Budapest, Hungary)
Co-authors: J. Dudas, T. Szarvas, G. Lengyel, Z. Tulassay, J. Feher, G. Ramadori,
I. Kovácszy

OP-G-28 TRANSIENT ELASTOGRAPHY AN ALTERNATIVE TO LIVER BIOPSY
(Elena Gomez-Dominguez, Madrid, Spain)
Co-authors: J. Moreno-Otero, A. Aboy, L. García-Buey, X. Salcedo, J. Mendoza,
J.A. Moreno-Monteagudo, S. Rubio

OP-G-29 GENE EXPRESSION PATTERN FOLLOWING PERIPORTAL INJURY INDUCED BY ALLYL ALCOHOL IN A MURINE MODEL
(Maria Assunta Zocca, Rome, Italy)
Co-authors: C. Di Campli, A. Piscaglia, N. Saulnier, G. Di Gioacchino, M. Novi,
A. Santoliquido, P. Pola, G. Gasbarrini, A. Gasbarrini

OP-G-30 GENE EXPRESSION PROFILES OF DRUG-METABOLIZING ENZYMES WITH HEPATOCELLULAR CARCINOMA GROWTH FACTOR UNDEREXPRESSION
(Satoru Kakizaki, Maebashi, Japan)
Co-authors: Y. Yamazaki, T. Kosone, N. Horiguchi, Y. Nakajima, K. Yuasa, T. Higuchi,
N. Sohara, K. Sato, H. Takagi, M. Mori
12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L7 IN HALL B: INTRA ABDOMINAL ABSCESS: RESECTION VERSUS DRAINAGE, TIMING OF SURGERY IN FISTULIZING CROHN’S DISEASE
Stefan Schreiber (Kiel, Germany), Tom Oresland (Gothenburg, Sweden)

14:00-15:30  GORD IN INFANCY AND CHILDHOOD
Chair: Anders Paerregaard (Copenhagen, Denmark)
       Peter Milla (London, UK)
20 minutes presentation including discussion
NON-ACIDIC REFLUX IN THE NEONATE: DOES IT MATTER?
(Christian Poets, Tuebingen, Germany)
REFLUX SYMPTOMS AND AGE
(Silvia Salvatore, Varese, Italy)
WHEN DOES BARRET’S OESOPHAGUS OCCUR IN CHILDREN?
(Frederic Gottrand, Lille, France)
SAFETY OF ANTISECRETORY DRUGS IN CHILDREN
(Marc Benninga, Amsterdam, The Netherlands)

15:45-17:15  CRC TUMOR CELLS IN THEIR BIOLOGICAL CONTEXT
Chair: Isaac P. Witz (Tel Aviv, Israel)
       Margareta Müller (Heidelberg, Germany)
20 minutes presentation including discussion
LOCAL IMMUNITY AND CYTOKINES
(W. H. Friedman, Paris, France)
GROWTH FACTORS AND TUMOR PROGRESSION
(Margareta Mueller, Heidelberg, Germany)
REGULATORY CIRCUITS OF ANGIOGENESIS
(Fernando Vidal-Vanacloc, Bizkaia, Spain)
TUMOR-ENDOTHELIAL INTERACTIONS
(Isaac P. Witz, Tel Aviv, Israel)

ROOM M4 IN HALL C

11:00-12:30  FREE PAPER SESSION: DYSPESIA AND PEPTIC ULCER DISEASE
Chair: Lars Agreus (Stockholm, Sweden)
       Chuka Nwokolo (Coventry, UK)
10 minutes presentation including 2 minutes discussion
OP-G-31  TEST-AND-TREAT OR TREAT-AND-TEST? A RANDOMIZED COMPARISON OF TREATMENT STRATEGIES FOR DYSPESIA
(Marcel J.R. Janssen, Nijmegen, The Netherlands)
Co-authors: R.J.F. Laheij, W.A. De Boer, J.B.M.J. Jansen
OP-G-32  CHANGES IN PATTERNS OF DYSPEPSIA, PEPTIC ULCER DISEASE AND THE ROLE OF HELICOBACTER PYLORI IN A GENERAL POPULATION: THE SØRREISA II STUDY
(Anne Mette Asfeldt, Tromsoe, Norway)
Co-authors: B. Straume, M. Løchen, J. Florholmen, E. Paulissen

OP-G-33  COMPARING 2 REVOLUTIONS: IMPACT OF H PYLORI ERADICATION AND INTRODUCTION OF SELECTIVE COX-2 INHIBITORS ON ULCER HOSPITALIZATIONS IN THE UNITED STATES
(Gurkipal Singh, Stanford, USA)
Co-authors: A. Mithal, G. Triadafilopoulos

OP-G-34  H. PYLORI INFECTION IS NO LONGER THE MAJOR CAUSE OF PEPTIC ULCER IN COPENHAGEN COUNTY
(Bo Søndergaard, Copenhagen, Denmark)
Co-authors: P. Bytzer

OP-G-35  E266K CARD4/NOD1 GENE POLYMORPHISM INCREASES THE RISK FOR PEPTIC ULCERATION IN HELICOBACTER PYLORI INFECTED PATIENTS
(Martijn G. H. Van Oijen, Nijmegen, The Netherlands)

OP-G-36  THE IMPROVEMENT OF ANTRAL HISTOLOGY, SERUM GASTRIN-17, PEPSINOGEN-I AND PEPSINOGEN-II LEVELS AFTER ERADICATION IS RELATED TO RESIDUAL BACTERIAL LOAD IN PATIENTS WITH DUODENAL ULCER
(Alena V. Makarenka, Vitebsk, Belarus)
Co-authors: S.I. Pimanov

OP-G-37  PEPTIC ULCERS DURING USE OF LOW-DOSE EFFERVESCENT CALCIUM CARBASALATE AND REGULAR LOW-DOSE ACETYLSALICYLIC ACID
(Martijn G. H. Van Oijen, Nijmegen, The Netherlands)
Co-authors: J.P. Dieleman, R.J.F. Laheij, M.C.J.M. Sturkenboom, J.B.M.J. Jansen, F.W.A. Verheugt

OP-G-38  ROLE OF HISTAMINE IN GHRELIN-INDUCED GASTRIC SECRETORY ACTIVITY AND GASTROPROTECTION AGAINST ACUTE GASTRIC LESIONS
(Robert Pajdo, Cracow, Poland)

OP-G-39  CENTRAL AND PERIPHERAL OREXIN-A EXERT A POTENT GASTROPROTECTIVE ACTIVITY AGAINST THE MUCOSAL DAMAGE INDUCED BY ETHANOL AND ISCHEMIA-REPERFUSION
(Tomasz Brzozowski, Cracow, Poland)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L8 IN HALL B: SURVEILLANCE FOR DISPLASIA IN IBD
Bryan Warren (Oxford, UK), Robert Lofberg (Stockholm, Sweden)
14:00-15:30  FREE PAPER SESSION: UPPER GI MOTOR AND SENSORY DISORDERS

Chair:  Jan Tack (Leuven, Belgium)
        Guy Boeckxstaens (Amsterdam, The Netherlands)

10 minutes presentation including 2 minutes discussion

OP-G-56  ROLE OF POSTPRANDIAL GASTRIC SENSITIVITY, COMPARED TO FASTING SENSITIVITY, TO SYMPTOM GENERATION IN FUNCTIONAL DYSPEPSIA
(George Karamanolis, Leuven, Belgium)
Co-authors: R. Vos, P. Caenepeel, J. Tack

OP-G-57  ROLE OF PYY(3-36) ON FOOD INTAKE AND BODY WEIGHT GAIN IN COLECTOMIZED RATS
(Mohan Babu Budikote Venkatappa, Kuopio, Finland)
Co-authors: A. Purhonen, T. Bansiewicz, K. Mäkelä, J. Walkowiak, P. Miettinen, K. Herzig

OP-G-58  THE INCRETIN HORMONES GIP AND GLP-1 IN HEALTHY VOLUNTEERS: EFFECTS ON GASTRIC EMPTYING RATE, INSULIN RESPONSE, HUNGER AND SATIETY
(Therese Edholm, Stockholm, Sweden)
Co-authors: P. Grybäck, P.T. Schmidt, H. Jacobsson, P.M. Hellström

OP-G-59  ESOPHAGEAL MANOMETRY ABNORMALITIES AFTER GASTRIC BANDING FOR MORBID OBESITY
(Razvan Andrei Iacob, Bucharest, Romania)
Co-authors: J. Quinton, F. Guillemot, F. Pattou, I. Bancila, C. Gheorghe, S. Iacob,
L. Gheorghe, M. Diculescu

OP-G-60  SMALL INTESTINAL BACTERIAL OVERGROWTH PREVALENCE IN PARKINSON’S DISEASE
(Andrea Lupascu, Rome, Italy)
Co-authors: C. Lauritano, E. Scarpellini, A. Bentivoglio, F. Soleti, M. Gabrielli, G. Nucera,
G. D’Antona, R. Flore, P. Tondi, G. Cammarota, G. Gasbarrini, P. Tonali, A. Gasbarrini

OP-G-61  MODIFIED SHAM FEEDING IMPROVE STOMACH FUNCTION AND POSTPRANDIAL SYMPTOMS IN FUNCTIONAL DYSPEPSIA
(Lars Michael M. Nordström, Bergen, Norway)
Co-authors: A.O. Haukelid, J.A. Lunding, T. Hausken

OP-G-62  RELATIONSHIP BETWEEN FEED INTOLERANCE AND FUNDIC SLOW VOLUME WAVE ABNORMALITIES IN CRITICALLY ILL PATIENTS
(Nam Q. Nguyen, Adelaide, Australia)
Co-authors: R. Fraser, M. Chapman, L. Bryant, C. Burgstad, C. Feinle-Bisset, M. Horowitz,
R.H. Holloway

OP-G-63  WHAT IS THE RISK OF NOCTURNAL SUPINE ENTERAL NUTRITION?
(Hélène Castel, Caen, France)
Co-authors: L. Tiengou, M. Piquet, C. Joubert, J. Reimund, T. Dao

OP-G-64  EFFICACY OF GASTRIC ELECTRICAL STIMULATION IN MEDICALLY REFRACTORY GASTROPARESIS
(Guillaume Gourcerol, Rouen, France)
Co-authors: I. Leblanc, A. Leroi, P. Ducrotté
15:45-17:15  FREE PAPER SESSION: BASIC INSIGHTS INTO PANCREATIC DISEASE

Chair: Helmut Friess (Heidelberg, Germany)  
Michael Raraty (Liverpool, UK)

10 minutes presentation including 2 minutes discussion

OP-G-91 EXPRESSION PROFILE OF SST2 SOMATOSTATIN RECEPTOR IN INTRADUCTAL PAPILLARY AND MUCINOUS TUMORS OF THE PANCREAS: A NEW TUMOR SUPPRESSOR GENE?  
(Frederic Marrache, Toulouse, France)  
Co-authors: A. Couvelard, P. Rochaix, P. Hammel, P. Cordelier, C. Susini, A. Sauvanet, P. Lévy, P. Ruszniewski, L. Buscail

OP-G-92 APOPTOTIC CELL ENGULFMENT BY PANCREATIC STELLATE CELLS IS REGULATED BY CYTOKINES AND PPAR-GAMMA LIGAND  
(Kyoko Shimizu, Tokyo, Japan)  
Co-authors: J. Tahara, K. Shiratori

OP-G-93 RECOMBINANT ARGinine DEIMINASE (R-ADI) INHIBITS ACTIVATION OF PANCREATIC STELLATE CELLS  
(Hong-Sik S. Lee, Ansan, South Korea)  

OP-G-94 EARLY BRAIN RESPONSE TO ELECTRICAL STIMULATION OF THE GASTROINTESTINAL TRACT IN PAINFUL CHRONIC PANCREATITIS  
(Georg Dimcevski, Aalborg, Denmark)  
Co-authors: S.A.K. Sami, P. Rössel, L. Arendt-Nielsen, A. Mohr Drewes

OP-G-95 TRANSCRIPTIONAL SUPPRESSION OF ETS-1 IN PANCREATIC CANCER: IS THIS THE MAGIC BULLET?  
(Liviu Paul P. Lefter, Sendai, Japan)  
Co-authors: M. Sunamura, S. Matsuno, V. Scripcariu, A. Horii

OP-G-96 TNF-ALPHA EXPRESSION AND SIGNIFICANCE IN THE BRAIN OF RAT WITH ACUTE NECROTIZING PANCREATITIS  
(Lei Kong, Shanghai, China)  
Co-authors: T. Han, L. Yu, R. Tian, R. Lei, S. Zhang

OP-G-97 GALACTIN-1 MEDIATES CELL FUNCTIONS OF PANCREATIC STELLATE CELLS  
(Atsushi Masamune, Sendai, Japan)  
Co-authors: M. Satoh, J. Hirabayashi, K. Kasai, T. Shimosegawa

OP-G-98 GHRELIN STIMULATES PANCREATIC ENZYME SECRETION THROUGH THE ACTIVATION OF ENTEROPANCREATIC REFLEX  
(Katarzyna Nawrot-Porabka, Cracow, Poland)  

OP-G-99 PROPHYLACTIC PROBIOTICS REDUCE BACTERIAL TRANSLOCATION IN EXPERIMENTAL ACUTE PANCREATITIS  
(Leo Paul Van Minnen, Utrecht, The Netherlands)  
11:00-12:30  FREE PAPER SESSION: THERAPEUTIC ADVANCES IN COLORECTAL CANCER

Chair:  Mario Dicato (Luxembourg, Luxembourg)
        Dan Aderka (Tel-Hashomer, Israel)

10 minutes presentation including 2 minutes discussion

OP-G-40  COMPARISON OF OROTATE PHOSPHORIBOSYL TRANSFERASE, THYMIDYLATE SYNTHASE AND DIHYDROPYRIMIDINE DEHYDROGENASE ACTIVITY AS PROGNOSTIC FACTORS IN RESECTABLE COLORECTAL CANCERS
(Takumi Ochiai, Tokyo, Japan)
Co-authors: K. Nishimura, M. Noguchi, M. Kitajima, E. Mano, A. Tsukada, S. Futagawa, I. Nagaoka

OP-G-41  PRINCIPAL INVOLVEMENT OF TUMORAL THYMIDINE PHOSPHORYLASE AND CYP2A6 FOR INTRATUMORAL 5-FU AFTER ADMINISTRATION OF TEGAFUR
(Atsushi Umemoto, Tokushima, Japan)
Co-authors: N. Tanida, A. Tangoku

OP-G-42  ELEVATION IN PERIPHERAL BLOOD CIRCULATING TUMOR CELL NUMBER PREDICTS MACROSCOPIC PROGRESSION IN DUKES STAGE D COLORECTAL CANCER PATIENTS. COMPARISON TO SERUM TUMORMARKERS
(Bela Molnar, Budapest, Hungary)
Co-authors: F. Sipos, L. Floro, A. Ladanyi, L. Sreter, Z. Tulassay

OP-G-43  NOTI-MSEI METHYLATION-SENSITIVE AFLP ESTIMATES GLOBAL DNA METHYLATION ALTERATIONS IN COLON CANCER
(Andreas Leodolter, La Jolla, USA)
Co-authors: K. Suzuki, S. Alonso, M. Perucho

OP-G-44  STAGING OF COLORECTAL CANCER: COMPARISON AMONG WHOLE BODY MULTI-DETECTOR COMPUTED TOMOGRAPHY, POSITRON EMISSION TOMOGRAPHY WITH GLUCOSE ANALOG [18F] FLUORO-2-DEOXY-D-GLUCOSE, AND SURGICAL EXPLORATION
(Hiroyoshi Furukawa, Suntogun, Japan)
Co-authors: A. Seki, H. Ikuma, T. Aramaki, S. Yuen

OP-G-45  DEVELOPMENT IN COLORECTAL CANCER OF A PROGNOSTIC BAR-CODE BASED ON QMPSF
(Frédéric Di Fiore, Rouen, France)

OP-G-46  CHARACTERISTICS OF LATERALLY SPREADING TUMORS IN COLORECTAL NEOPLASM
(Hiro-o Yamano, Akita, Japan)

OP-G-47  INTRAPERITONEAL TREATMENT WITH DIMETHYLTHIOAMPAL (DIMATE) ASSOCIATED TO SURGICAL DEBULKING IS EFFECTIVE FOR EXPERIMENTAL PERITONEAL CARCINOMATOSIS IN A RAT MODEL
(Olivier J. Y. Monneuse, Lyon, France)
Co-authors: J. Mestrallet, G. Quash, F. Gilly, O. Glehen

12:15-14:00  POSTER SESSIONS - HALL C
14:00-15:30  FREE PAPER SESSION: MICROBES AND THE GUT

Chair: Henrik Thorlacius (Sweden)
       Boris Vucelic (Zagreb, Croatia)

10 minutes presentation including 2 minutes discussion

OP-G-65  FACTORS INFLUENCING THE GUT MICROBIOTA COMPOSITION IN EARLY INFANCY
(John Penders, Maastricht, The Netherlands)
Co-authors: P.A. Van den Brandt, C. Thijs, E.E. Stobberingh

OP-G-66  DETECTION OF AN « ACTIVE » ESCHERICHIA COLI IN Faecal MICROFLORA
OF PATIENTS WITH ULCERATIVE COLITIS FLARE UP
(Harry Sokol, Paris, France)
Co-authors: P. Lepage, P. Seksik, J. Dore, P. Marteau

OP-G-67  TREATMENT OF COLLAGENOUS COLITIS WITH LACTOBACILLUS ACIDOPHILUS
AND BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS. A RANDOMISED DOUBLE-BLIND
PLACEBO-CONTROLLED TRIAL
(Sigrid Wildt, Copenhagen, Denmark)
Co-authors: L.K. Munck, L. Vinther-Jensen, B. Fischer Hansen, I. Nordgaard-Lassen,
S. Christensen, S. Avmstrem, S. Nørby Rasmussen, J.J. Rumessen

OP-G-68  LACTOBACILLUS FARCIMINIS TREATMENT DECREASES STRESS-INDUCED
OVEREXPRESSION OF FOS PROTEIN IN SPINAL CORD AFTER COLORECTAL
DISTENTION IN RATS
(Afifa Ait-Belgnaoui, Toulouse, France)
Co-authors: H. Eutamène, E. Houdeau, J. Fioramonti, L. Bueno, V. Theodorou

OP-G-69  EFFECT OF A PREBIOTIC MIXTURE ON ABDOMINAL COMFORT AND GENERAL WELL
BEING IN MAN
(Miriam Thumshirn, Zurich, Switzerland)
Co-authors: D. Menne, B. Stutz, K. Ornstein, M. Giarré, M. Fried

OP-G-70  BOSWELLIA SERRATA EXTRACT FOR THE TREATMENT OF COLLAGENOUS COLITIS
(Ahmed Madisch, Dresden, Germany)
Co-authors: S. Miehlke, E. Eichele, B. Bethke, J. Mrwa, E. Kuhlisch

OP-G-71  SHORT AND LONG TERM EFFECTS OF RESISTANT STARCH WITH OR WITHOUT
WHEAT BRAN BY MEANS OF LACTOSE-(15N, 15N')-UREIDE TO DETERMINE THE SITE
OF FERMENTATION IN THE COLON
(Lieselotte Cloetens, Leuven, Belgium)
Co-authors: V. De Preter, P. Rutgeerts, K. Verbeke

OP-G-72  INEFFECTIVENESS OF THE PROBIOTIC STRAIN LACTOBACILLUS JOHNSONII LA1 TO
PREVENT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE – A RANDOMIZED
DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
(Philippe Marteau, Paris, France)
Co-authors: M. Lémann, P. Seksik, D. Laharie, J. Colombel, Y. Bouhnik, G. Cadiot, J. Soulé,
A. Boureille, E. Metman, E. Lerebours, F. Carbonnel, J. Dupas, B. Coffin, M. Veyrac,
J. Moreau, V. Abitbol, J. Mary, GETAID

OP-G-73  LACTULOSE ADMINISTRATION IN HEALTHY VOLUNTEERS IS ASSOCIATED
WITH A REDUCED BETA-GLUCURONIDASE ACTIVITY AND AN INCREASE
IN FECAL BIFIDOBACTERIA
(Vicky De Preter, Leuven, Belgium)
**FREE PAPER SESSION: PELVIC FLOOR DISORDERS**

**Chair:** Christoph Beglinger (Basel, Switzerland)
Michael Kamm (Harrow, UK)

10 minutes presentation including 2 minutes discussion

**OP-G-100** MEAL-INDUCED RECTAL TONE MODIFICATION IN IRRITABLE BOWEL SYNDROME: EVIDENCE FOR A DIFFERENT PATTERN IN CONSTIPATION-PREDOMINANT VS. DIARRHEA-PREDOMINANT PATIENTS  
(Michele Di Stefano, Pavia, Italy)  
Co-authors: E. Miceli, A. Missanelli, S. Mazzocchi, P. Tana, G.R. Corazza

**OP-G-101** ENDOGENOUS INHIBITORY PAIN MODULATION AND SOMATIC HYPERSENSITIVITY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS)  
(Clive Wilder-Smith, Bern, Switzerland)  
Co-authors: J. Yap-Robert

**OP-G-102** IS THERE A LINK BETWEEN RECTAL SENSITIVITY AND SYMPTOM SEVERITY IN THE IRRITABLE BOWEL SYNDROME?  
(Iris Posserud, Goteborg, Sweden)  
Co-authors: A. Syrous, L. Lindström, E.S. Björnsson, H. Abrahamsson, M. Simrén

**OP-G-103** QUALITY OF LIFE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHOEA PREDOMINANCE FOLLOWING 12 OR 26 WEEKS OF CILANSETRON TREATMENT: A GENDER ANALYSIS  
(James S. Novick, Towson, USA)  
Co-authors: F. Mearin, H. Mönnikes

**OP-G-104** PREDICTIVE FACTORS OF THE EFFICACY OF SACRAL NERVE STIMULATION FOR THE TREATMENT OF FAECAL INCONTINENCE  
(Francois Mion, Lyon, France)  
Co-authors: H. Damon, I. Serraj, J. Galaup, L. Henry, S. Roman, X. Barth

**OP-G-105** ELECTRICAL STIMULATION AND PELVIC FLOOR MUSCLE TRAINING WITH BIOFEEDBACK IN PATIENTS WITH FAECAL INCONTINENCE: A COHORT STUDY OF 281 PATIENTS  
(Maaike P. Terra, Amsterdam, The Netherlands)  

**OP-G-106** IMPROVING QUALITY OF LIFE OF INCONTINENT PATIENTS WITH INJECTABLE BULKING AGENT  
(Lucia C. C. Oliveira, Rio de Janeiro, Brazil)  
Co-authors: A. Povedano

**OP-G-107** EXPRESSION OF ANTIMICROBIAL PEPTIDES IN EPITHELIA OF CHRONIC ANAL FISTULAS PROTECT FOR SYSTEMIC INFECTION  
(Karlheinz Kiehne, Kiel, Germany)  
Co-authors: A. Finke, G. Brunke, T. Lange, U.R. Fölsch, K.H. Herzig

**OP-G-108** PREVALENCE AND RISK FACTORS FOR ANAL CONDYLOMA AND ANAL DYSPLASIA IN HIV-INFECTED PATIENTS  
(Laurent Abramowitz, Paris, France)  
A1 CONGRESS HALL

08:30-10:30 BETTER INSIGHTS INTO THE NATURAL HISTORY OF IBD - TEN YEARS FOLLOW UP OF THE EUROPEAN COLLABORATIVE POPULATION BASED STUDY IN IBD (EC-IBD)

Chair: Maurice Russel (Enschede, The Netherlands)
Curt Tysk (Örebro, Sweden)

INTRODUCTION
(Boris Vucelic, Zagreb, Croatia)

20 minutes presentation including discussion
EUROPEAN GENOTYPE/PHENOTYPE CORRELATIONS IN IBD
(Lene Riis, Copenhagen, Denmark)
DISEASE OUTCOME IN CROHN’S DISEASE
(Frank Wolters, Maastricht, The Netherlands)
DISEASE OUTCOME IN ULCERATIVE COLITIS
(Bjørn Moum, Fredrikstad, Norway)
HEALTH CARE CONSUMPTION AND COSTS IN IBD
(Reinhold Stockbrügger, Maastricht, The Netherlands)

11:00-12:30 RECENT ADVANCES IN THE PATHOGENESIS OF IBD

Chair: Jean-Frédéric Colombel (Lille, France)
Jack Satsangi (UK)

20 minutes presentation including discussion
RECENT ADVANCES IN THE GENETICS OF IBD
(Severine Vermeire, Leuven, Belgium)
SIGNAL TRANSDUCTION IN IBD: A LOOK INSIDE THE CELLS
(Dan Hommes, Amsterdam, The Netherlands)
MYCOBACTERIA IN IBD: OLD FRIENDS REVISITED?
(Fergus Shanahan, Cork, Ireland)
CONTROL OF INTESTINAL INFLAMMATION BY REGULATORY T CELLS
(Kevin Maloy, Oxford, UK)

12:15-14:00 POSTER SESSIONS - HALL C

12:45-13:35 LUNCH SESSION - L1 IN HALL B: WHEN AND HOW TO PERFORM CHROMOENDOSCOPY
Thierry Ponchon (Lyon, France), Ralf Kiesslich (Mainz, Germany)
14:00-15:30  MANAGEMENT OF HCV/HBV HEPATITIS  
Chair: Antonio Craxi (Palermo, Italy)  
Yves Benhamou (France)  

20 minutes presentation including discussion  
MANAGEMENT OF ACUTE HCV HEPATITIS  
(Heiner Wedemeyer, Hannover, Germany)  
CURRENT TREATMENTS FOR HCV INFECTION  
(Ola Weiland, Stockholm, Sweden)  
CURRENT TREATMENTS OF HBV INFECTION  
(Antonio Craxi, Palermo, Italy)  
FUTURE TREATMENT STRATEGIES FOR HBV AND HCV  
(Francesco Negro, Geneva, Switzerland)  

15:45-17:15  SCREENING FOR CRC  
Chair: Fritz Hagenmüller (Hamburg, Germany)  
Bohumil Seifert (Prague, Czech Republic)  

20 minutes presentation including discussion  
IMPLEMENTATION OF A NATIONAL COLORECTAL CANCER SCREENING PROGRAM:  
THE EAST EXPERIENCE  
(Jaroslaw Regula, Warsaw, Poland)  
IMPLEMENTATION OF A NATIONAL COLORECTAL CANCER SCREENING PROGRAM:  
THE WEST EXPERIENCE  
(Alastair Watson, Liverpool, UK)  
SCREENING OF HNPCC: PROFICIENCY OF REVISED BETHESDA CRITERIA,  
IMMUNOHISTOCHEMISTRY AND MICROSATELLITE INSTABILITY TESTING IN GENERAL POPULATION  
(Antoni Castells, Barcelona, Spain)  
MOLECULAR APPROACHES TO STOOL SCREENING FOR COLORECTAL CANCER  
(David Ahlquist, Rochester, MN, USA)
08:30-10:30 MAASTRICHT-3 GUIDELINES FOR HELICOPACTER PYLORI INFECTION
Chair: Peter Malfertheiner (Magdeburg, Germany)
Ernst Kuipers (Rotterdam, The Netherlands)

30 minutes presentation including discussion
MAASTRICHT GUIDELINES: AN EVOLVING CONCEPT
(Peter Malfertheiner, Magdeburg, Germany)
INDICATIONS FOR HELICOPACTER PYLORI ERADICATION REVISITED
(Colm O’Morain, Dublin, Ireland)
MANAGEMENT OF HELICOPACTER PYLORI INFECTION
(Francis Mégraud, Bordeaux, France)
PREVENTION OF GASTRIC CANCER BY HELICOBACTER PYLORI ERADICATION
(Peter Malfertheiner, Magdeburg, Germany)

11:00-12:30 HCV HEPATITIS IN SPECIAL PATIENT GROUPS
Chair: Michael Manns (Hannover, Germany)
Flemming Bendtsen (Copenhagen, Denmark)

20 minutes presentation including discussion
HIV/HCV CO-INFECTION
(Yves Benhamou, Grenoble, France)
HCV IN CHILDREN
(Deirdre Kelly, UK)
THE PROBLEM OF HCV INFECTION RECURRENCE IN THE TRANSPLANTED PATIENT
(Marina Berenguer, Barcelona, Spain)
HCV IN DIALYSIS PATIENTS
(Christian Trepo, Lyon, France)

12:15-14:00 POSTER SESSIONS - HALL C
12:45-13:35 LUNCH SESSION - L2 IN HALL B: DISINFECTION AND STERILIZATION IN ENDSCOPY
Christiane Neumann (Birmingham, UK), Axel Kruse (Aarhus, Denmark)

14:00-15:30 TREATMENT OF CANCER AT THE OESOPHAGOGASTRIC JUNCTION
Chair: J. J. van Lanschot (Amsterdam, The Netherlands)
Lars Lundell (Goteborg, Sweden)

20 minutes presentation including discussion
THE ROLE OF EUS AND CT SCAN IN STAGING
(Marcin Polkowski, Warsaw, Poland)
NEO-ADJUVANT VERSUS ADJUVANT CHEMOTHERAPY
(E. Van Cutsem, Leuven, Belgium)
PALLIATIVE STRATEGIES
(P.D. Siersema, Rotterdam, The Netherlands)

SURGICAL APPROACH OF CARDIA CARCINOMA
(Stein, Munich, Germany)

ENDOSCOPIC RESECTION OF EARLY CANCER
(Christian Ell, Wiesbaden, Germany)

15:45-17:15 FREE PAPER SESSION: HOT TOPICS IN UPPER GI INTERVENTION

Chair: Simon Jackson (Devon, UK)
Jean Francois Rey (St. Laurent du Var, France)

10 minutes presentation including 2 minutes discussion

OP-G-201 MULTIMODALITY PERCUTANEOUS APPROACH FOR TREATMENT OF VISCERAL ARTERIES ANEURYSMS (VAAS)
(Gianpaolo Carrafiello, Varese, Italy)
Co-authors: D. Laganà, M. Mangini, C. Recaldini, G. Dionigi, G. Mancassola, G. Carcano, R. Caronno, C. Fugazzola

OP-G-202 LONG-TERM CLINICAL RESULTS OF TRANSARTERIAL CHEMOEMBOLIZATION FOLLOWED BY LIVER TRANSPLANTATION
(Irene Bargellini, Pisa, Italy)
Co-authors: C. Vignali, M. Perri, P. Petruzzi, R. Gioni, L. Urbani, C. Bartolozzi

OP-E-203 ASSESSMENT OF CROHN’S DISEASE ACTIVITY USING QUANTITATIVE PERFUSION MR IMAGING
(Sophie Aufort, Montpellier, France)
Co-authors: B. Gallix, M.A. Pierredon-Foulogne, M. Veyrac, P. Blanc, J.M. Bruel

OP-G-204 TRANSJUGULAR PORTO-SYSTEMIC SHUNT WITH EPTFE-COVERED STENT: LONG-TERM CLINICAL RESULTS FROM A MULTICENTER ITALIAN TRIAL
(Irene Bargellini, Pisa, Italy)

OP-G-205 PERFORATED PEPTIC ULCER. A NATIONAL AUDIT
(Sven Adamsen, Copenhagen, Denmark)
Co-authors: J. Bendix, F. Kallehave, P. Wille-Jørgensen, F. Moesgaard, A. Nakano, J. Mainz

OP-E-206 EVALUATION OF ENDOSCOPY OUTCOMES A DECADE AFTER NATIONWIDE INTRODUCTION OF PROTONPUMP INHIBITORS AND GUIDELINES FOR HELICOBACTER PYLORI ERADICATION
(Lieke A.S. Van Kerkhoven, Nijmegen, The Netherlands)
Co-authors: S.J. Van Rijswijck, L.G.M. Van Rossum, A.C.I.T. Tan, J.B.M.J. Jansen

OP-E-207 IS ELASTOGRAPHY GUIDED BY ENDOSCOPIC ULTRASOUND CAN DIFFERENTIATE BENIGN THAN MALIGNANT LYMPH NODES?
(Marc Giovannini, Marseille, France)
Co-authors: L. Hookey, E. Bories, C. Pesenti, G. Monges, V. Moutardier, J. Delpero

OP-E-208 LOCAL INFECTION AFTER PEG PLACEMENT - A PROSPECTIVE STUDY EVALUATING RISK FACTORS
(Dieter Schwab, Erlangen, Germany)
Co-authors: Y. Oeztuerk, R. Heide, A. Nuernberger, W. Hopfer, E.G. Hahn

OP-G-209 RESULTS OF LAPAROSCOPIC LIVER RESECTION. RETROSPECTIVE STUDY ABOUT 56 PATIENTS
(Ibrahim Dagher, Clamart, France)
Co-authors: H. Richa, A. Champault, J. Proske, A. Carloni, N. Helmy, C. Smadja, D. Franco
08:30-10:30  **HEALTH TECHNOLOGY ASSESSMENT IN GASTROINTESTINAL ENDOSCOPY**  
Chair:    Jean Francois Rey (St.Laurent du Var cedex, France)  
          Guido Costamagna (Rome, Italy)  

**20 minutes presentation including discussion**  
**THE CLINICIAN**  
(Guido Costamagna, Rome, Italy)  
**THE ECONOMIST**  
(Americo Cicchetti, Rome, Italy)  
**THE MEDICAL DIRECTOR**  
(Habiba Marwan, London, UK)  
**HTA PROVIDES STRUCTURED, BROAD AND EVIDENCE-BASED INPUT TO DECISION-MAKING**  
(Finn Borlum Kristensen, Copenhagen, Denmark)  
**THE INDUSTRY**  
(Keith Spencer, Birmingham, UK)  

11:00-12:30  **COMMUNITY APPROACH TO DYSPEPSIA**  
Chair:    Mattijs E. Numans (Utrecht, The Netherlands)  
          Lars Agreus (Stockholm, Sweden)  

**20 minutes presentation including discussion**  
**EPIDEMIOLOGY OF DYSPEPSIA IN THE COMMUNITY**  
(Roger Jones, London, UK)  
**COST EFFECTIVENESS ISSUES IN DYSPEPSIA MANAGEMENT**  
(B. Delaney, Birmingham, UK)  
**DETERMINANTS OF VARIANCE IN GUIDELINE DEVELOPMENT**  
(Lars Agreus, Stockholm, Sweden)  
**MULTIDISCIPLINARY GUIDELINE IMPLEMENTATION**  
(Niek J. de Wit, Utrecht, The Netherlands)  

12:15-14:00  **POSTER SESSIONS - HALL C**  
12:45-13:35  **LUNCH SESSION - L3 IN HALL B: MODERN 1ST, 2ND AND 3RD LINE HELICOBACTER PYLORI TREATMENT**  
Francis Megraud (Bordeaux, France), Franco Bazzoli (Bologna, Italy)
14:00-15:30  SELECTED HIGHLIGHTS OF AGA/DDW CHICAGO 2005

Chair: Michael Farthing (London, UK)
       Christoph Beglinger (Basle, Switzerland)

18 minutes presentation including discussion

PANCREATIC DISORDERS
(John Baillie, Durham, USA)

GASTROINTESTINAL CANCER
(Richard Boland, Dallas, USA)

FUNCTIONAL DISORDERS AND ENTERIC GASTROENTEROLOGY
(Michael Camilleri, Rochester, USA)

INFLAMMATORY BOWEL DISEASE
(Stephen Hanauer, Chicago, USA)

ACID-PEPTIC DISORDERS INCLUDING ENDOSCOPY
(Loren Laine, Los Angeles, USA)

15:45-17:15  FREE PAPER SESSION: LATE BREAKING NEWS

10 minutes presentation including 2 minutes discussion

OP-G-353 MAINTENANCE OF REMISSION OVER 1 YEAR IN PATIENTS WITH ACTIVE CROHN’S DISEASE TREATED WITH ADALIMUMAB: RESULTS OF CLASSIC II, A BLINDED, PLACEBO-CONTROLLED STUDY
(W. J. Sandborn, Rochester, USA)

OP-G-354 SPD476, A NOVEL, ONCE-DAILY, HIGH-DOSE MESALAZINE FORMULATION IS WELL TOLERATED AND EFFECTIVE FOR THE INDUCTION OF REMISSION OF MILD-TO-MODERATE ULCERATIVE COLITIS: A PHASE III STUDY
(W. J. Sandborn, Rochester, USA)
Co-authors: G. Lichtenstein, M. Kamm, P. Boddu, N. Gubergrits

OP-G-355 CERTOLIZUMAB PEGOL, A HUMANISED ANTI-TNF PEGYLATED FAB’ FRAGMENT, IS SAFE AND EFFECTIVE IN THE MAINTENANCE OF RESPONSE AND REMISSION FOLLOWING INDUCTION IN ACTIVE CROHN’S DISEASE: A PHASE III STUDY (PRECISE)
(S. Schreiber, Kiel, Germany)

OP-G-356 NOD2/CARD15 FREQUENCY IN CROHN’S DISEASE IN SICILY: AN EPIDEMIOLOGICAL AND GENETIC STUDY
(M. Cottone, Palermo, Italy)
Co-authors: M. Renda, A. Mattaliano, W. Fries, V. Criscuoli, I. Modesto, D. Scimeca, A. Maggio, A. Casà, S. Maisano, F. Moccia, L. Oliva, A. Orlando

OP-G-357 FRUIT AND VEGETABLES INTAKE AND RISK OF GASTRIC CANCER AND OESOPHAGEAL ADENOCARCINOMA IN A EUROPEAN PROSPECTIVE STUDY (EPIC-EURGAST)
(M. E. Numans, Utrecht, The Netherlands)
Co-authors: C. A. Gonzalez, G. Pera, D. Palli, H. Boeing, B. Bueno de Mesquita, H. Siman, K. Overvad, E. Riboli
OP-G-358  CLINICAL EVALUATION OF THE ENDOSCOPIC INCISION AND SUBMUCOSAL DISSECTION FOR THE TREATMENT OF GASTRIC NEOPLASMS
(Y. S. Kim, Seoul, South Korea)

OP-G-359  DIAGNOSIS FROM NUCLEUS PATTERN IMAGE ON COLORECTAL TUMORS WITH NORMAL MAGNIFIED CHROMO-ENDOSCOPY
(M. Tabuchi, Tokyo, Japan)
Co-authors: Y. Katoh, J. Kitayama

OP-G-360  GASTRIC EMPTYING AND INTRAGASTRIC BALLOON IN OBESE PATIENTS
(T. Cilluffo, Ancona, Italy)
Co-authors: P. Bonazzi, M. D. Petrelli, I. Lorenzini, E. Peruzzi, A. Nicolai, R. Galeazzi

AUDITORIUM 15

08:30-10:30  PREVENTION OF OESOPHAGEAL ADENOCARCINOMA
Chair: Rebecca Fitzgerald (Cambridge, UK)
       Jesper Lagergren (Stockholm, Sweden)

20 minutes presentation including discussion
EPIDEMIOLOGY OF BARRETT’S OESOPHAGUS AND OESOPHAGEAL ADENOCARCINOMA
(Jesper Lagergren, Stockholm, Sweden)
“Rising Star” Lecture:
MOLECULAR PATHOGENESIS AND RATIONALE FOR CHEMOPREVENTION
(Rebecca Fitzgerald, Cambridge, UK)
ENDOSCOPIC TREATMENT OF EARLY NEOPLASIA (PDT, EMR and APC)
(Andrea May, Wiesbaden, Germany)
IS SURVEILLANCE OF BARRETT’S OESOPHAGUS WORTHWHILE? – YES
(M. Robaszkiewic, Brest, France)
IS SURVEILLANCE OF BARRETT’S OESOPHAGUS WORTHWHILE? – NO
(R. Playford, Cambridge, UK)

11:00-12:30  PATHOGENESIS AND TREATMENT OF OBESITY
Chair: J. W. Greve (Maastricht, The Netherlands)
       Eric Näslund (Stockholm, Sweden)

20 minutes presentation including discussion
PATHOGENESIS AND MEDICAL TREATMENT OF OBESITY
(Lisbet Mathus-Vliegen, Amsterdam, The Netherlands)
ENDOSCOPIC TREATMENT OF OBESITY
(Jean-Marc Dumonceau, Geneva, Switzerland)
SURGICAL TREATMENT WITH LAPAROSCOPIC GASTRIC BY-PASS
(Eric Näslund, Stockholm, Sweden)
THE EFFECT OF SURGICALLY INDUCED WEIGHT LOSS ON CYTOKINES, ADIPOKINES AND ACUTE PHASE PROTEINS
(J. W. Greve, Maastricht, The Netherlands)

12:15-14:00  POSTER SESSIONS - HALL C

12:45-13:35  LUNCH SESSION - L4 IN HALL B: NON-H PYLORI NON-NSAID PEPTIC ULCERS
Ernst Kuipers (Rotterdam, The Netherlands), Klaus Mönkemüller (Magdeburg, Germany)

14:00-15:30  HORMONES, HELICOBACTER PYLORI AND INFLAMMATION
Chair: Colm O’Morain (Dublin, Ireland)
Leif Percival Andersen (Copenhagen, Denmark)

20 minutes presentation including discussion
THE GASTROPANEL: IS IT POSSIBLE TO ASSESS THE TYPE OF GASTRITIS SEROLOGICALLY?
(Penti Sipponen, Espo, Finland)
IMPORTANCE OF LEPTIN AND GHRELIN MODULATION BY HELICOBACTER PYLORI
(Chuka Nwokolo, Coventry, UK)
ROLE OF GASTRIN IN HELICOBACTER PYLORI-INDUCED GASTRIC ADENOCARCINOMA
(Sue Watson, Nottingham, UK)
GASTRIN AND COLONIC NEOPLASIA
(Colm O’Morain, Dublin, Ireland)

15:45-17:15  LIVER DISEASE IN THE POST-GENOMIC ERA
Chair: Massimo Levrero (Rome, Italy)
Norifumi Kawada (Osaka, Japan)

20 minutes presentation including discussion
BIOTECHNOLOGIES FOR GENOMICS AND TRANSCRIPTOMS
(Karsten Brand, Heidelberg, Germany)
BIOTECHNOLOGIES FOR PROTEOMICS
(Dan Bach Kristensen, Copenhagen, Denmark)
GENETIC SIGNATURES IN CHRONIC LIVER DISEASES
(Christian Strassburg, Hannover, Germany)
GENETIC SIGNATURES IN LIVER CANCER
(Massimo Levrero, Rome, Italy)
ROOM M1 IN HALL C

08:30-10:30 FREE PAPER SESSION: ENDOSCOPIC MUCOSAL RESECTION

Chair: Horst Neuhaus (Duesseldorf, Germany)
Paul Fockens (Amsterdam, The Netherlands)

INTRODUCTION (30 minutes)
(Horst Neuhaus, Duesseldorf, Germany)

10 minutes presentation including 2 minutes discussion

OP-E-109 ENDOSCOPIC SCREENING OF EARLY GASTRIC CANCER WITH AUTOFLUORESCENCE VIDEOENDOSCOPY
(Noriya Uedo, Osaka, Japan)
Co-authors: H. Iishi, Y. Takeuchi, K. Higashino, R. Ishihara, M. Tatsuta

OP-E-110 EX VIVO STUDY OF ENDO-CYTOSCOPY IN THE GASTROINTESTINAL TRACT TO DETERMINE THE BEST CONDITION FOR THE CLINICAL USE
(Shinya Kodashima, Tokyo, Japan)
Co-authors: M. Fujishiro, K. Takubo, M. Kammori, S. Nomura, N. Kakushima, K. Kobayashi, A. Tateishi, N. Yahagi, M. Kaminishi, M. Omata

OP-G-111 ENDOSCOPIC MUCOSAL RESECTION OF EARLY CANCER AND HIGH-GRADE DYSPLASIA IN BARRETT’S ESOPHAGUS IN 35 PATIENTS: RESULTS AFTER FIVE YEARS FOLLOW UP
(Thierry L Barrioz, Poitiers, France)
Co-authors: F. Kaffy, E. Blanchet, J. Gougeon, P. Babin

OP-G-112 LONG-TERM OUTCOME AFTER ENDOSCOPIC MUCOSAL RESECTION FOR EARLY GASTRIC CANCER IN KOREA
(Hwoon-Yong Jung, Seoul, South Korea)

OP-E-113 THE EFFICACY AND SAFETY OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR EARLY GASTRIC TUMORS IN HIGH-AGE PATIENTS
(Naomi Kakushima, Tokyo, Japan)
Co-authors: M. Fujishiro, S. Kodashima, K. Kobayashi, A. Tateishi, K. Ogura, N. Yahagi, M. Omata

OP-E-114 CLINICAL IMPACT OF ESD IN THE MANAGEMENT OF EARLY GASTRIC CANCER
(Ichiro Oda, Tokyo, Japan)

OP-E-115 A NOVEL MULTIBAND MUCOSECTOMY DEVICE FACILITATES CIRCUMFERENTIAL ENDOSCOPIC MUCOSAL RESECTION IN BARRETT’S ESOPHAGUS WITH EARLY MALIGNANT CHANGES
(Stefan Seewald, Hamburg, Germany)
Co-authors: S. Omar, S. Groth, T.L. Ang, F. Dy, U. Seitz, Y. Zhong, F. Thonke, S. Schroeder, N. Soehendra

OP-E-116 MULTI-BAND MUCOSECTOMY: A NEW AND EASY TECHNIQUE FOR WIDESPREAD MUCOSAL RESECTION. A FEASIBILITY STUDY OF 50 PROCEDURES IN PATIENTS WITH BARRETT’S ESOPHAGUS
(Femke P Peters, Amsterdam, The Netherlands)
OP-E-117  ENDOSCOPIC TREATMENT OF SEVERE DUODENAL POLYPOSIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
(Driffa Moussata, Pierre Bénite, France)

11:00-12:30  EUS GUIDED ENDOTHERAPY
Chair: Jaques Deviere (Brussels, Belgium)
       Peter Villman (Copenhagen, Denmark)

20 minutes presentation including discussion
PANCREATIC PSEUDOCYSTS
(Marco Bruno, Amsterdam, The Netherlands)
PANCREATICO-GASTROSTOMY
(Jaques Devière, Brussels, Belgium)
DRAINAGE OF PELVIC ABSCESSES
(Marc Giovannini, Marseille, France)
BILIARY DRAINAGE
(Annette Fritscher-Ravens, London, UK)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L5 IN HALL B: PORTAL HYPERTENSION: NON-RESPONDERS TO PRIMARY AND SECONDARY PROPHYLAXIS
Jaime Bosch (Barcelona, Spain), Andrew K. Burroughs (London, UK)

14:00-15:30  MOLECULAR PORTRAIT OF COLORECTAL CANCER
Chair: Stefan Lindgren (Sweden)
       David Kerr (Oxford, UK)

20 minutes presentation including discussion
MOLECULAR PORTRAIT OF COLORECTAL CANCER
(Mario Dicato, Luxembourg, Luxembourg)
FROM THE APC/MIN MUSE MODEL TO GENES AND MOLECULES
(Makoto Mark Taketo, Kyoto, Japan)
CANCER CELL GROWTH: POTENTIAL NEW MOLECULAR TARGETS TO DISRUPT
(Dan Aderka, Tel-Hashomer, Israel)
GENOMIC PROFILING OF COLORECTAL CANCER AND IMPLICATIONS FOR TREATMENT
(David Kerr, Oxford, UK)
FREE PAPER SESSION: NEW DIAGNOSTIC AND TREATMENT OF COLORECTAL CANCER

Chair: Bernard Levin (Houston, USA)
Freddy Penninckx (Leuven, Belgium)

10 minutes presentation including 2 minutes discussion

OP-G-210 DIAGNOSIS OF EARLY COLORECTAL NEOPLASMS USING MAGNIFYING COLONOSCOPY
(Kashida Hiroshi, Yokohama, Japan)
Co-authors: S. Kudo, K. Sasajima, K. Ohtsuka, F. Yamamura, J. Tanaka

OP-E-211 COLONOSCOPY USING HIGH RESOLUTION ENDOSCOPY, AUTOFLUORESCENCE IMAGING AND NARROW BAND IMAGING: A FEASIBILITY STUDY
(Evelien Dekker, Amsterdam, The Netherlands)
Co-authors: M.A. Kara, J. Bergman, J. Hardwick, J. Offerhaus, P. Fockens

OP-E-212 MAGNIFYING ENDOSCOPY COMBINED WITH NARROW BAND IMAGING (NBI) SYSTEM FOR COLORECTAL NEOPLASM
(Hisashi Hosaka, Tokyo, Japan)

OP-E-213 OPTICAL BIOPSY OF COLORECTAL LESIONS USING ENDO-CYTOSCOPY
(Keita Sasajima, Yokohama, Japan)
Co-authors: H. Inoue, H. Kashida, E. Hidaka, H. Kawachi, J. Tanaka, S. Kudo

OP-E-214 HIGH RESOLUTION CHROMOSCOPY VERSUS STANDARD COLONOSCOPY: A PROSPECTIVE, RANDOMIZED, PARALLEL-GROUP STUDY
(Emmanuel Coron, Nantes, France)

OP-E-215 COST-EFFECTIVE DETECTION OF POLYPS WITH CT-COLONOGRAPHY: A PROSPECTIVE COMPARISON WITH COLONOSCOPY
(Regnar B. Arnesen, Hillerød, Denmark)
Co-authors: B. Ginnerup Pedersen, P. Poulsen, E. Benzon, S. Adamsen, S. Laurberg, O. Hart Hansen

OP-G-216 POPULATION BASED COLORECTAL SCREENING FOR COLORECTAL CANCER: IMPACT ON LATER NEED FOR NON-SCREENING DISTAL GASTROINTESTINAL ENDOSCOPIES
(Espen Thiis-Evensen, Oslo, Norway)
Co-authors: B. Seip, M.H. Vatn, G.S. Hoff

OP-G-217 MESORECTAL GRADES PREDICT RECURRENCE AFTER CURATIVE RESECTION FOR RECTAL CANCER
(Sushil Maslekar, Cottingham, UK)
Co-authors: A. Sharma, A. MacDonald, J. Gunn, J.R.T. Monson, J.E. Hartley

P-G-218 ENDOSCOPIC TREATMENT OF LATERALLY SPREADING TUMORS OF THE COLORECTUM
(Kashida Hiroshi, Yokohama, Japan)
Co-authors: S. Kudo, Y. Omae, K. Sasajima, F. Yamamura, K. Ohtsuka
FREE PAPER SESSION: VIRAL HEPATITIS

Chair: Marina Berenguer (Barcelona, Spain)
       Michael Manns (Hannover, Germany)

INTRODUCTION (10 minutes)
Michael Manns (Hannover, Germany)

10 minutes presentation including 2 minutes discussion

OP-G-118  CHRONIC HEPATITIS C - NO INFLUENCE OF A DIFFERENT ACTIVITY STATUS
ON THE QUALITY OF LIFE
(Manfred Wiese, Leipzig, Germany)
Co-authors: K. Dames

OP-G-119  THE ROLE OF GENOTYPE AND PRECORE/BASAL CORE PROMOTER MUTATIONS
OF HEPATITIS B IN PATIENTS WITH ACUTE EXACERBATION OF CHRONIC HEPATITIS B
(W. L. Tsai, Kaohsiung, Taiwan)

OP-G-120  SIGNIFICANCE OF MEASURING BLOOD FERRITIN LEVELS IN PATIENTS WHO BECOME
HCV-RNA NEGATIVE AFTER FOUR WEEKS OF IFN AND RIB TREATMENT FOR CHRONIC
HEPATITIS C
(Masahisa Takase, Tokyo, Japan)
Co-authors: K. Abe, E. Murashima, K. Ueda, T. Katagami, M. Miyaoka

OP-G-121  IL-1B & MDR1 GENETIC POLYMORPHISM AND SUSTAINED RESPONSE IN CHRONIC
HEPATITIS C (1B) TO 12 MONTH INTERFERON-ALPHA2B AND RIBAVIRIN BITHERAPY
(Evgeny L. Nikonov, Moscow, Russian Federation)
Co-authors: A. Rogachikova, Y. Rogachikov

OP-G-122  BIOPSYCHOSOCIAL PREDICTORS OF FATIGUE IN PATIENTS WITH CHRONIC HEPATITIS C
(Winfried Häuser, Saarbrücken, Germany)
Co-authors: P. Schiedermair, D. Grandt

OP-G-123  A 24-WEEK CLEVUDINE THERAPY SHOWED POTENT ANTIVIRAL ACTIVITY AND
NORMALIZATION OF ALT LEVELS WITHOUT VIRAL BREAKTHROUGH IN HBEAG(-)
CHRONIC HEPATITIS B PATIENTS
(Byung Chul Yoo, Seoul, South Korea)
Co-authors: J. Kim, T. Kim, K. Koh, S. Um, Y. Kim, K. Lee, C. Chon, B. Han, B. Kim, H.
Kim, S. Ryu, K. Byun, J. Han, S. Hwang, Y. Kim, K. Yoo, Y. Lee, H. Lee, M. Cho, S. Choi,
Jeong, J. Choi, H. Yoo, H. Lee

OP-G-124  STUDIES ON TISSUE EXPRESSION OF HEPATITIS C VIRUS ANTIGENS IN BIOPSY
SPECIMENS OF PATIENTS WITH CHRONIC HEPATITIS TYPE C
(Agnieszka Adamek, Poznan, Poland)
Co-authors: A. Adamek, J. Seidel, W. Biczysko, J. Wysocki, R. Spachacz, J. Juszczyk,
M. Zabel

OP-G-126  THE EFFECT OF PEG-IFN THERAPY ON SERUM FIBROSIS MARKERS- TGF-BETA,
HYALURONIC ACID AND PROCOLLAGEN-III-PEPTID LEVELS- IN PATIENTS WITH
CHRONIC HEPATITIS C
(Alajos Par, Pecs, Hungary)
Co-authors: G. Par, T. Berki, P. Balogh, A. Miseta, B. Hunyady
OP-G-127  OCCULT HEPATITIS B VIRUS INFECTION IN PATIENTS WITH SEVERE FIBROSING CHOLESTATIC HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION  
(Ivo W Graziadei, Innsbruck, Austria)  
Co-authors: K. Nachbaur, B. Wimmer, G. Egg, R. Margreiter, W. Vogel

OP-G-128  VIRAL CLEARANCE, LAMIVUDINE RESISTANT MUTANTS APPEARANCE AND HBV REACTIVATION IN THE PATIENTS WITH CHRONIC HEPATITIS B (CHB) IN END-STAGE RENAL DISEASE (ESRD) TREATED WITH LAMIVUDINE  
(Dmytro E Telehin, Lviv, Ukraine)  
Co-authors: P. Kondrat, I. Tychka, S. Antonenko, M. Liulchuk, M. Kryzhanska, R. Hritsko

11:00-12:30  NEW MODELS AND MECHANISMS FOR ALCOHOL-MEDIATED LIVER TOXICITY  
Chair: Magnus Ingelmann-Sundberg (Stockholm, Sweden)  
Thomas Badger (Little Rock, USA)

20 minutes presentation including discussion

ALCOHOLIC-MEDIATED LIVER DAMAGE AND NUTRITION  
(Thomas Badger, Little Rock, USA)

EPIDEMIOLOGY OF ALCOHOLIC LIVER DISEASE; GENDER DIFFERENCES  
(Eric Christensen, Copenhagen, Denmark)

THE IMPACT OF ALCOHOL CONSUMPTION IN PATIENTS WITH NAFLD/NASH AND THE METABOLIC SYNDROME  
(Helmut Karl Seitz, Heidelberg, Germany)

IMMUNOTOXICITY AND GENETIC SUSCEPTIBILITY AS COFACTORS IN ALCOHOLIC LIVER DISEASE  
(Emanuele Albano, Pari, Italy)

12:15-14:00  POSTER SESSIONS - HALL C

12:45-13:35  LUNCH SESSION - L6 IN HALL B: IS CIRRHOSIS REVERSIBLE?  
Desmet Valeer (Herverlee, Belgium), Fabio Marra (Florence, Italy)

14:00-15:30  FREE PAPER SESSION: CONTROVERSESIES IN PANCREATITIS  
Chair: Jaques Deviere (Brussels, Belgium)  
Markus Lerch (Greifswald, Germany)

10 minutes presentation including 2 minutes discussion

OP-G-168  ANTIBIOTIC PROPHYLAXIS IN ACUTE NECROTISING PANCREATITIS: METHODOLOGICAL QUALITY OF RANDOMISED CONTROLLED TRIALS IN RELATION TO OUTCOME  
(Annemarie Charlotte C De Vries, Utrecht, The Netherlands)  
Co-authors: M.G.H. Besselink, C.I.B. Van de Kraats, E. Buskens, K.J. Van Erpecum, H.G. Gooszen

OP-G-169  SMOKING IS ASSOCIATED WITH ACUTE PANCREATITIS  
(Bjorn Lindkvist, Malmoe, Sweden)  
Co-authors: S. Appelros, G. Berglund, J. Manjer, A. Borgstrom
OP-G-170  IS THE ATLANTA-CLASSIFICATION SUFFICIENT IN DESCRIBING COLLECTIONS IN ACUTE NECROTIZING PANCREATITIS?
(Hjalmar C Van Santvoort, Utrecht, The Netherlands)
Co-authors: M.H.G. Besselink, T.L. Bollen, M.S. Van Leeuwen, H.G. Gooszen

OP-G-171  THE CLINICAL COURSE OF CHRONIC Pancreatitis IN CHILDREN ASSOCIATED WITH N34S-SPINK1 MUTATION
(Grzegorz Oracz, Warsaw, Poland)
Co-authors: B. Oralewska, A. Sobczynska-Tomaszewksa, M. Teisseyre, D. Bak, J. Socha, J. Bal

OP-G-172  WHAT IS THE NATURAL HISTORY OF CYSTIC DYSTROPHY OF ABERRANT PANCREAS (CDAP)?
(Vinciane Rebours, Clichy, France)
Co-authors: P. Lévy, M. Vullierme, A. Sauvanet, D. O’Toole, A. Aubert, L. Palazzo, F. Maire, P. Hammel, V. Vilgrain, J. Belghiti, P. Ruszniewski

OP-G-173  A PROSPECTIVE RANDOMISED TRIAL OF ENDOSCOPIC VERSUS SURGICAL PANCREATIC DUCT DRAINAGE IN CHRONIC PANCREATITIS: CLINICAL OUTCOME AND EXO- AND ENDOCRINE FUNCTION
(Djuna L Cahen, Amsterdam, The Netherlands)

OP-G-174  IMPACT OF REDUCING DUODENO-BILIARY REFLUX ON BILIARY STENT PATENCY: A PROSPECTIVE RANDOMIZED STUDY OF A BILIARY STENT WITH AN ANTI-REFLUX VALVE
(Kulwinder S Dua, Milwaukee, USA)
Co-authors: N. Reddy, G. Rao, R. Banerjee

OP-E-175  COMMON BILE DUCT STRUCTURES DUE TO CHRONIC PANCREATITIS MANAGED BY SELF-EXPANDABLE METAL STENTS (SEMS): RESULTS OF A LONG-TERM FOLLOW-UP STUDY
(Andrea Trincali, Rome, Italy)

OP-G-176  CHRONIC HELICOBACTER PYLORI INFECTION DOES NOT INFLUENCE THE RISK TO DEVELOP PANCREATIC CANCER
(Björn Lindkvist, Malmö, Sweden)
Co-authors: A. Borgström, J. Manjer, D. Johansen

15:45-17:15  MOLECULAR BASIS OF PANCREATITIS
Chair: David C. Whitcomb (Pittsburgh, USA)
Jörgen Larsson (Stockholm, Sweden)

20 minutes presentation including discussion
MONOGENIC AND COMPLEX TRAIT CAUSES OF PANCREATITIS
(David C. Whitcomb, Pittsburgh, USA)
GENO-PHENOTYPE CORRELATION IN EUROPE
(Michael Raraty, Liverpool, UK)
GENETICS OF IDEOPATHIC PANCREATITIS
(Heiko Witt, Berlin, Germany)
THE FUNCTIONAL ROLE OF PROTEASE MUTATIONS IN Pancreatitis
(Markus Lerch, Greifswald, Germany)
FREE PAPER SESSION: HELICOBACTER PYLORI PATHOGENESIS

Chair: 
Yoshio Yamaoka (Horston, USA)
Torkel Wadström (Lund, Sweden)

INTRODUCTION (10 minutes)
Torkel Wadström (Lund, Sweden)

10 minutes presentation including 2 minutes discussion

OP-G-129 EVOLUTION OF THE HELICOBACTER PYLORI CAG PATHOGENICITY ISLAND (PAI) BY PARTIAL DELETION IN STRAINS FROM RELATIVES OF GASTRIC CANCER PATIENTS
(John C. Atherton, Nottingham, UK)
Co-authors: R.H. Argent, R.J. Thomas, E.M. El-Omar

OP-G-130 ASSOCIATION BETWEEN BACTERIAL sabA STATUS AND PRESENCE OF ANTI-LEWIS X ANTIBODY IN PATIENTS WITH HELICOBACTER PYLORI INFECTION
(Fumika Nakasato, Hirosaki, Japan)
Co-authors: S. Fukuda, T. Shimoyama, K. Danjo, T. Yoshimura, A. Munakata

OP-G-131 INTERACTION OF HOST GASTRIC SIALYL-LEWIS X AND H. PYLORI SABA ENHANCES THE H. PYLORI DENSITY IN PATIENTS LACKING THE GASTRIC LEWIS B ANTIGEN
(Bor-Shyang Sheu, Tainan, Taiwan)
Co-authors: S. Odenbreit, K. Hung, H. Yang, J. Wu

OP-G-132 AN IMPORTANT NEW DETERMINANT OF VACA TOXICITY, INTERMEDIATE REGION TYPE 1 (I1), IS PREVALENT AMONG CHINESE HELICOBACTER PYLORI STRAINS
(John Atherton, Nottingham, UK)
Co-authors: J. Rhead, D. Letley, Y. Zhang

OP-G-133 HELICOBACTER PYLORI LIPOPOLYSACCHARIDE INDUCES INDUCIBLE NITRIC OXIDE SYNTHASE (iNOS) AND TOLL-LIKE RECEPTOR (TLR) 2 THROUGH TLR4-ERK-NFkB PATHWAY IN MURINE GASTRIC EPITHELIAL CELLS
(Kaname Uno, Sendai, Japan)

OP-G-134 DECREASED EXPRESSION OF CYCLOOXYGENASE-2 AND INDUCIBLE NITRIC OXIDE SYNTHASE 1 YEAR AFTER ERADICATION OF HELICOBACTER PYLORI
(Hyung Jun Kim, Seoul, South Korea)

OP-G-135 UPREGULATION OF TISSUE INHIBITORS OF METALLOPROTEINASES (TIMPS) - 1, 3 AND 4 IN THE GASTRIC MUCOSA IN H. PYLORI INFECTION
(Suhail Ahmed, Liverpool, UK)
Co-authors: K. Bodger, L. Pasmany, L. Khan, A. Varro, G. Dockray

OP-G-136 COORDINATE CELL-SURFACE EXPRESSION OF MATRIX METALLOPROTEINASES AND THEIR INHIBITORS COUPLED WITH AN INDUCTION OF HOST CELLULAR IMMUNE RESPONSE AGAINST H. PYLORI IN PROGRESSION OF H. PYLORI-ASSOCIATED GASTRITIS
(Shohei Koyama, Tsukuba-City, Japan)

OP-G-137 GASTRIC MUCOSAL AND CIRCULATING GHRELIN: INFLUENCE OF HELICOBACTER PYLORI INFECTION, CORPUS INFLAMMATION AND GASTRIN
(Suhail Ahmed, Liverpool, UK)
Co-authors: K. Bodger, A. Bassi, H. Kamarova, L. Pazmany
OP-G-138  THE EFFECT OF HELICOBACTER PYLORI ERADICATION ON GASTRIC GHRELIN EXPRESSION, APPETITE, AND BODY MASS INDEX IN PATIENTS WITH PEPTIC ULCER (Jk Ryu, Sungnam-Si, South Korea)
Co-authors: H.W. Baik, Y.M. Park, J.S. Park, E.J. Jang, S.J. Park

OP-G-139  EFFECT OF HELICOBACTER PYLORI INFECTION AND ERADICATION THERAPY ON INTERLEUKIN-6 LEVELS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (Melih Ozel, Istanbul, Turkey)
Co-authors: L. Demirturk, A. Aydogdu, M. Gultepe, Y. Yazgan, N. Imirzalioglu, A. Kemal Gurbuz, Y. Narin

11:00-12:30  PANCREATIC CANCER: FROM GENE TO THERAPY
Chair: John Neoptolemos (Liverpool, UK)
       Anders Borgström (Malmö, Sweden)

20 minutes presentation including discussion
SIGNALLING PATHWAYS IN PANCREATIC CANCER
(Stephan Hahn, Bochum, Germany)
VACCINATION IN PANCREATIC CANCER
(Gustav Gaudernack, Norway)
PHASE II TRIALS IN GENE AND ANTIBODY THERAPY
(Paula Ghaneh, Liverpool, UK)
SOMATOSTATIN RECEPTOR GENE TRANSFER FOR PANCREATIC CANCER THERAPY
(Louis Buscail, Toulouse, France)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L7 IN HALL B: NEUROENDOCRINE TUMORS: PAST, PRESENT AND FUTURE
Ursula Plöckinger (Berlin, Germany), Dermot O’Toole (Paris, France)

14:00-15:30  FREE PAPER SESSION: PORTAL HYPERTENSION
Chair: Alexander Gerbes (Munich, Germany)
       Carlos Merkel (Padua, Italy)

“Rising Star” Lecture including 15 minutes discussion
METABOLIC CONSEQUENCES OF AN UPPER GASTROINTESTINAL BLEED IN PATIENTS WITH CIRRHOSIS OF THE LIVER
(Steven W.M. Olde Damink, Maastricht, The Netherlands)

10 minutes presentation including 2 minutes discussion
OP-G-177  THE EXPRESSION OF E-SELECTIN, P-SELECTIN AND ICAM-1 IN THE PERITONEAL MICROVESSELS OF PORTAL HYPERTENSIVE AND CIRRHOTIC RATS TREATED WITH OR WITHOUT PEGINTERFERON-ALPHA2A
(Anja Geerts, Ghent, Belgium)
Co-authors: K. Cheung, E. Vanheule, H. Van Vlierberghe, M. De Vos, I. Colle
OP-G-178  INTRAVITAL MICROSCOPY STUDY OF THE INFLUENCE OF SOMATOSTATIN ON LIVER MICROCIRCULATION IN AN EXPERIMENTAL MOUSE MODEL OF CIRRHOSIS  
(Eline Vanheule, Ghent, Belgium)  
Co-authors: A.M. Geerts, H. Reynaert, H. Van Vlierberghe, A. Geerts, M. De Vos, I. Colle

OP-G-179  DIAGNOSTIC VALUE OF MDCT ESOPHAGOGRAPHY FOR ESOPHAGEAL VARICES IN PATIENTS WITH CIRRHOSIS: A PROSPECTIVE STUDY COMPARING WITH ENDOSCOPY  
(Yoon Jun Kim, Seoul, South Korea)  
Co-authors: S. Kim, K. Choi, Y. Chung, B. Choi, B. Kim

OP-G-180  PROGNOSTIC FACTORS OF LONG TERM SURVIVAL IN CIRRHOTIC PATIENTS UNDERWENT TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) FOR PORTAL HYPERTENSIVE COMPLICATIONS: RESULTS OF MULTIVARIATE ANALYSES  
(Adele D’Antoni, Palermo, Italy)  
Co-authors: A. Luca, R. Miraglia, M. Milazzo, S. Caruso, B. Gridelli

OP-G-181  THE EFFECT OF CARVEDILOL ON PORTAL HYPERTENSION DEPENDS ON THE SEVERITY OF ENDOTHELIAL DYSFUNCTION AND INFLAMMATORY CHANGES  
(T. Svestka, Prague, Czech Republic)  

OP-G-182  LONG-TERM RESULTS OF BALLOON-OCCCLUDED RETROGRADE TRANSVENOUS OBLITERATION (B-RTO) FOR FUNDAL VARICES AND ENCEPHALOPATHY  
(Kazuhiko Oho, Kurume, Japan)  
Co-authors: M. Kumamoto, Y. Morita, K. Emori, O. Tsuruta, A. Toyonaga, M. Sata

OP-G-183  OUTCOMES OF BALLOON-OCCCLUDED RETROGRADE TRANSVENOUS OBLITERATION FOR GASTRIC VARICEAL BLEEDING  
(Yong S. Choi, Seoul, South Korea)  
Co-authors: S.W. Baik, M.S. Choi, K.C. Koh, J.H. Lee, B.C. Yoo, J. Kim, J.C. Rhee

15:45-17:15  FOOD ALLERGY: FROM INFANCY TO ADULTHOOD  
Chair: Steffen Husby (Odense, Copenhagen)  
Mike Thomson (UK)

20 minutes presentation including discussion
DEFINITIONS AND PATHOGENESIS OF FOOD ALLERGY  
(Steohan Strobel, Plymouth, UK)

NATURAL HISTORY OF FOOD ALLERGY FROM INFANCY TO ADOLESCENCE  
(Susanne Halken, Sønderborg, Denmark)

EOSINOPHILIC OESOPHAGITIS AND FOOD ALLERGY, WHAT IS THE LINK?  
(Mike Thomson, UK)

FOOD ANAPHYLAXIS: PREVALENCE, DIAGNOSIS, MANAGEMENT  
(Stephan Bischoff, Stuttgart, Germany)
ROOM M4 IN HALL C

08:30-10:30  INTESTINAL PSEUDO-OBSTUCTION
Chair:       Per Hellstrom (Stockholm, Sweden)
             Jüri Rumessen (Copenhagen, Denmark)

20 minutes presentation including discussion
NOS AND CAJAL CELL ALTERATIONS
(Jean-Marie Vanderwinden, Brussels, Belgium)
INFLAMMATORY ENTERIC NEUROPATHIES AND MYOPATHIES
(Roberto De Giorgio, Bologna, Italy)
MEDICAL TREATMENT
(Anton V. Emmanuel, Harrow, UK)
FUNCTIONAL TESTS IN PSEUDO-OBSTUCTION
(Andre Smout, Utrecht, The Netherlands)
THE INTEGRATED APPROACH TO MANAGEMENT
(Michael Kamm, Harrow, UK)

11:00-12:30  FREE PAPER SESSION: OESOPHAGEAL NEOPLASIA: PROGNOSIS
             AND TREATMENT
Chair:       Rebecca Fitzgerald (Cambridge, UK)
             Jesper Lagergren (Stockholm, Sweden)

10 minutes presentation including 2 minutes discussion
OP-G-152  PROGNOSTIC VALUE OF ANGIogenic FACTORS IN RESECTED GASTRIC CANCER
          (Antonio Soriano-Izquierdo, Barcelona, Spain)
          Co-authors: O. Vidal, J.P. Metges, A. Palacín, J.I. Elizalde, C. Fondevila, A. Volant,
                      A. Castells, J.M. Piqué, M. Pera

OP-G-153  STATINS INHIBIT PROLIFERATION OF OESOPHAGEAL ADENOCARCINOMA CELLS
          (Olorunseun O Ogunwobi, Norwich, UK)
          Co-authors: I.L.P. Beales

OP-G-154  NSAIDS INDUCE SYNTHESIS OF A PEROxisome PROLIFERATOR ACTIVATED
          RECEPTOR A (PPARA) LIGAND: A POSSIBLE MECHANISM BY WHICH NSAIDS
          PREVENT OESOPHAGEAL CANCER
          (Anthony Shonde, Nottingham, UK)
          Co-authors: A.J. Bennett, C.J. Hawkey

OP-G-155  PH ADJUSTED AGGRESSIVE ACID SUPPRESSION IS SUPERIOR TO THE STANDARD ONE
          REGARDING INFLAMMATION BUT NOT APOPTOSIS RELATED PROTEINS AND CELL
          PROLIFERATION IN PATIENTS WITH BARRETT’S OESOPHAGUS
          (Konstantina D. Paraskeva, Athens, Greece)
          Co-authors: J.A. Karagiannis, N.N. Giannakou, N. Mathou, G. Skoulidakis, P. Isaacs

OP-G-156  ORAL ITRIGLUMIDE, A SPECIFIC CCK2/GASTRIN RECEPTOR ANTAgONIST, INHIBITS
          GASTRIN STIMULATED GASTRIC ACID SECRETION IN HUMANS
          (Christoph Beglinger, Basle, Switzerland)
          Co-authors: L. Degen, S. Schroller, M. D’Amato, S. Persiani
OP-G-157  ADMINISTRATION OF VITAMIN C IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS ENHANCES CHEMOSENSITIZATION IN OESOPHAGEAL CANCER CELLS IN VITRO
(Mohamed M. M. Abdel-Latif, Dublin, Ireland)
Co-authors: D. Kelleher, J.V. Reynolds

OP-G-158  HEALTH ECONOMIC EVALUATION OF STENT OR ENDOLUMINAL BRACHYTHERAPY AS PALLIATIVE STRATEGY IN PATIENTS WITH INCURABLE CANCER OF THE ESOPHAGUS AND GASTRO-ESOPHAGEAL JUNCTION. RESULTS OF A RANDOMIZED CLINICAL TRIAL
(Urs Wenger, Stockholm, Sweden)
Co-authors: E. Johnsson, H. Bergquist, J. Nyman, H. Ejnell, J. Lagergren, M. Ruth, L. Lundell

OP-G-159  RADICAL ENDOSCOPIC RESECTION FOR COMPLETE REMOVAL OF BARRETT’S ESOPHAGUS WITH HIGH-GRADE INTRAEPITHELIAL NEOPLASIA AND/OR EARLY CANCER; A PROSPECTIVE STUDY IN 39 PATIENTS
(Femke P. Peters, Amsterdam, The Netherlands)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L8 IN HALL B: MANAGEMENT OF DIFFICULT CONSTIPATED PATIENTS
Anne Maire Leroi (Rouen, France), Paul Enck (Tübingen, Germany)

14:00-15:30  FREE PAPER SESSION: UPPER GI MALIGNANCY – SCREENING, DIAGNOSIS AND FOLLOW-UP
Chair: Mattijs Numas (Utrecht, The Netherlands)
Bohumil Seifert (Prague, Czech Republic)

10 minutes presentation including 2 minutes discussion

OP-G-184  ALARM SYMPTOMS FOR GASTRIC/OESOPHAGEAL MALIGNANCY: A META-ANALYSIS USING INDIVIDUAL PATIENT DATA
(Marcel J. R. Janssen, Nijmegen, The Netherlands)

OP-G-185  GASTRIC CANCER IN YOUNG PATIENTS WITH NO ALARM SYMPTOMS: FOCUS ON THE NEED FOR EARLY DIAGNOSIS
(Anthia Gatopoulou, Thessaloniki, Greece)
Co-authors: I. Pilpilidis, Z. Antonopoulos, K. Soufreris, D. Paikos, P. Katsinelos, A. Tarpagos, I. Katsos

OP-G-186  FAST-TRACK SERVICE FOR ALARM SYMPTOMS SELECTS PATIENTS WITH POOR OUTCOME IN OESOPHAGEAL ADENOCARCINOMA
(Nick Stern, Liverpool, UK)
Co-authors: K. Bodger, N. Kapoor, R. Sturgess
IDENTIFICATION OF CLINICALLY-INFORMATIVE BIOMARKERS FOR RISK STRATIFICATION WITHIN THE SPECTRUM OF GASTRO-OESOPHAGEAL REFLUX DISEASE IN THE SOUTH AFRICAN POPULATION
(Christo J. Van Rensburg, Cape Town, South Africa)
Co-authors: N.J. De Villiers, C. Daniels, C.A. Wright, G. De Jong, M.J. Kotze, M. Kidd

DETECTION OF INTESTINAL METAPLASIA AT THE GASTRO-OESOPHAGEAL JUNCTION USING MAGNIFYING ENDOSCOPY
(Franco Coppola, Candiolo, Italy)
Co-authors: G. Galatola, C. Laudi, R. Ferraris, M. Risio

LONG-TERM COURSE OF INTESTINAL METAPLASIA OF THE OESOPHAGOGASTRIC JUNCTION
(Ulrich Peitz, Magdeburg, Germany)
Co-authors: M. Vieth, S. Lortz, K. Mönkemüller, H. Neumann, S. Schinkel, A. Roessner, P. Malfertheiner

TIME TRENDS IN THE INCIDENCE AND PREVALENCE OF DYSPLASIA IN BARRETT’S OESOPHAGUS IN THE LAST TWO DECADES
(Sunil A Sonwalkar, Leeds, UK)
Co-authors: O. Rotimi, S.M. Everett

GASTRIC ULCER, GASTRIC MALIGNANCY AND THE UTILITY OF ENDOSCOPIC FOLLOW-UP
(Rikke Christiansen, Odense, Denmark)
Co-authors: O.B. Schaffalitzky de Muckadell, A. Lassen

FREE PAPER SESSION: WHAT’S NEW IN DIAGNOSTING IBD?
Chair: O. Schaffalitzky de Muckadell (Odense, Denmark)
Geert D’Haens (Bonheiden, Belgium)

10 minutes presentation including 2 minutes discussion

NEURAL LESIONS IN CROHN’S DISEASE RESECTION SPECIMEN PREDICT EARLY ENDOSCOPIC RECURRANCE
(Marc Ferrante, Leuven, Belgium)
Co-authors: G. De Hertogh, F. Penninckx, A. D’Hoore, G. D’Haens, S. Vermeire, P. Rutgeerts, K. Geboes, G. Van Assche

THE SENSITIVITY OF THE LENNARD-JONES CRITERIA IN THE DIAGNOSIS OF CROHN’S DISEASE
(Karin Schweiger, Vienna, Austria)
Co-authors: E. Ho, C. Lichtenberger, C. Schenk, S. Mustafa, W. Reinisch

RE-EVALUATION OF THE DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN A POPULATION BASED FOLLOW-UP STUDY
(Magne Henriksen, Moss, Norway)

ENDOSCOPIC DIAGNOSIS OF SMALL BOWEL CROHN’S DISEASE: A PROSPECTIVE, COMPARATIVE STUDY OF CAPSULE ENDOSCOPY, BARIUM ENTEROGRAPHY, PUSH ENTEROSCOPY AND ILEO-COLONOSCOPY
(Ervin Toth, Malmo, Sweden)

ENDOSCOPIC REMISSION AND RESPONSE IN CROHN’S DISEASE: AN OBJECTIVE DEFINITION USING THE CDEIS
(Jean Yves Mary, Paris, France)
Co-authors: M. Lemann, J. Colombel, E. Lerebours, J. Soule, J. Gendre, R. Modigliani, Getaid
OP-G-224  AN EARLY POSTOPERATIVE LEUKOCYTE SCAN PREDICTS ENDOSCOPIC RECURRENCE OF CROHN’S DISEASE  
(Sven Almer, Linköping, Sweden)  

OP-G-225  ROXIMAL DISEASE EXTENSION IN ULCERATIVE COLITIS PATIENTS WITH PROCTITIS AND LEFT-SIDED COLITIS AT DIAGNOSIS: SURVIVAL ANALYSIS AND FACTORS INFLUENCING PROGRESSION  
(Christos Chatzicostas, Rethymnon, Greece)  
Co-authors: M. Roussomoustakaki, I. Koutroubakis, I. Mouzas, G. Paspatis, S. Potamianos, H. Mavrogeni, H. Kouroumalis

OP-G-226  PROTEOMIC USING SURFACE ENHANCED LASER DESORPTION IONIZATION-TIME OF FLIGHT - MASS SPECTROMETRY FOR THE DIAGNOSIS OF CROHN’S DISEASE AND ULCERATIVE COLITIS  
(Marie-Alice Meuwis, Liege, Belgium)  
Co-authors: M. Fillet, D. De Seny, P. Geurts, L. Wehenkel, J. Belaiche, M. Malaise, E. Louis, M. Merville

OP-G-227  DEVELOPMENT OF A SHORT DISEASE-RELATED QUALITY OF LIFE QUESTIONNAIRE FOR INFLAMMATORY BOWEL DISEASE  
(Greg Rubin, Sunderland, UK)  
Co-authors: D. Chinn, D. Dwarakanath, P. Hungin

ROOM M5 IN HALL C

08:30-10:30  FREE PAPER SESSION: SCREENING AND SURVEILLANCE IN COLORECTAL CANCER  
Chair: Nadir Arber (Tel Aviv, Israel)  
Robert Benamouzig (Bobigny, France)

10 minutes presentation including 2 minutes discussion

OP-G-140  CLINICAL SIGNIFICANCE OF SMALL COLORECTAL ADENOMA LESS THAN 10 MM: THE KASID PROSPECTIVE MULTICENTER STUDY  
(T. W. Yoo, Seoul, South Korea)  

OP-G-141  COLORECTAL CANCER SCREENING USING COLONOSCOPY IN JAPAN  
(Hideyo Goto, Kumamoto, Japan)  

OP-G-142  LIFE EVENTS AND INFLAMMATORY BOWEL DISEASE RELAPSE: A PROSPECTIVE STUDY OF PATIENTS ENROLLED IN REMISSION  
(Julián Panés, Barcelona, Spain)  

OP-G-143  DETECTION OF METACHRONOUS NEOPLASMS IN THE COLORECTAL CANCER (CRC). IDENTIFICATION OF RISK FACTORS  
(Xavier Bessa, Barcelona, Spain)  
Co-authors: V. Piñol, A. Castells, M. Andreu, AEG
OP-G-144 COST EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC SURVEILLANCE FOR COLORECTAL CANCER IN FRANCE
(R. Benamouzig, Bobigny, France)
Co-authors: J. Deyra, L. Gerlier, B. Bejou, R. Launois, S. Chausssade

OP-G-145 PUBLIC AWARENESS OF COLORECTAL CANCER SCREENING IN SPAIN
(Antonio Z Gimeno-garcia, La Laguna, Spain)
Co-authors: A. Parra-blanco, D. Nicolás-perez, M. Garcia, R. Curran, A. Jimenez, E. Quintero

OP-G-146 ENDOLUMINAL FINDINGS IN THE NON-VISUALIZED COLON WITH CT COLONOGRAPHY (CTC) IN 600 PATIENTS AFTER INCOMPLETE COLONOSCOPY
(Laurian Copel, Zerifin, Israel)
Co-authors: J. Sosna, J.B. Kruskal, V. Raptopoulos, R.J. Farrell, M.M. Morrin

OP-G-147 “BRANDENBURG AGAINST COLON CANCER” – FIRST RESULTS OF AN EXEMPLARY, CONCERTED ACTION TO IMPROVE EARLY DETECTION OF COLORECTAL CANCER IN A FEDERAL STATE IN GERMANY
(Dieter Nuernberg, Neuruppin, Germany)
Co-authors: M. Peters, W. Pommerien

OP-G-148 PREOPERATIVE DIAGNOSING FOR COLORECTAL CANCER BY CT COLONOGRAPHY (DUAL-CONTRAST CT ENEMA)
(Koichi Nagata, Yokohama, Japan)

OP-G-149 FACTORS AFFECTING PATIENT’S COMPLIANCE AFTER SUCCESSFUL POLYPECTOMY IN POSTPOLYPECTOMY SURVEILLANCE
(Dariusz Apel, Mannheim, Germany)
Co-authors: C. Koch-Schultheiss, J.F. Riemann

OP-G-150 UPPER GASTROINTESTINAL ENDOSCOPY IS NOT JUSTIFIED IN PERSONS WITH A POSITIVE FECAL OCCULT BLOOD TEST AND A NEGATIVE COLONOSCOPY IN A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAM
(Bernard Denis, Colmar, France)

OP-G-151 MASS SCREENING OF COLORECTAL CANCER WITH Fecal OCCULT BLOOD TEST IN FRANCE. RESULTS OF THE FIRST ROUND IN A PILOT REGION
(Jean F Bretagne, Rennes, France)
Co-authors: C. Piette, G. Mallard, G. Plihon, S. Manfredi, G. Durand

11:00-12:30 FREE PAPER SESSION: HEREDITARY COLON CANCER SYNDROMES
Chair: Richard Boland (Dallas, USA)
Angel Lanas (Zaragoza, Spain)

INTRODUCTION (10 minutes)
(Richard Boland, Dallas, USA)

10 minutes presentation including 2 minutes discussion

OP-G-160 GENE LOCATION OF GERM-LINE MUTATIONS IN HEREDITARY NONPOLYPOSIS COLORECTAL CANCER (HNPCC): IMPLICATIONS ON GENETIC DIAGNOSIS
(Sara Ferreira, Lisbon, Portugal)
OP-G-161  THE RELATIONSHIP BETWEEN FREQUENCIES OF EXTRACOLONIC MANIFESTATIONS AND THE POSITION OF APC GERMLINE MUTATION IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS
(Jose Reyes, Palma, Spain)
Co-authors: D. Ginard, L. Barranco, M. Vanrell, A. Llompart, J. Gaya, A. Obrador

OP-G-162  MULTIPLE ADENOMATOUS POLYPOSIS (MAP) PATIENTS IN FRANCE ARE MOSTLY MALES WITH HIGH ALCOHOL INTAKE AND TOBACCO CONSUMPTION
(Yvan Graber, Lyon, France)

OP-G-163  MYH ASSOCIATED POLYPOSIS; A NEW HEREDITARY COLORECTAL CANCER SYNDROME
(Susana M.A. Mao de Ferro, Lisboa, Portugal)

OP-G-164  HEREDITARY NONPOLYPOSIS COLORECTAL CANCER (HNPPC) WITH MICROSATELLITE STABLE COLORECTAL CANCERS: A DISTINCT ENTITY?
(Sara Ferreira, Lisbon, Portugal)

OP-G-165  INCIDENCE AND PREVALENCE OF COLORECTAL TUMOURS IN HEREDITARY NON-POLYPOSYS COLORECTAL CANCER - RESULTS OF A SURVEILLANCE PROGRAMME
(Susana M.A. Mao de Ferro, Lisboa, Portugal)

OP-G-166  SHOULD WE SUSPECT HEREDITARY NON POLYPOSIS COLORECTAL CANCER (HNPPC) IN PATIENTS WITH COLORECTAL ADENOMAS BEFORE 40?
(Drifa Moussata, Pierre B, France)
Co-authors: A. Glehen, M. Joly, B. Parmentier, S. Nancey, N. Clermontcarre, J. Scoazec, J. Saurin

OP-G-167  VESSELS’ MORPHOLOGY OF POLYPS DISTINGUISH SMAD4 AND BMPR1A-RELATED DIGESTIVE JUVENILE POLYPOSIS SYNDROME
(Adriana Handra-Luca, Bondy, France)
Co-authors: C. Condroyer, C. Boisson, M. Tepper, J. Flejou, S. Olschwang

12:15-14:00  POSTER SESSIONS - HALL C

14:00-15:30  FREE PAPER SESSION: BURNING ISSUES IN THE MANAGEMENT IN IBD
Chair: M. Gassull (Barcelona, Spain)
Renzo Caprilli (Rome Italy)

10 minutes presentation including 2 minutes discussion

OP-G-192  INFLIXIMAB DOES NOT INCREASE THE RISK OF NEWLY DIAGNOSED NEOPLASIA IN CROHN’S DISEASE: A MULTICENTER MATCHED-PAIR STUDY
(Livia Biancone, Rome, Italy)
OP-G-193  TACROLIMUS IS SAFE AND EFFECTIVE IN PATIENTS WITH SEVERE STEROID-REFRACTORY OR STEROID-DEPENDENT INFLAMMATORY BOWEL DISEASE – A LONG TERM FOLLOW-UP
(Daniel C. Baumgart, Berlin, Germany)
Co-authors: J.P. Pintoffl, A. Sturm, B. Wiedenmann, A.U. Dignass

OP-G-194  MOLECULAR CARACTERISATION OF CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE
(Joanna Pofelski, Grenoble, France)
Co-authors: P. Morand, X. Roblin, B. Gratacap, G. Bargues, S. Nicod, J. Seigneurin, B. Bonaz

OP-G-195  IBDQ SCORE RELIABLY AND PROMPTLY REFLECTS CHANGES IN THE DISEASE-RELATED QUALITY OF LIFE IN PATIENTS WITH LUMINAL CROHN’S DISEASE
(Tibor Hlavaty, Leuven, Belgium)
Co-authors: P. Persoons, S. Vermeire, M. Ferrante, M. Pierik, L. Henckaerts, M. Joossens, G. Van Assche, P. Rutgeerts

OP-G-196  THE 6-THIOGUANINE (6-TG) ONLINE SURVEY PLATFORM: AN INTERNATIONAL, MULTI-CENTRIC APPROACH TO SUMMARIZE CLINICAL DATA COLLECTED DURING THE USE OF 6-TG IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
(Alexander Teml, Vienna, Austria)

OP-G-197  HIGH 6-THIOGUANINE NUCLEOTIDE (6-TGN) LEVELS AFTER AZATHIOPRINE TREATMENT ARE NOT ASSOCIATED WITH INCREASED RISK FOR SERIOUS HEPATIC DAMAGE
(Denis Chatelain, Amiens, France)

OP-G-198  6-THIOGUANINE ASSOCIATED NODULAR REGENERATIVE HYPERPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE MAY INDUCE PORTAL HYPERTENSION
(Arnulf Ferlitsch, Vienna, Austria)
Co-authors: A. Teml, W. Reinisch, M. Peck-Radosavljevic, F. Wrba, G. Ulbrich, H. Vogelsang

OP-G-199  THIOPURINE TREATMENT DURING PREGNANCY IN INFLAMMATORY BOWEL DISEASE (IBD)
(Clemens Dejaco, Vienna, Austria)

OP-G-200  EXCRETION OF AZATHIOPRINE METABOLITES IN MATERNAL MILK
(Lisbet A. Christensen, Aarhus, Denmark)
Co-authors: J.F. Dahlerup, K. Schmiegelow
15:45-17:15  FREE PAPER SESSION: NEW TOOLS FOR DIAGNOSIS AND ASSESSMENT OF GORD

Chair: Philippe Pouderoux (Nimes, France)
       Gerald Holtmann (Adelaide, Australia)

INTRODUCTION (10 minutes)
(Philippe Pouderoux, Nimes, France)

10 minutes presentation including 2 minutes discussion

OP-G-228  24-HOUR AMBULATORY OESOPHAGEAL IMPEDANCE-PH IN HEALTHY EUROPEAN SUBJECTS: NORMAL VALUES AND REPRODUCIBILITY TESTS FOR ACID, WEAKLY ACIDIC AND WEAKLY ALKALINE GASTRO-ESOPHAGEAL REFLUX
(Frank Zerbib, Bordeaux, France)
Co-authors: S. Bruley des Varannes, S. Roman, P. Pourderoux, E. Verin, F. Artigue, U. Chaput, F. Caillol, F. Mion, P. Ducrotte, J. Galmiche, D. Sifrim

OP-G-229  TO WHAT EXTENT MULTICHANNEL INTRALUMINAL IMPEDANCEMETRY (MII) MAY INCREASE THE DIAGNOSTIC YIELD IN GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)?
(Stanislas Bruley des Varannes, Nantes, France)
Co-authors: S. Sacher-Huvelin, F. Vavasseur, J. Galmiche

OP-G-230  IMPACT OF AMBULATORY ESOPHAGEAL PH-IMPEDANCE MONITORING IN THE MANAGEMENT OF PATIENTS WITH POSSIBLY GER-RELATED SYMPTOMS: RESULTS OF A MULTICENTER STUDY
(François Mion, Lyon, France)
Co-authors: I. Serraj, S. Bruley des Varannes, F. Zerbib, F. Artigue, S. Roman, J. Galmiche

OP-G-231  EFFECTS OF A 5-HT4 RECEPTOR AGONIST ON ESOPHAGEAL PERISTALSIS AND BOLUS TRANSIT: STUDIES USING COMBINED IMPEDANCE-MANOMETRY
(Radu Tutuian, Charleston, USA)
Co-authors: I. Mainie, R. Allen, K. Hargreaves, A. Agrawal, J. Gale, J. Freeman, D.O. Castell

OP-G-232  EFFECTS OF A 5-HT4 RECEPTOR AGONIST ON POST-PRANDIAL ACID AND NON-ACID REFLUX: STUDIES USING COMBINED IMPEDANCE-PH
(Radu Tutuian, Charleston, USA)
Co-authors: I. Mainie, R. Allen, K. Hargreaves, A. Agrawal, J. Freeman, J. Gale, D.O. Castell

OP-G-233  GERDYZER™: VALIDATION OF A NEW SCALE FOR THE ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE IN GASTROESOPHAGEAL REFLUX DISEASE (GERD)
(Gerald Holtmann, Adelaide, Australia)

OP-G-234  ENDOSCOPIC DIAGNOSIS OF NERD - EVALUATION OF NEW CRITERIA
(David Antos, Munich, Germany)
Co-authors: E. Bayerdorffer, E. Bastlein, A. Elkhader, H. Leick, J. Alter, M. Vieth, M. Stolte

OP-G-235  THE REQUEST™ / LA-CLASSIFICATION: A NOVEL INTEGRATED APPROACH FOR THE COMPREHENSIVE ASSESSMENT OF TREATMENT OUTCOME OF GASTROESOPHAGEAL REFLUX DISEASE (GERD)
(Hubert Mönnikes, Berlin, Germany)
Co-authors: K.D. Bardhan, D. Armstrong, R. Fass, P. Berghöfer, G. Gatz
## A1 Congress Hall

### 08:30-10:30 Video Marathon

| Chair: | Andrej Nowak (Katowice, Poland)  
Rainer Schoefl (Linz, Austria),  
Spiros Ladas (Athens, Greece) |
|--------|

**10 minutes presentation including 2 minutes discussion**

<table>
<thead>
<tr>
<th>Video</th>
<th>Title</th>
</tr>
</thead>
</table>
| VID-E-10 | COLONOSCOPY USING A DOUBLE-BALLOON ENDOSCOPE FOR TECHNICALLY DIFFICULT CASES  
(Hironori Yamamoto, Tochigi, Japan) |
| VID-E-11 | EUS-DIRECTED MANAGEMENT OF AN EARLY AMPULLARY CARCINOMA SUCCESSFULLY TREATED BY ENDOCUTOPIC RESECTION  
(Alessandro Repici, Turin, Italy) |
| VID-E-12 | HIGH-MAGNIFICATION ENDOSCOPY (HME) IMPROVES DETECTION OF SPECIALIZED INTESTINAL METAPLASIA (SIM) IN PATIENTS WITH GERD  
(Sergey Kashin, Yaroslavl, Russian Federation) |
| VID-E-13 | DIAGNOSTIC AND THERAPEUTIC IMPACT OF DOUBLE BALLON ENTEROSCOPY (DBE)  
(Klaus Mönkemüller, Magdeburg, Germany) |
| VID-G-14 | MINIMALLY INVASIVE APPROACH FOR ESOPHAGEAL LEIOMYOMA  
(Giuseppe Portale, Padova, Italy) |
| VID-E-15 | TIPS FOR DOUBLE ENDOCUTOPIC BYPASS  
(Mánuel Pérez-Miranda, Valladolid, Spain) |
| VID-G-16 | DIRECT PERCUTANEOUS ENDOSCOPIC JEJUNOSTOMY FOR ENTERAL NUTRITION  
(Marie-George Lapalus, Lyon, France) |
| VID-E-17 | “COLONOSCOPE WITH DISPOSABLE CARTRIDGES” - SELF-PROPELLING! - DOES NOT NEED DESINFECTION!  
(Anda Borisova, Riga, Latvia) |
| VID-E-18 | ENDOCUTOPIC CLOSURE OF BENIGN ESOPHAGOBRONCHIAL FISTULA ARISING IN A TRACTION DIVERTICULUM, WITH CIANOACRYLATE  
(Juan F. Arguto, Buenos Aires, Argentina) |
| VID-E-19 | SMALL SPHINCTEROTOMY COMBINED WITH PAPILLARY DILATION WITH LARGE BALLOON PERMITS RETRIEVAL OF LARGE STONES WITHOUT CRUSHING  
(Atsushi Minami, Yokohama, Japan) |
VID-G-20  ROBOTIC ENDOSURGERY  
(Daniel Rabreau, Paris, France)

VID-E-21  EUS-GUIDED CHOLEDOCHODUODENOSTOMY  
(Manuel Pérez-Miranda, Valladolid, Spain)  
Co-authors: H. Núñez, E. Saracíbar, F. Pons, F. Frías, A. Caro-Patón

11:00-12:30  FUNCTIONAL DYSPEPSIA, WHAT IS REALLY NEW?  
Chair:  
Greg Rubin (Sunderland, UK)  
M. Simren (Gothenburg, Sweden)

20 minutes presentation including discussion  
PATHOPHYSIOLOGY: FROM SENSATION TO GENETICS  
(Gerald Holtman, Adelaide, Australia)  
FRONTIERS WITH OTHER DISEASES: WHAT NEEDS TO BE INVESTIGATED?  
(M. Simren, Gothenburg, Sweden)  
REDUCTION OF UNNECESSARY PRESCRIPTION IN GI DISEASE  
(Mattijs Numans, Utrecht, The Netherlands)  
ARE EFFECTIVE NEW TREATMENTS REALLY COMING?  
(Jan Tack, Leuven, Belgium)

12:15-14:00  POSTER SESSIONS - HALL C

12:45-13:35  LUNCH SESSION - L1 IN HALL B: AGGRESSIVE THERAPY IN PANCREATIC CANCER  
Helmut Friess (Heidelberg, Germany), Chris Verslype (Leuven, Belgium)

A2+A3 CONGRESS HALL

08:30-10:30  STRUCTURES IN CROHN’S DISEASE  
Chair:  
Francesco Pallone (Rome, Italy)  
George Bruce (Oxford, UK)

20 minutes presentation including discussion  
PATHOGENESIS OF STRUCTURES: FIBROBLASTS FUNCTIONS AND DYSFUNCTIONS IN IBD  
(P. Ronan O’Connell, Dublin, Ireland)  
RADIIOLOGICAL EVALUATION OF IBD STRUCTURES  
(Karin Herrmann, Muenchen, Germany)  
STRUCTURES AS COMPLICATIONS OF MEDICAL THERAPY  
(Gert Van Assche, Leuven, Belgium)  
MEDICAL AND ENDOSCOPIC APPROACH TO CROHN STRICTURES  
(Marc Lémann, Paris, France)  
SURGICAL INTERVENTION FOR CROHN’S STRICTURES  
(George Bruce, Oxford, UK)
11:00-12:30  FUTURE THERAPY FOR IBD: MORE THAN A CHALLENGE?
Chair:  
Geert D’Haens (Bonheiden, Belgium)  
Walter Reinisch (Vienna, Austria)

20 minutes presentation including discussion
APOPTOSIS: A KEY TO SUCCESSFUL IBD MANAGEMENT?
(Markus Neurath, Mainz, Germany)
PHARMACOGENETICS IN IBD: CLUES FOR HIGHER SUCCESS RATES?
(Yehuda Chowers, Tel-Hashomer, Israel)
TOLERANCE INDUCTION IN IBD
(Yaron Ilan, Jerusalem, Israel)
RATIONAL USE OF BIOLOGICAL IN IBD
(Brian Feagan, London, UK)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35 LUNCH SESSION - L2 IN HALL B: NEW INDICATIONS FOR CAPSULE ENDOSCOPY
Abraham R. Eliakim (Israel), Istvan Racz (Hungary)

14:00-15:30  THE LIVER AND SEPSIS
Chair:  
Andrew Burroughs (London, UK)  
Hendrik Vilstrup (Aarhus, Denmark)

20 minutes presentation including discussion
BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS
(Hendrik Vilstrup, Aarhus, Denmark)
FUNGAL INFECTIONS IN PATIENTS WITH CIRRHOSIS
(Nicola Petrosillo, Rome, Italy)
SPONTANEOUS BACTERIAL PERITONITIS
(Vicente Arroyo, Barcelona, Spain)
SEPSIS AFTER ORTHOTOPIC LIVER TRANSPLANTATION
(Andrew Burroughs, London, UK)
08:30-10:30  FREE PAPER SESSION: CONVENTIONAL AND EMERGING THERAPIES IN ULCERATIVE COLITIS

Chair:  Jean-Frédéric Colombel (Lille, France)
Stephen Hanauer (Chicago, USA)

10 minutes presentation including 2 minutes discussion

OP-G-236  MODIFIED-RELEASE ORAL MESALAZINE 4.8 G/DAY (800 MG TABLET) VERSUS 2.4 G/DAY (400 MG TABLET) FOR TREATMENT OF MODERATELY ACTIVE ULCERATIVE COLITIS: COMBINED ANALYSIS OF TWO RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIALS
(Stephen B. Hanauer, Chicago, USA)
Co-authors: W.D. Sandborn, A. Kornbluth, R. Hardi, G. Regalli, C. Yeh

OP-G-237  A DOSE-RANGING STUDY OF ONCE-DAILY MESALAZINE WITH A NOVEL DELIVERY SYSTEM IN PATIENTS WITH ACUTE, MILD-TO-MODERATE ULCERATIVE COLITIS
(Geert D’Haens, Bonheiden, Belgium)
Co-authors: D. Hommes, L. Engels, L. Van der Waaij, P. Connor, J. Ramage, O. Dewitt, M. Palmen, D. Stephenson

OP-G-238  BECLOMETHASONE DIPROPIONATE (TOPSTER®) IN DISTAL ULCERATIVE COLITIS: A MULTICENTRE, RANDOMIZED, OPEN LABEL STUDY COMPARING RECTAL ENEMA AND FOAM VERSUS MESALAZINE RECTAL ENEMA AND FOAM
(Livia Biancone, Rome, Italy)

OP-G-239  A 10-YEAR FOLLOW-UP STUDY OF PATIENTS GIVEN INTENSIVE INTRAVENOUS CORTICOSTEROID THERAPY FOR A SEVERE ATTACK OF ULCERATIVE COLITIS
(Anders Gustavsson, Orebro, Sweden)
Co-authors: J. Halfvarson, H. Sandberg-Gertzén, C. Tysk, G. Järnerot

OP-G-240  LONG-TERM FOLLOW-UP OF LEUKOCYTE ADSORPTIVE APERHESIS (LAA) TREATMENT IN PATIENTS WITH MODERATELY ACTIVE STERIOD-DEPENDENT ULCERATIVE COLITIS (UC)
(Robert Löfberg, Stockholm, Sweden)
Co-authors: N. Hittel, A. Dignass, J. Moessner, S. Schreiber, M. Vecchi, A. Malesci, M. Reinshagen, W. Kruis

OP-G-241  ADACOLUMN APERHESIS REDUCES RELAPSE RATES IN PATIENTS WITH IBD AT SIGNIFICANT RISK OF CLINICAL RELAPSE
(Laurence Maiden, London, UK)

OP-G-242  A MULTICENTER, RANDOMIZED, CONTROLLED TRIAL BETWEEN WEEKLY AND SEMI-WEEKLY TREATMENT WITH GRANULOCYTE AND MONOCYTE ADSORPTION APERHESIS FOR ACTIVE ULCERATIVE COLITIS
(Atsushi Sakuraba, Tokyo, Japan)
Co-authors: N. Inoue, Y. Kohgo, A. Terano, T. Matsui, Y. Suzuki, T. Hibi
OP-G-243  THE PHASE I/II VISILIZUMAB STUDY. A REPORT OF SAFETY AND EFFICACY OF TREATMENT AND RETREATMENT IN ULCERATIVE COLITIS PATIENTS REFRACTORY TO TREATMENT WITH IV STEROIDS (IVSR-UC)
(Daniel C. Baumgart, Berlin, Germany)

OP-G-244  KINETICS OF PERIPHERAL LYMPHOCYTE COUNTS IN VISILIZUMAB-TREATED INTRAVENOUS STEROID REFRACTORY ULCERATIVE COLITIS PATIENTS
(James P. Sheridan, Fremont, USA)
Co-authors: J. Woo, J. Shi, L. Efros, S. Keller, J. Lowder, V. Vexler

OP-G-245  INFliximab Therapy reduces hospitalizations in ulcerative colitis patients
(Paul Rutgeerts, Leuven, Belgium)

OP-G-246  RESPONSE AND REMISSION ARE ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS
(William J. Sandborn, Rochester, USA)
Co-authors: B.G. Feagan, W. Reinisch, M. Bala, A. Olson, P. Rutgeerts

OP-G-247  INFliximab induces and maintains mucosal healing in patients with active ulcerative colitis: the ACT trial experience
(Paul Rutgeerts, Leuven, Belgium)

11:00-12:30  HERBAL MEDICINE AND THE LIVER
Chair: Pauline Hall (Australia)
       Peter Ferenci (Vienna, Austria)

20 minutes presentation including discussion
OVERVIEW: GOOD AND BAD OF HERBAL MEDICINE
(Kenjro Wake, Tokyo, Japan)
HERBAL HEPATOTOXICITY
(Pauline Hall, South Africa)
MEDICINAL HERBS FOR LIVER DISEASES
(Peter Ferenci, Vienna, Austria)
MEDICINAL HERBS AS ANTIFIBROTIC AGENTS
(Norifumi Kawada, Osaka, Japan)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L3 IN HALL B: MANAGEMENT OF SEVERE FUNCTIONAL DYSPEPSIA
Robert C. Heading (Glasgow, UK), Jan Tack (Leuven, Belgium), Greg Rubin (Sunderland, UK)
**14:00-15:30  MANAGEMENT OF PANCREATIC CYSTIC LESIONS**

**Chair:**
- Dirk Gouma (Amsterdam, The Netherlands)
- Johan Perment (Stockholm, Sweden)

*20 minutes presentation including discussion*

- **RADIOLOGICAL DIAGNOSIS AND INTERVENTION**
  (Simon Jackson, Devon, UK)
- **NEW ASPECTS OF EUS AND FNA**
  (Marc Giovannini, Marseille, France)
- **ENDOSCOPIC MANAGEMENT**
  (Julius Spicak, Prague, Czech Republic)
- **SURGICAL TREATMENT**
  (Claudio Bassi, Verona, Italy)

---

**AUDITORIUM 15**

**08:30-10:30  HELICOBACTER PYLORI-ASSOCIATED DISEASES WORLDWIDE**

**Chair:**
- John Atherton (Nottingham, UK)
- Lars Engstrand (Solna, Sweden)

*20 minutes presentation including discussion*

- **THE AFRICAN AND ASIAN ENIGMAS: DO THEY EXIST?**
  (D. Forman, Leeds, UK)
- **TO WHAT EXTENT MIGHT GEOGRAPHIC DIFFERENCES IN DISEASE PREVALENCE BE EXPLAINED BY: DIFFERENCES BETWEEN H. PYLORI STRAINS**
  (Yoshio Yamaoka, Horston, USA)
- **TO WHAT EXTENT MIGHT GEOGRAPHIC DIFFERENCES IN DISEASE PREVALENCE BE EXPLAINED BY: HOST GENETIC POLYMORPHISMS**
  (J. C. Machado, Porto, Portugal)
- **TO WHAT EXTENT MIGHT GEOGRAPHIC DIFFERENCES IN DISEASE PREVALENCE BE EXPLAINED BY: PARASITE MODULATION OF THE T HELPER CELL RESPONSE**
  (Mark T. Whary, Cambridge, USA)
- **TO WHAT EXTENT MIGHT GEOGRAPHIC DIFFERENCES IN DISEASE PREVALENCE BE EXPLAINED BY: DIETARY AND OTHER ENVIRONMENTAL FACTORS**
  (Carlos Gonzalez, Barcelona, Spain)
11:00-12:30  WHEN CROHN’S GOES WRONG
Chair:  Renzo Caprilli (Rome, Italy)
       Robert Lofberg (Stockholm, Sweden)

20 minutes presentation including discussion
NUTRITIONAL MANAGEMENT OF INTESTINAL FAILURE
(M. Gassull, Barcelona, Spain)
INTESTINAL FAILURE AND SMALL BOWEL TRANSPLANTATION FOR CROHN’S DISEASE
(Gordon Carlson, Salford, UK)
DEADLY COMPLICATIONS OF THERAPEUTIC INTERVENTIONS
(Pierre Michetti, Lausanne, Switzerland)
SURGICAL INTERVENTION FOR DESPERATE CASES OF CD
(J. Frederic M. Slors, Amsterdam, The Netherlands)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L4 IN HALL B: ENDOSCOPIC PALLIATION OF OESOPHAGEAL AND GASTRIC CANCER
Julius Spicak (Prague, Czech Republic), Remi Dumas (Monaco)

14:00-15:30  CRC EVALUATION AND TREATMENT
Chair:  Angel Lanas (Zaragosa, Spain)
       Anders Fischer (Copenhagen, Denmark)

20 minutes presentation including discussion
ADJUVANT CHEMOTHERAPY FOR STAGE II AND III CRC
(Mario Dicato, Luxembourg, Luxembourg)
POST SURGICAL SURVEILLANCE: HOW INTENSIVE SHOULD IT BE?
THE EUROPEAN CONSENSUS
(Eric Van Cutsem, Leuven, Belgium)
PALLIATIVE THERAPY IN CRC
(Angel Lanas, Zaragoza, Spain)
NOVEL THERAPIES IN CRC; THE ROLE OF VEGF AND ITS INHIBITORS
(M. Toi, Tokyo, Japan)
ROOM M1 IN HALL C

08:30-10:30  CIRRHOSIS AND PORTAL HYPERTENSION
Chair: Helmer Ring-Larsen (Copenhagen, Denmark)
Jaime Bosch (Barcelona, Spain)

20 minutes presentation including discussion
PORTAL HYPERTENSION: NEW INSIGHTS IN DIAGNOSIS AND TREATMENT - THE LESSON OF BAVENO 4
(Roberto De Franchis, Italy)
PRIMARY PROPHYLAXIS OF SMALL OESOPHAGEAL VARICES
(Carlos Merkel, Padua, Italy)
NEO-ANGIOGENESIS AND PORTO-SYSTEMIC SHUNTS
(Mercedes Fernandez, Spain)
NITRIC OXIDE AND CARBON MONOXIDE AS THERAPEUTIC TOOLS FOR PORTAL HYPERTENSION
(Kevin Moore, London, UK)
REDUCTION OF PORTAL PRESSURE FOR THE TREATMENT OF ASCITES AND HEPATORENAL SYNDROME
(Alexander Gerbes, Muenchen, Germany)

11:00-12:30  NOVEL APPROACHES TO THE MANAGEMENT OF GI EMERGENCIES
Chair: Freddy Penninckx (Leuven, Belgium)
Dag Arvidsson (Stockholm, Sweden)

20 minutes presentation including discussion
LAPAROSCOPY IN ACUTE ABDOMINAL INFLAMMATORY DISORDERS
(Benoit Navez, Gilly, Belgium)
RADIOLOGY IN ACUTE GI/ABDOMINAL BLEEDING
(Otto M. Van Delden, Amsterdam, The Netherlands)
ENDOSCOPIC STENTING IN ACUTE ABDOMINAL OBSTRUCTION
(A. Repici, Turin, Italy)
MANAGEMENT OF ACUTE MESENTERIC ISCHEMIA
(Jean-Georges Kretz, Strasbourg, France)

12:15-14:00  POSTER SESSIONS - HALL C

12:45-13:35  LUNCH SESSION - L5 IN HALL B: CLINICAL ASSESSMENT OF IRON OVERLOAD
Pierre Brissot (France), Rolf Hultcrantz (Stockholm, Sweden)
14:00-15:30  FREE PAPER SESSION: ASH AND NASH

Chair: Kevin Moore (London, UK)
       Isabelle Leclercq (Brussels, Belgium)

INTRODUCTION (10 minutes)
(Kevin Moore, London, UK)

“Rising Star” Lecture including 15 minutes discussion
RHO-KINASE SIGNALING REGULATES CHEMOKINE EXPRESSION, LEUKOCYTE
RECRUITMENT AND HEPATOCELLULAR APOPTOSIS IN ENDOTOXIN-INDUCED
LIVER INJURY
(Henrik Thorlacius, Lund, Sweden)

10 minutes presentation including 2 minutes discussion
OP-G-316  A RABBIT MODEL OF NON-ALCOHOLIC STEATOHEPATITIS
(Kouji Otogawa, Osaka, Japan)
Co-authors: K. Kinoshita, Y. Imanishi, H. Fujii, H. Matsuiz, R. Shiga, K. Nakatani, K. Ikeda

OP-G-317  THE GUT MICROFLORA IS INVOLVED IN ETHANOL METABOLISM AND ETHANOL-
INDUCED IMPAIRMENT OF THE EPITHELIAL BARRIER IN RODENTS
(Laurent Ferrier, Toulouse, France)
Co-authors: F. Bérard, L. Debrauwer, P. Langella, L. Buéno, J. Fioramonti

OP-G-319  THE EFFECT OF PROBIOTICS ON GUT FLORA, LEVEL OF ENDOTOXIN AND MINIMAL
ENCEPHALOPATHY IN CIRRHOTIC PATIENTS; PRELIMINARY RESULTS OF DOUBLE
BLIND RANDOMIZED STUDY
(Jan Lata, Brno, Czech Republic)
Co-authors: J. Jurankova, P. Fric, V. Pribramska, M. Senkyrik

OP-G-320  FATTY LIVER: LONG-TERM PROGNOSIS AND CLINICAL FOLLOW-UP
(Sanne Dam-Larsen, Copenhagen, Denmark)
Co-authors: U. Becker, M. Franzmann, K. Larsen, P. Christoffersen, F. Bendtsen

OP-G-321  LIVER STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS B. FACTORS ASSOCIATED
AND ITS RELATIONSHIP WITH FIBROSIS
(Konstantinos C. Thomopoulos, Patras, Greece)
Co-authors: A.C. Tsamandas, V. Arvaniti, D. Dimitropoulou, C.A. Gogos, D. Siagris,
G.J. Theocharis, C. Lambropoulou-Karatza

“Rising Star” Lecture including 15 minutes discussion
NASH - FROM PATHOPHYSIOLOGY TO CURE?
(Isabelle Leclercq, Brussels, Belgium)
**FREE PAPER SESSION: HEPATOCELLULAR CARCINOMA**

**Chair:** Massimo Levrero (Rome, Italy)  
Rolf Hultcrantz (Stockholm, Sweden)

**INTRODUCTION (20 minutes)**
Massimo Levrero (Rome, Italy)

10 minutes presentation including 2 minutes discussion

**OP-G-248**  
**OCCULT HEPATITIS B VIRUS INFECTION IN HEPATOCELLULAR CARCINOMA AFTER INTERFERON-INDUCED DISAPPEARANCE OF HEPATITIS C VIRUS**  
(Akihiro Tamori, Osaka, Japan)  

**OP-G-249**  
**C-JUN DOWNREGULATION SENSITIZES HEPATOMA CELLS TO RECEPTOR INDUCED APOPTOSIS**  
(Niluefer Sonuc, Munich, Germany)  

**OP-G-250**  
**EVALUATION OF THE INHIBITORY EFFECT OF ANTISENSE Oligodeoxyxynucleotides ON THE GROWTH OF HEPATITIS C-ASSOCIATED HEPATOCELLULAR CARCINOMA CELLS IN VITRO**  
(Mona A. Amin, Cairo, Egypt)  
Co-authors: M.R. Awadin, H.G. Metwaly

**OP-G-251**  
**THE RESPONSE TO PREOPERATIVE TRANSARTERIAL CHEMOEMBOLISATION PREDICTS THE OUTCOME OF PATIENTS WITH HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION**  
(Ivo W. Graziadei, Innsbruck, Austria)  
Co-authors: G. Millonig, M.C. Freund, W. Jaschke, S. Stadlmann, W. Mark, R. Margreiter, W. Vogel

**OP-G-252**  
**HUMAN TELOMERASE REVERSE TRANSCRIPTASE-TARGETING TRANS-SPICING RIBOZYME AS TUMOR-TARGETED GENE THERAPY AND LEAST HEPATOTOXICITY, IN VIVO**  
(Jin S. Jeong, Busan, South Korea)  
Co-authors: S.Y. Han, S.W. Lee, S.H. Hong, I.H. Kim

**OP-G-253**  
**TELOMERE SHORTENING OF PRIMARY HEPATOCELLULAR CARCINOMA CORRELATES WITH INCREASING ANEUPLOIDY OF CHROMOSOME 8 ON A CELLULAR LEVEL**  
(Ruben R. Plentz, Hannover, Germany)  
Co-authors: B. Schlegelberger, P. Flemming, M.P. Manns, K.L. Rudolph, L. Wilkens

**OP-G-254**  
**THE PROGNOSTIC MOLECULAR MARKERS IN HEPATOCELLULAR CARCINOMA**  
(Mona A. Amin, Cairo, Egypt)  
Co-authors: M.T. Abel Aziz, D. Elmelegy, H.H. Ahmed, D. Sabry

**OP-G-255**  
**PERCUTANEOUS US-GUIDED LASER THERMOABLATION IN THE TREATMENT OF „NAIVE“ HEPATOCELLULAR CARCINOMA NODULES ≤ 4 CM**  
(Giampiero Francica, Caloria, Italy)  
Co-authors: G. Iodice, M. Delle Cave, F. De Marino, R. Sarrantonio, F. Scarano, G. Lapicciarella
OP-G-256  LONG-TERM PROGNOSIS AND COMPLICATIONS OF PERCUTANEOUS RADIOFREQUENCY ABLATION FOR SMALL HEPATOCELLULAR CARCINOMA (Mikiya Kitamoto, Hiroshima, Japan)
Co-authors: T. Onitake, H. Yamada, M. Imagawa, H. Nakahara, Y. Matsugu, Y. Fukuda

11:00-12:30  INNOVATIVE IMAGING FOR HEPATOCELLULAR CARCINOMA
Chair: Simon Jackson (Devon, UK)
       Riccardo Lencioni (Pisa, Italy)

20 minutes presentation including discussion
MICRO BUBBLES AND CONTRAST AGENTS IN ULTRASOUND: WHEN AND WHY?
(Laura Crocetti, Pisa, Italy)
LIVER-SPECIFIC CONTRAST AGENTS IN MRI
(Aslie Guthrie, Leeds, UK)
IMAGING STRATEGIES FOR BORDERLINE LESIONS IN CIRRHOSIS
(Riccardo Lencioni, Pisa, Italy)
UPDATE ON SURVEILLANCE STRATEGIES IN THE CIRRHOTIC PATIENT
(Bart Op de Beck, Edegem, Belgium)

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L6 IN HALL B: THE CLINICAL SPECTRUM OF AUTOIMMUNE LIVER DISEASE
Ulrika Broome (Stockholm, Sweden), Ulrich Beuers (Muenchen, Germany)

14:00-15:30  FREE PAPER SESSION: GORD – PATHOGENESIS AND EXTRA OESOPHAGEAL MANIFESTATIONS
Chair: Fabio Pace (Milano, Italy)
       Daniel Sifrim (Leuven, Belgium)

INTRODUCTION (10 minutes)
(Fabio Pace, Milano, Italy)

10 minutes presentation including 2 minutes discussion
OP-G-322  TRIGGERING OF TRANSIENT LOWER OESOPHAGEAL SPHINCTER RELAXATION: IS TRANSIENT GASTRIC DISTENION A RELEVANT STIMULUS?
(R. Penagini, Milan, Italy)
Co-authors: D. Savojardo, P. Cantù, S. Carmagnola, S. De Simoni

OP-G-323  NERD AND OESOPHAGEAL SENSITIVITY
(Filippo Antonini, L’Aquila, Italy)
Co-authors: M. Tanga, B. Galletti, P. Saltarelli, G. Latella, L. Onori, M. Chiaromonte, G. Frieri

OP-G-324  LONG-TERM CLINICAL COURSE OF EXTRA-ESOPHAGEAL MANIFESTATIONS IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE: THE PROGERD STUDY
(Daniel J. Jasperson, Fulda, Germany)
OP-G-325  NATURAL HISTORY OF CHEST PAIN IN PRIMARY CARE
(Ana Ruigómez, Madrid, Spain)
Co-authors: L.A. García Rodríguez, M. Wallander, S. Johansson, R. Jones

OP-G-326  LARYNGEAL STRESS PROTEIN RESPONSE TO PEPSIN
(Nikki Johnston, Winston-Salem, USA)
Co-authors: P.W. Dettmar, M.O. Lively, P.C. Belafsky, M. Birchall, J.A. Koufman

OP-G-327  ASSAY OF PEPSIN IN MIDDLE EAR EFFUSION AS A DIAGNOSTIC MARKER FOR
LARYNGOPHARYNGEAL REFLUX IN CHILDREN WITH OTITIS MEDIA WITH EFFUSION
(Ahmed M. Abd El-Fattah, Mansoura, Egypt)
Co-authors: G.A. Abdul Maksoud, A.S. Ramadan, M.M. El Farargy, A.F. Abdalla,
M.M. Abdel Aziz

OP-G-328  ESOMEPRAZOLE 40 MG TWICE DAILY FOR 16 WEEKS IN ADULTS WITH
MODERATE-TO-SEVERE ASTHMA: A RANDOMISED PLACEBO-CONTROLLED TRIAL
(Ola Beckman, Lund, Sweden)
M. Illueca, M. Sosteck

ROOM M3 IN HALL C

08:30-10:30  FREE PAPER SESSION: BASIC SCIENCE IN IBD
Chair: Silvio Danese (Rome, Italy)
Yehuda Chowers (Tel-Hashomer, Israel)

“How Rising Star” Lecture including 15 minutes discussion
HOW DENDRITIC CELLS ORCHESTRATE INFLAMMATION IN IBD
(Arthur Kaser, Innsbruck, Austria)
10 minutes presentation including 2 minutes discussion

OP-G-257  GALECTIN-2 MODULATES T CELL APOPTOSIS AND IMPROVES DISEASE ACTIVITY
IN AN EXPERIMENTAL MODEL OF MURINE COLITIS
(Andreas Sturm, Berlin, Germany)
Co-authors: D. Paclik, A. Rexin, A. Dankof, H. Gabius, B. Wiedenmann, A. Dignass

OP-G-258  EFFECT OF REBAMIPIDE ON COLONIC EPITHELIAL BARRIER AND IMMUNE RESPONSE
IN IL-10 DEFICIENT MICE INFECTED WITH HELICOBACTER HEPATICUS
(David Laharie, Bordeaux, France)
Co-authors: S. Menard, C. Asencio, T. Vidal-Martinez, A. Rullier, F. Zerbib, C. Candalh,
F. Megraud, M. Heyman, T. Matysiak-Budnik

OP-G-259  EVEROLIMUS, IN CONTRAST TO DEXAMETHASONE, REVERSES ESTABLISHED
T CELL INDUCED COLITIS IN SCID MICE WITHOUT SIGNIFICANTLY INHIBITING
T CELL PROLIFERATION
(Henrietta D. Moore, Vienna, Austria)
Co-authors: M. Edjlalipour, M. Pfann, A. Martland, E. Kern, I. Buttron, E. Kowalsky
OP-G-260  THE NOVEL IL-10 RELATED CYTOKINE IL-22 IS INCREASED IN ACTIVE CROHN’S DISEASE AND PROMOTES THE INTESTINAL BARRIER INTEGRITY  
(Florian Beigel, Munich, Germany)  

OP-G-261  INFLIXIMAB TREATMENT RESULTS IN THE REDUCTION OF INFLAMMATION AND INFLAMMATORY MARKERS IN THE MUCOSA OF PATIENTS WITH ULCERATIVE COLITIS: THE ACT 1 TRIAL EXPERIENCE  
(Karel Geboes, Leuven, Belgium)  
Co-authors: P. Rutgeerts, A. Olson, C.W. Marano  

OP-G-262  GM-CSF IN EXPERIMENTAL COLITIS - PROTECTIVE EFFECTS AND UNIQUE MECHANISM OF ACTION  
(John F. Parkinson, Richmond, USA)  

OP-G-263  CARD15 VARIANTS DETERMINE A DISTURBED RESPONSE OF MONOCYTES TO ADHERENT-INVASIVE ESCHERICHIA COLI LF82 IN CROHN’S DISEASE  
(Harald Peeters, Gent, Belgium)  
Co-authors: S. Bogaert, D. Laukens, P. Rottiers, F. De Keyser, A. Darfeuille-Michaud, D. Elewaut, M. De Vos  

OP-G-264  THE CONTRIBUTION OF BONE MARROW TO COLONIC SUBEPITHELIAL MYOFIBROBLASTS IN INTERLEUKIN-10 KNOCKOUT MICE  
(Shigeki Bamba, Ohtsu, Japan)  
Co-authors: W.R. Otto, C. Lee, M. Brittan, S.L. Preston, T. Bamba, N.A. Wright  

OP-G-265  LCK AND FYN, TWO NOVEL TARGETS OF RAPID GLUCOCORTICOID ACTION  
(Mark Lowenberg, Amsterdam, The Netherlands)  
Co-authors: J. Tuynman, J. Bilderbeek, T. Gaber, F. Buttgereit, S. Van Deventer, M. Van Deventer, D. Hommes  
“Rising Star” Lecture including 15 minutes discussion  
STARVING THE INFLAMED GUT: ANGIOGENESIS BLOCKADE AS A NOVEL THERAPEUTIC APPROACH TO EXPERIMENTAL COLITIS  
(Silvio Danese, Rome, Italy)  
Co-authors: H. Liker, P. DuCrotte, K. Ballard  

FREE PAPER SESSION: CLINICAL CONTROVERSIES IN PANCREATIC NEOPLASIA  
Chair: Paula Ghaneh (Liverpool, UK)  
Marc Giovannini (Marseille, France)  

10 minutes presentation including 2 minutes discussion  
OP-G-289  PANCREATIC RESECTIONS IN FRANCE IN 2004: FREQUENCY, INDICATIONS AND COMPLICATIONS  
(Philippe Levy, Suresnes, France)  
Co-authors: F. Dyard, A. Sauvanet, J. Arnaud, D. Brassier, G. Lorimier  

OP-G-290  CONTRAST-ENHANCED ULTRASONOGRAPHY (CEUS) OF SOLID PANCREATIC LESIONS  
(Mirko D’Onofrio, Verona, Italy)  
Co-authors: R. Malagò, G. Zamboni, R. Pozzi Mucelli
OP-E-291  ELASTOGRAPHY AND CONTRAST-ENHANCED (SONOVUE) COLOR DOPPLER PANCREATIC ENDOSCOPIC ULTRASOUND TO CHARACTERIZE PANCREATIC MASS. RESULTS IN 25 PATIENTS
(Marc Giovannini, Marseille, France)
Co-authors: E. Bories, C. Pesenti, G. Monges, V. Moutardier, J. Delpero

OP-G-292  PREVALENCE OF NON FUNCTIONING PANCREATIC ENDOCRINE TUMOURS IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (MEN 1) USING ENDOSCOPIC ULTRASONOGRAPHY. FINAL RESULTS OF A PROSPECTIVE STUDY
(Guillaume Cadot, Reims, France)

OP-G-293  EUS-FNA OF SMALL PANCREATIC TUMOR LESS THAN 3 CM: RESULTS OF A PROSPECTIVE MULTICENTER STUDY ON 155 PATIENTS
(Marc Giovannini, Marseille, France)
Co-authors: G. Monges, P. Arcidiacono, P. Deprez, C. Ardengh, S. Gualdi, I. Karamboulis, R. Fogel, C. Bergele

OP-G-294  NATURAL HISTORY OF BRANCH DUCT TYPE INTRADUCTAL PAPILLARY MUCINOUS TUMOR OF THE PANCREAS: FOLLOW-UP STUDY
(Elham Hobeika, Clichy, France)
Co-authors: L. Palazzo, J. Boujaoude, P. Ponsot, M.C. Vullierme, P. Levy, V. Vilgrain, M. Fabre, P. Ruszniewski

OP-G-295  INTRADUCTAL PAPILLARY MUCINOUS TUMOURS OF THE PANCREAS IN KOREA: AN ANALYSIS OF 83 PATHOLOGICALLY PROVEN CASES
(Won Jae Yoon, Seoul, South Korea)
Co-authors: J. Park, S. Lee, J. Lee, K. Lee, J. Ryu, Y. Kim, Y. Yoon

OP-G-296  ENDOSCOPIC MANAGEMENT OF METAL STENT MALFUNCTION IN MALIGNANT COMMON BILE DUCT STRICTURES
(Pietro Familiari, Rome, Italy)
Co-authors: F. Iacopini, C. Spada, A. Tringali, M. Marchese, G.A. Pirozzi, M. Mutignani, P. Giglio Fiorito, G. Costamagna

OP-G-297  ENDOSCOPIC ULTRASOUND FINE NEEDLE INJECTION (EUS-FNI) OF A NOVEL GENE TRANSFER THERAPY AGAINST PANCREATIC CANCER: A SINGLE INSTITUTION EXPERIENCE
(James J. Farrell, Los Angeles, USA)
Co-authors: J. Macko, J.R. Hecht

12:15-14:00  POSTER SESSIONS - HALL C
12:45-13:35  LUNCH SESSION - L7 IN HALL B: MAINTENANCE THERAPY IN IBD
Yehuda Chowers (Tel-Hashomer, Israel), Pia Munkholm (Copenhagen, Denmark)
14:00-15:30  FREE PAPER SESSION: GENETICS IN IBD

**Chair:**  Stefan Schreiber (Kiel, Germany)
Jean-Frédéric Colombel (Lille, France)

10 minutes presentation including 2 minutes discussion

**OP-G-329**  A POLYMORPHISM IN IGG FC RECEPTOR GENE FCGR3A IS NOT ASSOCIATED WITH CLINICAL RESPONSE TO INFliximab: AN ACCENT I SUB ANALYSIS
(Edouard Louis, Liege, Belgium)
Co-authors: S. Schreiber, H. Watier, A. Olson, F. Taillard, J. Colombel

**OP-G-330**  ASSOCIATION BETWEEN NOD2/CARD15 GENE VARIANTS AND RESPONSE TO ANTIBIOTICS IN PERIANAL FISTULIZING CROHN’S DISEASE
(Sieglinde Angelberger, Vienna, Austria)
Co-authors: M. Schwab, C. Dejaco, T. Waldhoer, C. Lichtenberger, M. Harrer, E. Schaefefler, H. Vogelsang, W. Reinisch

**OP-G-331**  A PANEL OF SEROLOGIC MARKERS IN TWINS WITH INFLAMMATORY BOWEL DISEASE
(Sofie Joossens, Leuven, Belgium)

**OP-G-332**  PREVALENCE OF TOLL-LIKE RECEPTOR 2 AND 4 POLYMORPHISMS IN TWINS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION BASED DANISH SWEDISH COHORT STUDY
(Jonas Halfvarson, Örebro, Sweden)

**OP-G-333**  GENETIC POLYMORPHISMS IN GSTM1, GSTT1, AND GSTP1 IN PATIENTS WITH THE CHRONIC INFLAMMATORY BOWEL DISEASES; ULCERATIVE COLITIS AND CROHN’S DISEASE
(Anja Ernst, Aalborg, Denmark)
Co-authors: I.S. Pedersen, H. Okkels, A.M. Drewes, H.B. Krarup

**OP-G-334**  VARIANTS IN THE IMMUNITY GENES CARD8 AND CARD15 STIMULATE A SEROLOGIC RESPONSE TO MICROBIAL COMPOUNDS IN IBD
(Marie Pierik, Leuven, Belgium)
Co-authors: S. Joossens, L. Henckaerts, M. Joossens, P. Rutgeerts, S. Vermeire

**OP-G-335**  FUNCTIONAL VARIANTS OF OCTN CATION TRANSPORTER GENE ARE ASSOCIATED WITH PERIANAL CROHN’S DISEASE
(Cécile F. Libioule, Liege, Belgium)

**OP-G-336**  NOD2 VARIANTS IN CROHN’S DISEASE - ARGUMENTS FOR GAIN-OF-FUNCTION ALLELES IN HUMANS
(Zuzana Zelinkova, Amsterdam, The Netherlands)
Co-authors: A.J. Van Beelen, A.A. Te Velde, E.C. De Jong, S.J. Van Deventer, D.W. Hommes

**OP-G-337**  COMBINED TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) AND NOD2/CARD15 GENOTYPING PREDICTS CROHN’S DISEASE BEHAVIOUR
(Julián Panés, Santiago de Chile, Chile)
**08:30-10:30 FREE PAPER SESSION: MANAGING GORD IN REAL LIFE**

**Chair:** Karsten Lauritsen (Odense, Denmark)
Jean-Paul Galmiche (Nantes, France)

**INTRODUCTION (10 minutes)**
(Karsten Lauritsen, Odense, Denmark)

*10 minutes presentation including 2 minutes discussion*

**OP-G-266**
**REASONS WHY INDIVIDUALS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE SEEK MEDICAL ATTENTION**
(Roger Jones, London, UK)
Co-authors: H. Liker, P. DuCrotte, K. Ballard

**OP-G-267**
**DIFFERENCES BETWEEN FREQUENT (AT LEAST ONCE PER WEEK) AND LESS FREQUENT GASTRO-OESOPHAGEAL REFLUX PATIENTS: RESULTS OF A LARGE POPULATION STUDY**
(Jean-François Bretagne, Rennes, France)
Co-authors: B. Richard-Molard, C. Honnorat, A. Caekaert, P. Barthélémy

**OP-G-268**
**WHAT IS THE BENEFIT OF UPPER GASTRO-INTESTINAL ENDOSCOPY IN YOUNG DYSEPTIC PATIENTS**
(Per C. Valle, Harstad, Norway)
Co-authors: R.K. Breckan

**OP-G-269**
**SYMPTOM PREVALENCE IN PATIENTS TAKING OVER-THE-COUNTER AND PRESCRIBED MEDICATION FOR GASTROESOPHAGEAL REFLUX DISEASE? RESULTS OF A MULTINATIONAL SURVEY**
(Roger Jones, London, UK)
Co-authors: H.R. Liker, P. DuCrotte

**OP-G-270**
**INCOMPLETE SYMPTOM RESPONSE – DOES IT MATTER TO THE PATIENT?**
(Ingela Wiklund, Mölndal, Sweden)
Co-authors: O. Junghard

**OP-G-271**
**A PHARMACO-EPIDEMIOLOGIC STUDY ON ACID SUPPRESSIVE THERAPY: INTERACTIONS BETWEEN PRESCRIPTIONS IN HOSPITAL AND IN PRIMARY CARE**
(Aleksander Krag, Svendborg, Denmark)
Co-authors: L.S. Teglbjerg, A. Malchow-Møller, J. Hallas, P. Bytzer

**OP-G-272**
**AN INTERVENTION PROGRAMME FOR EVIDENCE BASED CHRONIC ANTACID DRUG USE**
(Hugo M. Smeets, Utrecht, The Netherlands)
Co-authors: N.J. De Wit, A.W. Hoes

**OP-G-273**
**AN ACID SUPPRESSION TRIAL WITH ESOMEPRAZOLE IDENTIFIES PATIENTS WITH NON-GERD DYSEPSIA WHO WILL RESPOND TO PROLONGED ACID SUPPRESSION: A RANDOMISED CONTROLLED TRIAL OF 1250 UNINVESTIGATED PRIMARY CARE PATIENTS**
(Sander J. O. Veldhuyzen Van Zanten, Halifax, Canada)
Co-authors: N. Flook, N.J. Talley, N.B. Vakil, K. Lauritsen
OP-G-274  INCREASED OESOPHAGEAL ACID EXPOSURE ON PROTON PUMP INHIBITORS IN ASYMPTOMATIC PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE
(Roberto Penagini, Milan, Italy)
Co-authors: A. Grigolon, P. Cantù, D. Savojardo

OP-G-275  FIVE YEAR’S SUBJECTIVE AND OBJECTIVE RESULTS OF ANTIREFLUX SURGERY: A RANDOMISED CONTROLLED TRIAL OF LAPAROSCOPIC VERSUS CONVENTIONAL NISSEN FUNDOPICATION
(Werner A. Draaisma, Utrecht, The Netherlands)

OP-G-276  HEARTBURN IN PREGNANCY INCREASES THE RISK OF GASTROESOPHAGEAL REFLUX DISEASE
(Serhat Bor, Izmir, Turkey)
Co-authors: G. Kitapcioglu, P. Dettmar, T. Baxter

11:00-12:30  FREE PAPER SESSION: AETIOLOGY AND PATHOGENESIS OF UPPER GI CANCER
Chair: David Forman (Leeds, UK)
Lars Lundell (Stockholm, Sweden)

10 minutes presentation including 2 minutes discussion

OP-G-298  THE RELATIONSHIP BETWEEN HELICOBACTER PYLORI, PEPSINOGEN, AND GASTRIC ADENOCARCINOMA
(Kazumasa Miki, Tokyo, Japan)

OP-G-299  BONE MORPHOGENETIC PROTEIN (BMP) SIGNALING SUPPRESSES TUMORIGENESIS AT THE ESOPHAGOGRASTIC AND GASTROINTESTINAL EPITHELIAL JUNCTIONS
(Sylvia A. Bleuming, Amsterdam, The Netherlands)

OP-G-300  A COMPARATIVE ANALYSIS OF GENE EXPRESSION PROFILES OF BARRETT’S ESOPHAGUS, NORMAL SQUAMOUS ESOPHAGUS AND GASTRIC CARDIA USING SAGE
(Jantine W. P. M. Van Baal, Amsterdam, The Netherlands)

OP-G-301  LEPTIN ENHANCES THE CELL PROLIFERATIVE AND ANTI-APOPTOTIC ACTIONS OF ACID IN BARRETT’S ADENOCARCINOMA
(Olorunseun O. Oggunwobi, Norwich, UK)
Co-authors: K. Elamin, E. Cameron, M. Wilkinson, I.L.P. Beales

OP-G-302  OVER-EXPRESSION OF THE LEPTIN RECEPTOR IN BARRETT’S METAPLASIA AND CANCER
(Suhail Ahmed, Liverpool, UK)
Co-authors: K. Bodger, L. Pazmany
OP-G-303 THE NOD2 GENE MUTATIONS AND THE RISK OF GASTRIC CANCER
(Teresa Starzynska, Szczecin, Poland)

OP-G-304 COMPARISON OF MANUAL AND AUTOMATED FISH ANALYSIS FOR DETECTION OF GENETIC ABNORMALITIES IN BARRETT’S ESOPHAGUS CYTOLOGY SPECIMENS
(Agnieszka M. Rygiel, Amsterdam, The Netherlands)
Co-authors: J.J. Bergman, J.W. Van Baal, F. Milano, M. Peppelenbosch, K.K. Krishnadath

OP-G-305 EXPLANATIONS FOR DISCREPANCIES BETWEEN ENDOSCOPIC AND HISTOLOGIC DIAGNOSIS OF BARRETT’S OESOPHAGUS
(Ulrich Peitz, Magdeburg, Germany)
Co-authors: M. Vieth, A. Roessner, P. Malfertheiner

OP-G-306 MEASUREMENTS OF DNIC IN THE TISSUE AT GASTRO-ESOPHAGEAL JUNCTION IN RAT ANIMAL MODEL AND HUMAN BEING
(Kiyotaka Asanuma, Sendai, Japan)

12:15-14:00 POSTER SESSIONS - HALL C
12:45-13:35 LUNCH SESSION - L8 IN HALL B: THE USE OF SIMULATORS IN TEACHING ENDOSCOPY
Simon Bar Meir (Israel), Stanislas Chaussade (France)

14:00-15:30 FREE PAPER SESSION: BLEEDING AND NSAID DAMAGE IN THE UPPER GI TRACT
Chair: Karsten Lauritsen (Odense, Denmark)
Jørgen Rask-Madsen (Copenhagen, Denmark)

10 minutes presentation including 2 minutes discussion

OP-G-338 A RANDOMIZED, CONTROLLED TRIAL OF BANDING LIGATION PLUS DRUG THERAPY VS. DRUG THERAPY ALONE IN THE PREVENTION OF ESOPHAGEAL VARICEAL REBLEEDING
(Gin H. Lo, Kaohsiung, Taiwan)
Co-authors: W.C. Chen, M.H. Chen, K.H. Lai

OP-G-339 IRRATIONAL EMPIRICAL URGENT PPI PRESCRIBING IN HOSPITALS WITH TIMELY ACUTE UPPER GI BLEEDING (AUGIB) SERVICES. TIME TO BREAK THE PRE-ENDOSCOPY “MAELENA – PPI REFLEX”? 
(Richard M.H. Lee, London, UK)
Co-authors: D.S. Samuel, F.L. Lim, H. Madani, S. McCartney

OP-G-340 DO NITRATES PROTECT AGAINST GASTROINTESTINAL BLEEDING?
(Paul J. Fortun, Nottingham, UK)
Co-authors: C.J. Hawkey, J. West, L. Tata, R. Hubbard, L. Smeeth, J. Leonardi-Bee
OP-G-341  ACUTE CHANGES IN HUMAN GASTRIC MUCOSAL GENE EXPRESSION WITH NAPROXEN AND NITRIC OXIDE DONATION  
(Christopher J. Hawkey, Nottingham, UK)  
Co-authors: J.A. Smith, A.C. Rose, M.W. James, J.R. Bebb, A. Zaitoun  

OP-G-342  SELECTIVE COX-2 INHIBITORS ARE USED AT INCREASINGLY HIGHER DOSES IN THE UNITED STATES: A CAUSE FOR CONCERN?  
(Gurkipal Singh, Stanford, USA)  
Co-authors: H. Wang, S. Malla, A. Mithal, G. Triadafilopoulos  

OP-G-343  RISK OF UPPER GASTROINTESTINAL ULCER BLEEDING ASSOCIATED WITH SELECTIVE COX-2, TRADITIONAL NON-ASPIRIN NSAIDS, ASPIRIN AND COMBINATIONS  
(Angel Lanas, Zaragoza, Spain)  

OP-G-344  VERY LOW RATE OF DEFINITE ULCER COMPLICATIONS IN LOWER RISK PATIENTS ON LUMIRACOXIB IN THE TARGET STUDY  
(Christopher J. Hawkey, Nottingham, UK)  
Co-authors: W. Smalley, F. Weinstein  

ROOM M5 IN HALL C  

08:30-10:30  FREE PAPER SESSION: CELIAC DISEASE AND INTESTINAL INFLAMMATION  
Chair: Steven Husby (Odense, Denmark)  
Yigael Finkel (Stockholm, Sweden)  

10 minutes presentation including 2 minutes discussion  

OP-G-277  INTESTINAL AND BRAIN TARGETING BY TRANSGLUTAMINASE ANTIBODIES IN GLUTEN ATAXIA  
(Ilma R. Korponay-Szabo, Debrecen, Hungary)  
Co-authors: M. Hadjivassiliou, C. Williamson, K. Laurila, N. Woodrofe, D.S. Sanders, M. Maki  

OP-G-278  COELIAC DISEASE AND TYPE 1 DIABETES IN ADULT DANISH PATIENTS  
(Hanne Skovbjerg, Copenhagen, Denmark)  
Co-authors: L. Tarnow, H. Locht, H. Parving  

OP-G-279  HLA-DQ2 HOMOZYGOTY IS A RISK FACTOR FOR THE DEVELOPMENT OF REFRACTORY COELIAC DISEASE AND ENTEROPATHY ASSOCIATED T-CELL LYMPHOMA  
(Chris C. J. Mulder, Amsterdam, The Netherlands)  
Co-authors: A. Al-toma, M.S. Goerres, J.W. Meijer, A. Zwiers, A.S. Pena, J.B. Crusius
OP-G-280  GUT MUCOSAL GRANULOCYTE ACTIVATION PRECEDES NITRIC OXIDE PRODUCTION: STUDIES IN COELIAC PATIENTS CHALLENGED WITH GLUTEN AND CORN
(Gudjon Kristjánsson, Uppsala, Sweden)
Co-authors: M. Högman, P. Venge, R. Hällgren

OP-G-281  INFLUENCE OF A GLUTEN FREE DIET ON BONE MINERAL DENSITY IN ADULT PATIENTS WITH COELIAC DISEASE
(Agata Mulak, Wroclaw, Poland)
Co-authors: E. Waszczyk, J. Szymczak, A. Bohdanowicz-Pawlak

OP-G-282  L-CARNITINE AND MUSCULAR ASTHENIA IN CELIAC DISEASE: RESULTS OF A RANDOMISED DOUBLE-BLIND STUDY
(Carolina Ciacci, Napoli, Italy)
Co-authors: G. Peluso, E. Iannoni, R. Romano, M. Siniscalchi, P. Iovino, A. Rispo, M. Calvani

OP-G-283  CHARACTERISTICS AND REVERSE ACTIVITY OF PURIFIED HUMAN INTESTINAL NEUTRAL CERAMIDASE
(Lena Ohlsson, Lund, Sweden)
Co-authors: M. Olsson, J. Wu, R. Duan, Å. Nilsson

OP-G-284  IMPAIRED PHOSPHORYLATION OF LINKER FOR ACTIVATING T-CELL (LAT) IS ASSOCIATED WITH T-CELL RECEPTOR (TCR)-DEPENDENT HYPORESONSIVENESS OF HUMAN LAMINA PROPRIA T-CELLS (LPT)
(Jugoh Itoh, Hirosaki, Japan)
Co-authors: J. Wong, A.D. Levine, C. Fiocchi

OP-G-285  CRITICAL ROLE OF P-SELECTIN-DEPENDENT LEUKOCYTE RECRUITMENT IN ENDOTOXIN-INDUCED INTESTINAL PERMEABILITY IN MICE
(Peter Mangell, Malmö, Sweden)
Co-authors: A. Mihaescu, Y. Wang, B. Jeppsson, H. Thorlacius

OP-G-286  CHARACTERISTICS OF GASTROINTESTINAL DISEASES ASSOCIATED WITH COMMON VARIABLE IMMUNODEFICIENCY
(Georgia Malamut, Paris, France)

OP-G-287  MUSCULAR EXPRESSION OF SARA2 MUTATION IN ANDERSON’S DISEASE
(Thomas Aparicio, Paris, France)
Co-authors: D. Bligny, A. Lachaux, J. Hespel, J. Schmitz, L. Aggerbeck, M. Samson-Bouma

OP-G-288  SMALL INTESTINAL BACTERIAL OVERGROWTH PREVALENCE IN HYPOTHYROIDISM
(Ernesto Cristiano Lauritano, Rome, Italy)
11:00-12:30  FREE PAPER SESSION: NEW DIAGNOSTICS FOR SMALL BOWEL DISEASE

Chair:  Thierry Ponchon (Lyon, France)
Roberto De Franchis (Milano, Italy)

10 minutes presentation including 2 minutes discussion

(Christian Boustiere, Marseille, France)
Co-authors: O. Lebars, P. Castellani, V. Oules, G. Lambot, F. Huart, L. Lecomte, M. Bourliere

OP-E-308  ENDOSCOPIC CAPSULE IN CIRRHOTIC PATIENTS WITH PORTAL HYPERTENSION: SPECTRUM AND PREVALENCE OF SMALL BOWEL LESIONS
(Alessandro Repici, Turin, Italy)
Co-authors: M. Pennazio, A. Ottobrelli, V. Barbon, C. De Angelis, A. De Lio, S. Caronna, S. Martini, G. Saracco, M. Rizzetto

OP-E-309  CAPSULE ENDOSCOPY FOLLOWED BY PUSH-PULL ENTEROSCOPY (DOUBLE BALLOON ENTEROCOPY): DIAGNOSTIC YIELD IN PATIENTS WITH SUSPECTED INTESTINAL DISEASE
(Michel Delvaux, Vandoeuvre les Nancy, France)
Co-authors: I. Fassler, G. Gay

OP-E-310  EFFICIENCY OF CAPSULE ENDOSCOPY AND PUSH ENTEROSCOPY AS THE FIRST LINE EXPLORATION OF OBSCURE GASTROINTESTINAL BLEEDING. FINAL RESULTS OF A RANDOMIZED CONTROLLED TRIAL
(Antoine De Leusse, Paris, France)
Co-authors: R. Jian, K. Vahedi, J. Edery, Y. Bouhnik, C. Cellier

OP-E-311  THE EXPERIENCE OF A NEWLY-DEVELOPED CAPSULE ENDOSCOPE
(Haruhiko Ogata, Tokyo, Japan)

OP-E-312  DOUBLE-BALLOON ENDOSCOPY FOR THE DIAGNOSIS AND TREATMENT OF SMALL INTESTINAL DISEASES
(Hiroto Kita, Tochigi, Japan)

OP-E-313  THE FIRST U.S. MULTICENTER STUDY ON DOUBLE-BALLOON ENTEROSCOPY
(Simon Lo, Los Angeles, USA)

OP-E-314  THE VALUE OF WIRELESS CAPSULE ENDOSCOPY IN INDETERMINATE COLITIS
(Jean-Frederic Colombel, Lille, France)
Co-authors: V. Maunoury, A. Bourreille, E. Ben Soussan, M. Jarry, G. Savoye, S. Sacher-Huvelin, E. Lerebours, J. Galmiche

OP-E-315  PROSPECTIVE EVALUATION OF A NEW ULTRATHIN ONE-PLAN BENDING HIGH RESOLUTION VIDEOENDOSCOPE FOR TRANSNASAL EGD: A COMPARATIVE STUDY ON PERFORMANCE AND TOLERANCE
(Jerome Dumortier, Lyon, France)
12:15-14:00  POSTER SESSIONS - HALL C

14:00-15:30  FREE PAPER SESSION: INVITRO AND IN VIVO INNOVATIONS IN COLORECTAL CANCER

Chair: David Ahlquist (Rochester, MN, USA)
Nadir Arber (Tel Aviv, Israel)

10 minutes presentation including 2 minutes discussion

OP-G-345  INHIBITION OF AKT-MEDIATED SIGNAL TRANSDUCTION IN HUMAN COLORECTAL CANCER CELLS BY VIOLACEIN ABROGATES 5-FUOROURACIL CHEMoresistance
(Liudmila L. Kodač, Amsterdam, The Netherlands)
Co-authors: C.L. Bos, N. Durán, M.P. Peppelenbosch, C.V. Ferreira, J.C.H. Hardwick

OP-G-346  PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA (PPAR-ALPHA) DEPENDANT TUMOUR FORMATION IN APC (MIN)/+ MICE
(Anthony Shonde, Nottingham, UK)
Co-authors: D.R. Bell, A.J. Bennett, C.J. Hawkey

OP-G-347  ANTITUMOR EFFECTS OF VITAMINS K2, K3 AND K5 ON COLONIC ADENOCARCINOMA INVITRO AND IN VIVO
(Mutsumi Ogawa, Kita-gun, Japan)

OP-G-348  C-SRC SUPPRESSES APOPTOSIS MEDIATED THROUGH CD95 AND TUMOUR NECROSIS FACTOR-RELATED APOPTOSIS INDUCING LIGAND RECEPTOR
(Enrico N. De Toni, Munich, Germany)

OP-G-349  TARGETING EGFR IN GASTROINTESTINAL MALIGNANCIES. A TISSUE MICROARRAYS AND IMAGE ANALYSIS STUDY
(E. Tsiambas, Athens, Greece)
Co-authors: D. Tsounis, G. Vilaras, P. Tzoumakari, G. Triantafillou, A. Karameris

OP-G-350  GENE-EXPRESSION PROFILE OF COLORECTAL CANCER TISSUE AND NORMAL MUCOSA OF EITHER PATIENTS WITH COLORECTAL CANCER OR HEALTHY SUBJECTS IDENTIFIED BY GENE MICROARRAY ANALYSIS AND RT-PCR
(Francesco Franceschi, Rome, Italy)

OP-G-351  LIDOCAINE INHIBITS PROLIFERATION AND PROMOTES APOPTOSIS OF COLON ADENOCARCINOMA CELLS
(Herma H. Fidder, Ramat Gan, Israel)
Co-authors: E. Fudim, O. Picard, Y. Goldschmidt, A. Lang, S. Bar-Meir, Y. Chowers

OP-G-352  COULD RADIOACTIVE RESIN MICROSHERES BE USED AS PHYPHILACTIC TREATMENT FOR COLORECTAL LIVER METASTASES IN RATS?
(Cintia Y. Morioka, Sao Paulo, Brazil)
LUNCH SESSIONS

Eight lunch sessions will be offered every day from Monday till Wednesday and will be held in rooms L1 - L8 in the Hall B of the Bella Center, always between 12:45 - 13:45.

The applicants for lunch sessions will be accepted on “first-come, first-served” basis.
Maximum number of participants for lunch sessions is strictly limited.
The fee for a lunch session is 50 EUR and includes admittance for one lunch session and lunch.

Please contact the Registration Desk for updated information on lunch sessions still available.

MONDAY, 17 OCTOBER 2005

1. EMR VERSUS ESD
Jacques Bergman (Amsterdam, The Netherlands), Horst Neuhaus (Düsseldorf, Germany)

2. MANAGEMENT OF PANCREATIC STONES
M. Delhaye (Brussels, Belgium), Dirk Gouma (Amsterdam, The Netherlands)

3. MODERN MANAGEMENT OF OESOPHAGEAL MOTILITY DISORDERS
Andrew Smout (Utrecht, The Netherlands), P. Poudreux (Nimes, France)

4. SUBCLASSIFICATION OF FUNCTIONAL DYSPPEPSIA - HELPFUL FOR TREATMENT?
Fermin Mearin (Barcelona, Spain), Guy Boeckxstaens (The Netherlands)

5. ANTIFIBROTIC THERAPY
Massimo Pinzani (Florence, Italy), Norifumi Kawada (Osaka, Japan)

6. MANAGEMENT OF NASH
Elisabetta Bugianesi (Italy), Helena Cortez-Pinto (Lisbon, Portugal)

7. INTRAABDOMINAL ABSCESS: RESECTION VERSUS DRAINAGE, TIMING OF SURGERY
IN FISTULIZING CROHN’S DISEASE
Stefan Schreiber (Kiel, Germany), Tom Oresland (Gothenburg, Sweden)

8. SURVEILLANCE FOR DISPLASIA IN IBD
Bryan Warren (Oxford, UK), Robert Lofberg (Stockholm, Sweden)
TUESDAY, 18 OCTOBER 2005

9. WHEN AND HOW TO PERFORM CHROMOENDOSCOPY
Thierry Ponchon (Lyon, France), Ralf Kiesslich (Mainz, Germany)

10. DISINFECTION AND STERILIZATION IN ENDOSCOPY
Christiane Neumann (Birmingham, UK), Axsel Kruse (Aarhus, Denmark)

11. MODERN 1ST, 2ND AND 3RD LINE HELICOBACTER PYLORI TREATMENT
Francis Megraud (Bordeaux, France), Franco Bazzoli (Bologna, Italy)

12. NON-H PYLORI NON-NSAID PEPTIC ULCERS
E.J. Kuipers (Rotterdam, The Netherlands), Klaus Mönkemüller (Magdeburg, Germany)

13. PORTAL HYPERTENSION: NON-RESPONDERS TO PRIMARY AND SECONDARY PROPHYLAXIS
Jaime Bosch (Barcelona, Spain), Andrew K. Burroughs (UK)

14. IS CIRRHOSIS REVERSIBLE?
Desmet Valeer (Heroverlee, Belgium), Fabio Marra (Florence, Italy)

15. NEUROENDOCRINE TUMORS: PAST, PRESENT AND FUTURE
Bertram Wiedenmann (Berlin, Germany), Philippe Ruzniewsky (France)

16. MANAGEMENT OF DIFFICULT CONSTIPATED PATIENTS
Anne Maire Leroi (Rouen, France), Paul Enck (Tübingen, Germany)

WEDNESDAY, 19 OCTOBER 2005

17. AGGRESSIVE THERAPY IN PANCREATIC CANCER
Helmut Friess (Heidelberg, Germany), Chris Verslype (Leuven, Belgium)

18. NEW INDICATIONS FOR CAPSULE ENDOSCOPY
Abraham R. Eliakim (Israel), Istvan Racz (Hungary)

19. MANAGEMENT OF SEVERE FUNCTIONAL DYSEPSISIA
Robert C. Heading (UK), Jan Tack (Leuven, Belgium), Greg Rubin (UK)

20. ENDOSCOPIC PALLIATION OF OESOPHAEGAL AND GASTRIC CANCER
Julius Spicak (Prague, Czech Republic), Remi Dumas (Monaco)

21. CLINICAL ASSESSMENT OF IRON OVERLOAD
Pierre Brissot (France), Rolf Hultcrantz (Stockholm, Sweden)

22. THE CLINICAL SPECTRUM OF AUTOIMMUNE LIVER DISEASE
Ulrika Broome (Stockholm, Sweden), Ulrich Beuers (Muenchen, Germany)

23. MAINTENANCE THERAPY IN IBD
Yehuda Chowers (Tel-Hashomer, Israel), Pia Munkholm (Copenhagen, Denmark)

24. THE USE OF SIMULATORS IN TEACHING ENDOSCOPY
Simon Bar Meir (Israel), Stanislas Chaussade (France)
ABSTRACT REVIEW PROCESS

The UEGF Scientific Committee and the Local Organising Committee would like to thank the following abstract reviewers who contributed their time and expertise to the UEGW 2005. Each abstract was reviewed by between 4 and 10 qualified reviewers during very complete and vigorous selection process.

Out of 2273 abstracts that were submitted, 1399 were accepted which represents an acceptance percentage of 61.54 %. Additional 114 abstracts were submitted for the late breaking abstract submission and 8 of them were accepted.

LIST OF REVIEWERS

Abstract Review Process Chairman: Prof. Michael J. G. Farthing

L. M. A. Akkermans
Joerg Albert
Tomasz Andrzej Marek
Vito Annese
Reza Ansari
Sandro Ardizzone
Josep R. Armengol-Miro
Constantine Arvanitakis
James Ashley Guthrie
Eric Assenat
John Atherton
Adolfo Attili
F. Azpiroz
Mehdi Babaei
C.G.M.I. Baeten
Anil Bagul
Ying Bao
Pradip Bardhan
Antonio Basoli
Laurent Beaughter
Christoph Beglinger

Robert Benamouzig
Jean Benhattar
Pradeep Bhandari
Janek Binek
Ulrich Böcker
Arnaud Bourreille
Henri Braat
Stanislas Bruley Des Varannes
Jørn Brynskov
Markus Büchler
Jan Bures
Peter Bytzer
Miguel Cameiro De Moura
Simon Campbell
Renzo Caprilli
Monica Carol
Luis Carrilho-Ribeiro
Filipe Caseiro-Alves
Laurent Castera
Augustin Castiella
Alessia Ciancio
Stefania Recalcati
Jaroslaw Regula
Luigi Ricciardiello
Xavier Roblin
Dietrich Rothenbacher
Greg Rubin
Riina Salupere
Javier Santos
Murat Saruc
Ove Schaffalitzky de Muckadell
Jürgen Schölmerich
Stefan Schreiber
Erik Schrumpf
Richard Schwab
Jean-Yves Scoazec
Alexandra Sermeus
Virender Sharma
Barbara Sheil
James Sheridan
Koichi Shibasaki
Gurkirpal Singh
Iraj Sobhani
Johan Söderholm
Sunil Sonwalkar
Federico Sopena
Rita Sousa
Robin Spiller
Aravamuthan Sreedharan
Vincenzo Stanghellini
Ketil Stordal
Ferenc Szalay
Akihiro Tamori
Ronan Thibault
Henrik Thorlacius
Karim Tifratene
Herbert Tilg
Ervin Toth
Trevisani
Anc Trifan
Jurriaan Tuynman
Vaidotas Urbonas
Dino Vaira
John Valentine
Gert Van Assche
J.J. Van Lanshott
Martijn Van Oijen
Gabor Varga
Hans Vasen
Enrique Velasco Sánchez
Severine Vermeire
Peter Vilmann
Hendrik Vilstrup
Libor Vitek
Moritz Wente
Clive Wilder-Smith
Heiko Witt
Henning Wittenburg
Kenshi Yao
Spyros Yarmenitis
Cihan Yurdaydin
Giovanni Zaninotto
Zuzana Zelinkova
Frank Zerbib
K.P. Zimmer
COMBINED EAGE, EDS, ISDS, EAES - POSTGRADUATE COURSE

GI ONCOLOGY AND INNOVATIVE ASPECTS IN GASTROENTEROLOGY

Course Organisers: Rudolf Arnold - EAGE (Marburg, Germany)
Peter Malfertheiner - EAGE (Magdeburg, Germany)
Dirk J. Gouma - EDS, ISDS, EAES (Amsterdam, The Netherlands)

SATURDAY, 15 OCTOBER 2005

Afternoon Session

Location: Auditorium 15

13:25 – 13:30 INTRODUCTION
Rudolf Arnold (Marburg, Germany)

SESSION I: GASTROINTESTINAL ONCOLOGY 1: GENERAL PRINCIPLES IN TUMOUR GENESIS: HOW DOES CANCER ARISE?

Chairmen: Peter Malfertheiner (Magdeburg, Germany)
J. J. Misiewicz (London, UK)

13:30 – 14:00 NEW PATHOLOGICAL ASPECTS
Günter Klöppel (Kiel, Germany)

14:00 – 14:30 MOLECULAR BIOLOGY
Mohammad Ilyas (Leeds, UK)

14:30 – 15:00 GENETICS
Marco Novelli (London, UK)

15:00 – 15:30 STEM CELLS
Nicholas Wright (London, UK)

15:30 – 16:00 COFFEE BREAK
**SESSION II: GASTROINTESTINAL ONCOLOGY 2: OESOPHAGEAL CANCER AND CANCER OF THE CARDIA**

**Chairmen:** Jean-Paul Galmiche (Nantes, France)  
Lars Lundell (Stockholm, Sweden)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 – 16:25</td>
<td>EPIDEMIOLOGY, DIVERSITY AND PATHOGENESIS</td>
<td>Mario Sarbia (Munich, Germany)</td>
</tr>
<tr>
<td>16:25 – 16:50</td>
<td>STAGING: THE ROLE OF ENDOSONOGRAPHY, CT/MRT AND PET</td>
<td>T. Lerut (Leuven, Belgium)</td>
</tr>
<tr>
<td>16:50 – 17:15</td>
<td>TREATMENT: BRACHYTHERAPY VS. STENTING FOR PALLIATION</td>
<td>Peter D. Siersema (Rotterdam, The Netherlands)</td>
</tr>
<tr>
<td>17:15 – 17:40</td>
<td>TREATMENT: THE ROLE OF ENDO SCOPY</td>
<td>Christian Ell (Wiesbaden, Germany)</td>
</tr>
<tr>
<td>17:40 – 18:05</td>
<td>TREATMENT: HOW TO OPTIMIZE SURGICAL OUTCOME</td>
<td>Hubert J. Stein (Munich, Germany)</td>
</tr>
<tr>
<td>18:30 – 18:55</td>
<td>IS OESOPHAGEAL CANCER A PREVENTABLE DISEASE?</td>
<td>Rudolf Arnold (Marburg, Germany)</td>
</tr>
</tbody>
</table>
SUNDAY, 16 OCTOBER 2005

Morning Session

Location: Auditorium 15

SESSION III: GASTROINTESTINAL ONCOLOGY 3: GASTRIC CANCER

Chairmen: Antonio Basoli (Rome, Italy)
Guide N. J. Tytgat (Amsterdam, The Netherlands)

09:00 – 09:25 EPIDEMIOLOGY, DIVERSITY AND PATHOGENESIS
Marcis Leja (Riga, Latvia)

09.25 – 09:50 TREATMENT: THE ROLE OF ENDOSCOPY
Horst Neuhaus (Düsseldorf, Germany)

09:50 – 10:15 TREATMENT: THE ROLE OF EXTENDED SURGERY
Cornelius van de Velde (Leiden, The Netherlands)

10:15 – 10:40 TREATMENT: THE ROLE OF CHEMOTHERAPY AND RADIOTHERAPY
Eric van Cutsem (Leuven, Belgium)

10:40 – 11:05 IS GASTRIC CANCER A PREVENTABLE DISEASE?
Ernst J. Kuipers (Rotterdam, The Netherlands)

11:05 – 11:35 COFFEE BREAK

SESSION IV: GASTROINTESTINAL ONCOLOGY 4: COLORECTAL AND ANAL CANCER

Chairmen: M. Classen (Munich, Germany)
Alberto Montori (Rome, Italy)

11:35 – 12:00 EPIDEMIOLOGY, GENETICS, DIVERSITY AND PATHOGENESIS
Heinz Hammer (Graz, Austria)

12:00 – 12:25 TREATMENT: COLONIC STENTING AS THE “BRIDGE TO SURGERY”
AND PALLIATIVE TREATMENT
Søren Meisner (Copenhagen, Denmark)

12:25 – 12:50 TREATMENT: IS LAPAROSCOPIC COLONIC SURGERY FIRST CHOICE?
Antonio Lacy (Barcelona, Spain)

12:50 – 14:00 LUNCH

14:00 – 14:25 TREATMENT: THE ROLE OF ADJUVANT CHEMOTHERAPY
Wolff Schmiegel (Bochum, Germany)

14:25 – 14:50 TREATMENT: RADIOTHERAPY IN RECTAL CANCER: PRE- OR POSTOPERATIVE?
Lars Pahlman (Uppsala, Sweden)
14:50 – 15:30  **ROUND TABLE: COLON CANCER PREVENTION IN EUROPE**  
**Chair:** M. Classen (Munich, Germany)  
Bohumil Seifert (Prague, Czech Republic)  
Jean Faivre (Dijon, France)  
Christoph Beglinger (Basel, Switzerland)

15:30 – 16:00  **COFFEE BREAK**

**SESSION V:**  **GASTROINTESTINAL ONCOLOGY 5: BILIO PANCREATIC CANCER**

**Chairmen:** Dirk J. Gouma (Amsterdam, The Netherlands)  
Juan Malagelada (Barcelona, Spain)

16:00 – 16:25  **EPIDEMIOLOGY AND RISK FACTORS**  
Guenter Krejs (Graz, Austria)

16:25 – 16:50  **DIAGNOSTIC WORK UP OF PATIENTS WITH BILIARY-PANCREATIC CANCER**  
Julius Spicak (Prague, Czech Republic)

16:50 – 17:15  **TREATMENT: ENDOSCOPIC MANAGEMENT OF OBSTRUCTIVE JAUNDICE AND GASTRIC OUTLET OBSTRUCTION**  
Guido Costamagna (Rome, Italy)

17:15 – 17:40  **TREATMENT: SURGICAL TREATMENT OF PANCREATIC CANCER**  
Helmut Friess (Heidelberg, Germany)

17:40 – 18:05  **TREATMENT: SURGICAL TREATMENT OF BILE DUCT CANCER**  
Jean-Francois Gigot (Brussels, Belgium)

18:05 – 18:30  **ROLE OF CHEMO- AND RADIOTHERAPY**  
J. Luc. Van Laethem (Brussels, Belgium)

18:30 – 18:35  **CONCLUSION**  
Rudolf Arnold (Marburg, Germany)
EASL POSTGRADUATE COURSE

TRANSLATING LIVER CELL BIOLOGY IN REGENERATIVE THERAPIES

Date: Sunday, 16 October 2005
Location: Auditorium 10

Course Directors: Massimo Pinzani (Florence, Italy)
Tania Roskams (Leuven, Belgium)
Hanne Cathrine Bisgaard (Copenhagen, Denmark)

09:30 - 09:45  INTRODUCTION
Massimo Pinzani (Florence, Italy)

09:45 - 10:15  CELL BIOLOGY OF LIVER REGENERATION: LESSONS FROM ANIMAL MODELS
Malcolm Alison (London, UK)

10:15 - 10:45  BIOLOGY OF HUMAN LIVER REGENERATION
Tania Roskams (Leuven, Belgium)

10:45 - 11:15  COFFEE BREAK

11:15 - 11:45  STRATEGIES FOR IDENTIFICATION OF MOLECULES AND PATHWAYS WITH ROLES IN LIVER REGENERATION
Hanne Cathrine Bisgaard (Copenhagen, Denmark)

11:45 - 12:15  STRATEGIES PROMOTING LIVER REGENERATION
Christian Trautwein (Hannover, Germany)

12:15 - 12:45  ISOLATION OF HUMAN PROGENITOR CELLS AND THEIR POSSIBLE THERAPEUTIC APPLICATION: COMPARISON WITH OTHER POSSIBLE SOURCES
Mario Strazzabosco (Bergamo, Italy)

12:45 - 13:45  LUNCH

13:45 - 14:15  HEPATOCYTE TRANSPLANTATION: ISOLATION, PRESERVATION AND THERAPEUTIC USE: WHERE DO WE STAND?
Ragai Mitry (London, UK)

14:15 - 14:45  TRANSPLANTATION WITH GENETICALLY MODIFIED CELLS
Jurgen Seppen (Amsterdam, The Netherlands)

14:45 - 15:15  DEVELOPMENT OF A HYBRID LIVER SUPPORT SYSTEM
J. C. Gerlach (Pittsburgh, PA, USA)

15:15 - 15:45  COFFEE BREAK

15:45 - 16:15  BIOARTIFICIAL LIVER: NEW TECHNOLOGIES FOR LIVER SUPPORT AND DRUG SCREENING
Skalk Van Der Merwe (Pretoria, South Africa)

16:15 - 16:45  BIOETHICS OF CELL THERAPY
Kris Dierickx (Leuven, Belgium)

16:45 - 17:00  FINAL REMARKS
Tania Roskams (Leuven, Belgium)
Hanne Cathrine Bisgaard (Copenhagen, Denmark)
ESPHERAN Postgraduate Course

PEDiATRiC PROCEDUREs

Date:  
Sunday, 16 October 2005
Location:  
Room 19
Chairmen:  
Michael Lentze (Bonn, Germany)
Steffen Husby (Odense, Denmark)

09:00 – 09:40  UPPER GI ENDOsCOpy
Jean Pierre Olives (Toulouse, France)

09:40 – 10:20  ESOPHAGUS pH-METRY AND BEYOND
Yvan Vandenplas (Brussels, Belgium)

10:20 – 10:40  BREAK

10:40 – 11:20  COLONOSCOPY/LOWER GI ENDOsCOpy
Mike Thomson (Sheffield, UK)

11:20 – 12:00  DiAGNOSTiC TOOLS FOR ANORECTRAL DISORDERS
Marc Benninga (Amsterdam, The Netherlands)
ESGE TEACHING ACTIVITIES

SATURDAY, 15 OCTOBER
Location: Auditorium 10, 11, 12

The ESGE Postgraduate Course offers state of the art presentation of current endoscopy practice. Through satellite transmissions from expert centers in Bruxelles, Rome and Copenhagen the core technologies, as well as the cutting edge of novel methods will be shown for discussion. This year we will focus even more on basic elements of the techniques, to enable more participants to feel confident about taking up the methods themselves. The live transmissions will alternate with review talks on core topics for the GI endoscopy practice of today and tomorrow.

MORNING SESSION, 08:30 – 12:45

New Technologies

Moderators
Lars Aabakken (Oslo, Norway)
Brian P. Saunders (Harrow, UK)

Technical director
Rainer Schöfl (Linz, Austria)

08:30 - 08:40 OPENING REMARKS
Lars Aabakken (Oslo, Norway)

08:40 - 09:10 THE FUTURE OF MUCOSAL IMAGING - AUTOFLUORESCENCE/NBI/HDTV
E. Dekker (Amsterdam, The Netherlands)

09:10 - 10:30 LIVE DEMONSTRATION (ROME, BRUSSELS, COPENHAGEN)
Guido Costamagna (Roma, Italy)
Jacques Devière (Brussels, Belgium)
Søren Meisner (Copenhagen, Denmark)
Aksel Kruse (Aarhus, Denmark)
Peter Vilmann (Copenhagen, Denmark)

10:30 - 11:00 COFFEE BREAK

11:00 - 11:30 SMALL BOWEL IMAGING – VIDEO CAPSULE OR DOUBLE BALLOON ENTEROSCOPY?
Christian Ell (Wiesbaden, Germany)

11:30 - 12:45 LIVE DEMONSTRATION (ROME, BRUSSELS, COPENHAGEN)
Guido Costamagna (Roma, Italy)
Jacques Devière (Brussels, Belgium)
Aksel Kruse (Aarhus, Denmark)
Peter Vilmann (Copenhagen, Denmark)
AFTERNOON SESSION, 14:00 – 17:30

Practice of Endoscopy

Moderators
- Horst Neuhaus (Düsseldorf, Germany)
- Sören Meisner (Copenhagen, Denmark)

Technical director
- Paul Fockens (Amsterdam, The Netherlands)

14:00 - 14:30
ENDOSCOPE AND ACCESSORY CLEANSING
Jean-Francois Rey (Laurent du Var Cedex, France)

14:30 - 15:30
LIVE DEMONSTRATION (ROME, BRUSSELS, COPENHAGEN)
- Guido Costamagna (Roma, Italy)
- Jacques Devière (Brussels, Belgium)
- Aksel Kruse (Aarhus, Denmark)
- Peter Vilmann (Hellerup, Denmark)

15:30 - 16:00
COFFEE BREAK

16:00 - 16:30
SEDATION IN EUROPE – SIMILARITIES AND DIFFERENCES
Spiros D. Ladas (Athens, Greece)

16:30 - 17:30
LIVE DEMONSTRATION (ROME, BRUSSELS, COPENHAGEN)
- Guido Costamagna (Roma, Italy)
- Jacques Devière (Brussels, Belgium)
- Aksel Kruse (Aarhus, Denmark)
- Peter Vilmann (Hellerup, Denmark)

ESGE VIDEO CASE MARATHON

WEDNESDAY, 19 OCTOBER, 8:30 – 10:30
Location: A1 Congress Hall

The main goal of the ESGE Video Case Marathon is to present unusual cases or new technologies based on diagnostics of therapeutic endoscopy. During this session, short videos showing examples of new, unexpected, or exceptional endoscopic practice will be presented and briefly discussed.

ESGE brochure containing detailed information about all ESGE teaching activities is included in your congress bag.
BUSINESS MEETINGS

ASNEMGE

SUNDAY, 16 OCTOBER 2005
9:00 - 17:00  ASNEMGE YOUNG INVESTIGATOR MEETING WORKSHOP
               room 26

TUESDAY, 18 OCTOBER 2005
7:00 - 10:00  ASNEMGE GOVERNING COUNCIL EXECUTIVE MEETING
               room 25
11:30 - 14:00 ASNEMGE AGM MEETING
               room 26

BMI BOARD

WEDNESDAY, 19 OCTOBER 2005
8:30 - 12:00  BMI BOARD MEETING
               room 21

EAGE

SATURDAY, 15 OCTOBER 2005
19:00 - 20:45  EAGE BOARD MEETING
               room 21

ECCO

SUNDAY, 16 OCTOBER 2005
16:30 - 19:00  ECCO ANNUAL GENERAL ASSEMBLY MEETING
               Bella Vista 1

ECSSID

WEDNESDAY, 19 OCTOBER 2005
8:30 - 10:30  ECSSID MEETING
               room 19
EDS

TUESDAY, 18 OCTOBER 2005
7:00 - 8:30  EDS COUNCIL MEETING
    room 26

TUESDAY, 18 OCTOBER 2005
12:15 - 14:00  EDS GENERAL ASSEMBLY MEETING
    room 20

ESGE

SUNDAY, 16 OCTOBER 2005
8:30 - 10:00  ESGE EXECUTIVE COMMITTEE MEETING
    room 21
10:00 - 13:00  ESGE GOVERNING BOARD MEETING
    room 21

MONDAY, 17 OCTOBER 2005
7:30 - 8:30  ENDOSCOPY EDITORIAL BOARD MEETING
    room 18
12:30 - 14:00  ESGE EDUCATION COMMITTEE MEETING
    room 20
15:00 - 16:30  ESGE VIDEO CAPSULE ENDOSCOPY INTEREST GROUP MEETING
    room 20
17:00 - 19:00  ESGE GUIDELINES COMMITTEE MEETING
    room 20

TUESDAY, 18 OCTOBER 2005
8:00 - 10:30  ESGE NEED PROJECT MEETING
    room 20
12:00 - 13:30  ESGE GENERAL ASSEMBLY
    room 18
15:00 - 16:00  ESGE RESEARCH COMMITTEE CORE MEETING
    room 20
16:00 - 17:30  ESGE RESEARCH COMMITTEE MEETING
    room 20
17:45 - 19:00  ESGE PEG GROUP MEETING
    room 20
**ESGENA**

**SATURDAY, 15 OCTOBER 2005**
8:00 - 12:00  
ESGENA BOARD MEETING  
room 21

**SUNDAY, 16 OCTOBER 2005**
17:15 - 18:15  
ESGENA GENERAL ASSEMBLY MEETING  
room 19

**MONDAY, 17 OCTOBER 2005**
11:00 - 16:00  
ESGENA EDUCATION WORKING GROUP MEETING  
room 19

**EPC**

**TUESDAY, 18 OCTOBER 2005**
12:00 - 14:00  
EUROPEAN PANCREATIC CLUB COUNCIL MEETING  
room 25

**SAGIM**

**WEDNESDAY, 19 OCTOBER 2005**
15:30 - 18:00  
STEERING COMMITTEE MEETING AND GENERAL ASSEMBLY 2005  
room 26

**UEGF**

**MONDAY, 17 OCTOBER 2005**
8:30 - 10:00  
UEGF EXTRAORDINARY COUNCIL MEETING  
room 21

17:30 - 19:00  
UEGF GENERAL ASSEMBLY MEETING  
room 19

**WEDNESDAY, 19 OCTOBER 2005**
8:30 - 16:00  
UEGF COUNCIL MEETING  
room 20

**UEGF SCIENTIFIC COMMITTEE**

**TUESDAY, 18 OCTOBER 2005**
16:00 - 19:30  
UEGF SCIENTIFIC COMMITTEE MEETING  
room 25
COMMON INTEREST GROUPS

COLLABORATE MEETING OF THE FOUR COCHRANE GI GROUPS DURING THE UEGW

Date: Sunday, 16 October
Time: 14:00 - 16:00
Room: Room 19

Chairman: Christian Gluud, The Cochrane Hepato-Biliary Group

14:00 - 14:05
WELCOME AND INTRODUCTION TO THE COCHRANE COLLABORATION AND THE MEETING
Christian Gluud (Copenhagen, Denmark)

14:05 - 14:25
VASOACTIVE DRUGS AND TIPS FOR HEPATORENAL SYNDROME
Lise Lotte Gluud, Mette Kjaer, Erik Christensen (Copenhagen, Denmark)

14:25 - 14:45
MECHANICAL BOWEL CLEANSING BEFORE ELECTIVE COLORECTAL SURGERY
Peer Wille-Jørgensen, Katia F. Guenaga, Delcio Matos, Aldemar A. Castro, Alvaro N. Atallah (Copenhagen, Denmark)

14:45 - 15:05
RIBAVIRIN PLUS INTERFERON VERSUS INTERFERON FOR CHRONIC HEPATITIS C
Jesper Brok, Lise Lotte Gluud, Christian Gluud (Copenhagen, Denmark)

15:05 - 15:25
PEGYLATED INTERFERON PLUS RIBAVIRIN VERSUS NON-PEGYLATED INTERFERON PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Marija Simin, Jesper Brok, Davor Stimac, Christian Gluud, Lise Lotte Gluud (Rijeka, Croatia)

15:25 - 15:45
HEPATITIS B PROPHYLAXIS FOR NEWBORNS OF HEPATITIS B SURFACE ANTIGEN-POSITIVE MOTHERS
Chanfang Lee, Yan Gong, Jesper Brok, Elisabeth H. Boxall, Christian Gluud (Copenhagen, Denmark)

15:45 - 16:00
TRANSCATHETER ARTERIAL EMBOLISATION AND CHEMOEMBOLISATION FOR HEPATOCELLULAR CARCINOMA
Roberto S. Oliveri, Christian Gluud (Copenhagen, Denmark)
SATellite Symposium: Altana Pharma

Advanced Insight Into the True Measures of GERD

Date: Sunday, 16 October 2005
Time: 18:00 – 19:30
Room: A2+A3 Congress Hall

Chairman: Robert C. Heading

Overlapping Abdominal Symptoms: Why do GERD and IBS Often Coexist?
Nicholas Talley, Rochester, USA

The Complete Remission Concept
Hubert Mönnikes, Berlin, Germany

Debate Session: Is Endoscopy Unnecessary in the Management of Uncomplicated GERD?
Endoscopy: Stuart Spechler, Dallas, USA
Symptoms: Peter Malfertheiner, Magdeburg, Germany

Long-term GERD Management: The Individualized Approach
Guido Tytgat, Amsterdam, The Netherlands
SATELLITE SYMPOSIUM: ASTRazeneca

MEETING THE CLINICAL DEMANDS IN ACID RELATED DISORDERS

Date: Monday, 17 October 2005
Time: 18:00 – 19:30
Room: A2+A3 Congress Hall

Chairman: Karsten Lauritsen

WELCOME
Karsten Lauritsen

THE BURDEN OF REFLUX DISEASE – HAVE WE MEASURED IT ADEQUATELY?
Jan Hattlebak

UNMET NEEDS IN REFLUX DISEASE – HOW TO APPROACH THESE IN THE REFERRED PATIENT?
Jean-Paul Galmiche

THE PRAGUE CLASSIFICATION OF BARRETT’S OESOPHAGUS - WHY DOES IT MATTER?
Prateek Sharma

EVOLVING AREAS OF ACID INHIBITION – WHAT EVIDENCE IS NEEDED TO PROGRESS CURRENT PRACTICE?
Nimish Vakil

Discussion and concluding remarks
**SATELLITE SYMPOSIUM: ELAN/BIOGEN IDEC.**

**OPTIMIZING THE TREATMENT OF CROHN’S DISEASE: THE ROLE OF BIOLOGICS**

<table>
<thead>
<tr>
<th>Date:</th>
<th>Tuesday, 18 October 2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time:</td>
<td>18:00 – 19:30</td>
</tr>
<tr>
<td>Room:</td>
<td>Auditorium 15</td>
</tr>
<tr>
<td>Chairman:</td>
<td>Dr. Stefan Schreiber</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18:00 – 18:10</th>
<th>THE EVOLUTION OF THE TREATMENT OF IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stefan Schreiber, MD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18:10 – 18:30</th>
<th>CURRENT LIMITATIONS OF LONG-TERM THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Michael A. Kamm, MD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18:30 – 19:00</th>
<th>BIOLOGICS: OVERCOMING THE LIMITATIONS?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>William Sandborn, MD</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>19:00 – 19:30</th>
<th>Q&amp;A</th>
</tr>
</thead>
</table>
SATELLITE SYMPOSIUM: NOVARTIS

DYSMOTILITY AND SENSORY SYMPTOMS: UNDERSTANDING AND TREATING IBS-C

Date: Sunday, 16 October 2005
Time: 16:00–17:30
Room: Auditorium 11,12

WELCOME AND INTRODUCTION
Michael Camilleri

IBS: A DISEASE WORTH TREATING
Eamonn Quigley
Q&A session Michael Camilleri

PATHOPHYSIOLOGY OF IBS: UNDERSTANDING THE SCIENTIFIC BREAKTHROUGHS
Magnus Simrén
Q&A session Michael Camilleri

REDEFINING TREATMENT EXPECTATIONS IN IBS: THE SEROTONERGIC AGENTS
Jan Tack
Q&A session Michael Camilleri

A NEW APPROACH TO TREATING IBS-C: TEGASEROD – EFFICACY AND REPEATED TREATMENT
Michael A Kamm

A NEW APPROACH TO TREATING IBS-C: TEGASEROD – SAFETY AND QUALITY OF LIFE
Benoit Coffin
Q&A session Michael Camilleri

TEGASEROD: THE REALITY OF CLINICAL PRACTICE
Lin Chang
Q&A session Michael Camilleri

CONCLUSIONS AND CLOSE
Michael Camilleri
SATELLITE SYMPOSIUM:
SCHERING-PLOUGH

BREAKING THE FLARE CYCLE: TIME-BOUND TREATMENT STRATEGIES FOR ULCERATIVE COLITIS AND CROHN’S DISEASE

Date: Tuesday, 18 October 2005
Time: 20:00 - 21:30
Room: A1 Congress Hall

20:00 – 20:15 WELCOME AND INTRODUCTION
Paul Rutgeerts, MD, PhD, FRCP, Chair
Professor of Medicine, University of Leuven, Leuven, Belgium

20:15 – 20:30 INFLIXIMAB: EXPERIENCE IN CROHN’S DISEASE
Subrata Ghosh, MD, FRCP
Chair in Gastroenterology, Imperial School of Medicine, London, United Kingdom

20:30 – 20:45 THE IMPACT OF IBD: THE PATIENT PERSPECTIVE
Rod Mitchell
Chairman, European Federation of Crohn’s & Ulcerative Colitis Associations (EFCCA), Bournemouth, United Kingdom

20:45 – 21:00 INFLIXIMAB EXPERIENCE IN ULCERATIVE COLITIS:
ACT 1 AND 2 TRIAL DATA
Paul Rutgeerts, MD, PhD, FRCP

21:00 – 21:15 TREATMENT ALGORITHMS IN ULCERATIVE COLITIS
Remo Panaccione, MD
Associate Professor of Medicine, Director, Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada

21:15 – 21:30 QUESTION-AND-ANSWER SESSION

PROGRAMME REGISTRATION
Admittance to the symposium is complimentary for all participants of both UEGW and the ESGENA Conference.
A PRECISE LOOK AT ANTI-TNFS: FOCUSING ON THE NEEDS OF PATIENTS WITH CROHN’S DISEASE

Date:       Wednesday, 19 October 2005
Time:       15:45-17:15
Room:       Auditorium 10, 11, 12

INSIGHTS FROM LARGE-SCALE CROHN’S DISEASE TRIALS: IMPROVING CLINICAL PRACTICE
William Sandborn

DO ALL TNF INHIBITORS AFFECT THIS T-CELL MEDIATED DISEASE THE SAME WAY?
Brian Feagan

PRECISE 2: NEW CLINICAL RESULTS WITH CERTOLIZUMAB IN CROHN’S DISEASE
Stefan Schreiber
ALTANA Pharma Satellite Symposium

Advanced Insight into the True Measures of GERD

Sunday, October 16, 2005
18:00–19:30
Bella Center, Hall A2 + A3, Copenhagen, Denmark

Programme

Welcome and Introduction
Robert C. Heading, Edinburgh, UK
Chairman

Overlapping abdominal symptoms: why do GERD and IBS often coexist?
Nicholas Talley, Rochester, USA

The complete remission concept
Hubert Mönnikes, Berlin, Germany

Debate session: Endoscopy or symptoms: which is more important?
Stuart Spechler, Dallas, USA
Peter Malfertheiner, Magdeburg, Germany

An individualized approach to long-term GERD management
Guido Tytgat, Amsterdam, The Netherlands

COME AND VISIT US
at the ALTANA Pharma booth no. E 008 at the Bella Center, Copenhagen, Denmark
The Power of Protection

- Clinically proven to heal more reflux esophagitis patients compared to omeprazole, lansoprazole and pantoprazole.
- Faster and sustained freedom from GERD symptoms in more patients than omeprazole, lansoprazole and pantoprazole.
- More effective acid control compared to all other PPIs.

Nexium®
esomeprazole

ABBREVIATED PRESCRIBING INFORMATION: Nexium® (esomeprazole magnesium). See local prescribing information for full details. PHARMACODYNAMIC PROPERTIES: Nexium® reduces gastric acid secretion through a highly targeted mechanism of action by being a specific inhibitor of the acid pump in the parietal cell. INDICATIONS AND DOSAGE: Treatment of erosive reflux esophagitis: Nexium® 40 mg once daily for 4-8 weeks. Long-term management of patients with healed erosive esophagitis to prevent relapse: Nexium® 20 mg once daily. Symptomatic treatment of gastro-esophageal reflux disease: Nexium® 20 mg once daily in patients without esophagitis. Once symptoms have resolved, an on-demand regimen of 20 mg once daily can be used when needed, to control subsequent symptoms. Helicobacter pylori-associated peptic ulcer disease: Healing of H. pylori-associated duodenal ulcer, prevention of relapse of peptic ulcers in patients with H. pylori-associated ulcers: Nexium® 20 mg, amoxicillin 1 g and clarithromycin 500 mg, all bid for 7 weeks. USA - Nexium® 40 mg once daily, amoxicillin 1 g and clarithromycin 500 mg twice daily, for 10 days. CONTRAINDICATIONS: Known hypersensitivity to esomeprazole, substituted benzamides or any other components of the formulation. WARNINGS AND PRECAUTIONS: In the presence of any alarm symptoms (e.g., significant unintentional weight loss, recurrent vomiting, dysphagia, haematoma or melanosis) and when gastric ulcer is suspected or present, the possibility of gastric malignancy should be excluded before treatment is initiated. INTERACTIONS: Due to the decreased intragastric acidity, the absorption of ketoconazole and itraconazole can decrease during esomeprazole treatment. Concomitant administration of esomeprazole resulted in a 45% decrease in clearance of diazepam. Concomitant administration of esomeprazole resulted in a 15% increase in trough plasma levels of phenytoin in epileptic patients; but dose adjustments were not required in this study. In healthy volunteers, combined therapy with esomeprazole and clarithromycin resulted in a 37% increase in AUC and a 32% prolongation of elimination half-life but no significant increase in peak plasma levels of clarithromycin. Concomitant administration of 20 mg esomeprazole to warfarin-treated patients showed that, despite a slight elevation in the trough plasma concentration of the less potent R-isomer of warfarin, the coagulation times were within the accepted range. However, as with all patients receiving warfarin, monitoring is recommended during concomitant treatment with esomeprazole. PREGNANCY AND LACTATION: Caution should be exercised when prescribing Nexium® to pregnant women. Nexium® should not be used during breast-feeding. UNDESIRABLE EFFECTS: The following adverse drug reactions have been identified or suspected in the clinical trials programme. None was found to be dose related. Common: Nausea/vomiting, diarrhoea, constipation, abdominal pain, flatulence and headache. Uncommon: Dermatitis, pruritus, arthralgia, dizziness and dry mouth. From marketed use, there have been rare reports of increased liver enzymes and of hypersensitivity reactions e.g., angioedema, anaphylactic reaction. For further information please contact AstraZeneca, SE-451 35 Mölndal or the local AstraZeneca subsidiary.

Nexium® is a registered trademark of the AstraZeneca group of companies.


A Guiding Star in Gastroenterology
www.gastrosource.com
FAST FACTS
IN AN HOUR

FAST BIRD
A Peregrine Falcon can reach speeds in excess of 200 miles per hour.

FAST PPI
Pariet 20mg starts reducing acid secretion within one hour of the first dose!

FAST FACTS #21

*Fast facts are provided for educational purposes only and should not be used as a substitute for professional medical advice. Always consult a healthcare professional for diagnosis and treatment of any health condition. This material is not intended to cover all possible information, precautions, or adverse reactions.

*Pariet and Rabeprazole are trademarks of Eisai Company Limited, Tokyo, Japan. Functions and indications for Pariet and Rabeprazole may differ from country to country. The information provided is based on current knowledge and may be subject to change. Refer to the product information and consultation with healthcare professionals for detailed information.

*The information provided is not intended to replace professional medical advice, diagnosis, or treatment. Always consult a healthcare professional or your pharmacist for appropriate medical advice.

*Pariet is available as a generic drug under the names Rabal喀al, AcipHex, Zegeral (in the U.S.), and Rabcat.
Novartis Satellite Symposium

Dysmotility and sensory symptoms: understanding and treating IBS-C

UEGW 2005
Auditoriums 11 and 12
Bella Center
Copenhagen, Denmark

Sunday 16 October 2005
16.00–17.30

Program

Welcome and introduction
Michael Camilleri

IBS: a disease worth treating
Eamonn Quigley
Q&A session Michael Camilleri

Pathophysiology of IBS: understanding the scientific breakthroughs
Magnus Simrén
Q&A session Michael Camilleri

Redefining treatment expectations in IBS: the serotonergic agents
Jan Tack
Q&A session Michael Camilleri

A new approach to treating IBS-C: tegaserod – efficacy and repeated treatment
Michael A Kamm

A new approach to treating IBS-C: tegaserod – safety and quality of life
Benoit Coffin
Q&A session Michael Camilleri

Tegaserod: the reality of clinical practice
Lin Chang
Q&A session Michael Camilleri

Conclusions and close
Michael Camilleri
True innovation comes when you explore beyond the limits!

Join us to redefine endoscopy at the Olympus booth!

Introducing the new EVIS EXERA II generation. A breakthrough in imaging technology and compatibility, which extends beyond current medical limitations – giving you all the options for the future.

Find out more at: www.olympus-europa.com
BREAKING THE FLARE CYCLE: TIME-BOUND TREATMENT STRATEGIES FOR ULCERATIVE COLITIS AND CROHN’S DISEASE

SATELLITE SYMPOSIUM
Tuesday 18 October 2005
19:30 – 20:00 Light Dinner Reception — A1 Foyer
20:00 – 21:30 Symposium — A1 Congress Hall
BC Copenhagen Congress Center
Bella Center
Copenhagen, Denmark

SYMPOSIUM AGENDA
Welcome and Introduction
Paul Rutgeerts, MD, PhD, FRCP, Chair

Infliximab: Experience in Crohn's Disease
Subrata Ghosh, MD, FRCP

The Impact of IBD: The Patient Perspective
Rod Mitchell

Infliximab Experience in Ulcerative Colitis: ACT 1 and 2 Trial Data
Paul Rutgeerts, MD, PhD, FRCP

Treatment Algorithms in Ulcerative Colitis
Remo Panaccione, MD

Question-and-Answer Session

This activity is sponsored by Schering-Plough
Designed to Deliver

The scientific design of Creon® ensures that our patented Minimicrospheres® release their full digestive power while, at the same time, completely protecting enzymes from inactivation.

Today, Solvay looks back on more than 100 years of expertise in enzyme supplementation. Our passion and commitment to improve the quality of life of patients around the world continues unabated into the future.

For more information please visit
www.creonmms.com

Creon
The most prescribed enzyme preparation for pancreatic exocrine insufficiency in the world.
BREAKFAST MEETING: ABBOTT IMMUNOLOGY

BUILDING A NEW PARADIGM IN CROHN’S DISEASE THERAPY: TODAY’S LESSONS AND FUTURE OPPORTUNITIES

Date: Tuesday, 18 October 2005
Time: 07:00 – 08:00
Room: Room M4 in Hall C

Chairman: Prof. Paul Rutgeerts

07:00–07:05 INTRODUCTION
Prof. Paul Rutgeerts (University of Leuven, Belgium)

07:05–07:25 MAPPING THE PROGRESS OF CROHN’S DISEASE THERAPY: CONSIDERING NEW PARADIGMS FOR FUTURE THERAPY
Prof. Paul Rutgeerts (University of Leuven, Belgium)

07:25–07:45 ROADMAP TO THE FUTURE IN CROHN’S DISEASE: WHAT’S NEXT FOR BIOLOGICS?
Dr William Sandborn (Mayo Clinic, Rochester, MN, USA)

07:45–08:00 DISCUSSION AND CLOSE
BREAKFAST MEETING:
FERRING
PHARMACEUTICALS

MESALAZINE IN IBD IN THE 21ST CENTURY

Date: Tuesday, 18 October 2005
Time: 07:00 – 08:00
Room: Room M1 in Hall C

Chairman: Prof. Michael Kamm (UK)

07:00–07:05 WELCOME & INTRODUCTION
Prof. Michael Kamm (UK)

07:05–07:25 OPTIMAL USE OF MESALAZINE, AND CANCER PREVENTION, IN ULCERATIVE COLITIS
Prof. Michael Kamm (UK)

07:25–07:45 OPTIMISING COMPLIANCE, AND USE OF MESALAZINE IN CROHN’S DISEASE
Dr. Sunanda Kane (USA)

07:45–08:00 DISCUSSION & CLOSING REMARKS
BREAKFAST MEETING: SCHERING AG

REGULATING IMMUNE FUNCTION IN CROHN’S DISEASE: NEW TREATMENT STRATEGIES

Date: Tuesday, 18 October 2005
Time: 07:00 – 08:00
Room: Room M2 in Hall C

Chairman: Pia Munkholm, MD, DMSci (Copenhagen, Denmark)

07:00–07:05 WELCOME: THE NEED FOR NEW TREATMENT STRATEGIES IN CROHN’S DISEASE: HOW MUCH PROGRESS ARE WE MAKING?
Pia Munkholm, MD, DMSci (Copenhagen, Denmark)

07:05–07:30 TARGETING THE INNATE AND ADAPTIVE IMMUNE SYSTEMS IN CROHN’S DISEASE
Sander van Deventer, MD, PhD (Amsterdam, The Netherlands)

07:30–07:55 SARGRAMOSTIM (GM-CSF) FOR ACTIVE CROHN’S DISEASE: REDEFINING THE THERAPEUTIC PARADIGM
Joshua Korzenik, MD (Boston, MA, USA)

07:55–08:00 SUMMARY
Pia Munkholm, MD, DMSci (Copenhagen, Denmark)
BREAKFAST MEETING:
SHIRE PHARMACEUTICALS

A REVOLUTIONARY ADVANCE IN 5-ASA DELIVERY

Date: Wednesday, 19 October 2005
Time: 07:00 – 08:00
Room: Room M1 in Hall C

INTRODUCTION
Michael Kamm (UK)

COMPLIANCE AS A DRIVER FOR IMPROVED THERAPEUTIC OUTCOMES
Sunanda Kane (USA)

SPD476: LEADING THE WAY
Geert D’Haens (Belgium)

SPD476: COMBINING CONVENIENCE, COMPLIANCE AND COMPLETE COLON COVERAGE
Michael Kamm (UK)

DISCUSSION
## ESGENA SCIENTIFIC PROGRAMME

### ESGENA WORKSHOPS

<table>
<thead>
<tr>
<th>SATURDAY, 15 OCTOBER 2005</th>
<th>1st Floor</th>
<th>1st Floor</th>
<th>1st Floor</th>
<th>1st Floor</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROOM 18</td>
<td>ROOM 19</td>
<td>ROOM 20</td>
<td>ROOM 26+27</td>
<td></td>
</tr>
<tr>
<td><strong>LANGUAGE</strong></td>
<td>English</td>
<td>English</td>
<td>English</td>
<td>Danish</td>
</tr>
<tr>
<td><strong>REGISTRATION &amp; WORKSHOPS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESGE Postgraduate Course (€20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00 Registration opens</td>
<td>13:30-15:00 WORKSHOP 1</td>
<td>13:30 - 15:00 WORKSHOP 2</td>
<td>13:30 - 15:00 WORKSHOP 3</td>
<td>13:30 - 15:00 WORKSHOP 4</td>
</tr>
<tr>
<td>ENDOTRAINER</td>
<td>ADVANCED TECHNOLOGIES FOR IMPROVED GI DISEASE MANAGEMENT (BOSTON SCIENTIFIC)</td>
<td>ENDOSCOPY TODAY AND TOMORROW (OLYMPUS)</td>
<td>PATIENT SAFETY</td>
<td></td>
</tr>
<tr>
<td>1x BRONCHO</td>
<td>1x ERCP NO X-RAY</td>
<td>1x OGD</td>
<td>1x COLON</td>
<td></td>
</tr>
<tr>
<td>1x COLON</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COFFEE BREAK</strong></td>
<td>15:00 - 15:30</td>
<td>15:00 - 15:30</td>
<td>15:00 - 15:30</td>
<td>15:00 - 15:30</td>
</tr>
<tr>
<td><strong>REGISTRATION &amp; WORKSHOPS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESGE Postgraduate Course (€20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00 WORKSHOP 5</td>
<td>15:30-17:00 WORKSHOP 6</td>
<td>15:30-17:00 WORKSHOP 7</td>
<td>15:30-17:00 WORKSHOP 8</td>
<td></td>
</tr>
<tr>
<td>ENDOTRAINER</td>
<td>ADVANCED SYSTEMS FOR ENDOSCOPY AND ERCP (COOK)</td>
<td>HYGIENE AND INFECTION CONTROL “SURGERY”</td>
<td>FAST-TRACK COLONIC SURGERY</td>
<td></td>
</tr>
<tr>
<td>1x BRONCHO</td>
<td>1x ERCP NO X-RAY</td>
<td>1x OGD</td>
<td>1x COLON</td>
<td></td>
</tr>
<tr>
<td>1x COLON</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**19:30 – 21:00**

**ESGENA WELCOME PARTY & OPENING OF ESGENA CONFERENCE**

**ODD FELLOW PALÆET**

**ENTRANCE TO THE WORKSHOPS IS BY TICKET ONLY.**

To book your (free) ticket please go to the **Registration Desk outside the Lecture Halls.** Tickets will be issued on a first come basis.
SATURDAY, 15 OCTOBER 2005

WORKSHOP 1: DUMMY TRAINING

Time: 13:30 – 15:00
Room: Room 18
Language: English

Endotrainer: Dr. Martin Neumann
Co-ordinators: Christine Petersen (Amsterdam, The Netherlands) Eric Pflimlin (Basle, Switzerland)

INTENSIVE HANDS-ON-TRAINING ON THE FOLLOWING MODELS (PIG-DUMMIES):

Table 1
BRONCHOSCOPY
Dr. P. Chhajed (Basle, Switzerland)
Michael Ortmann (Basle, Switzerland)
Brigitte Koch (Basle, Switzerland)

Table 2
ERCP (NO X-RAY)
Prof. Andreas Püspök (Vienna, Austria)
Gerlinde Weilguny (Vienna, Austria)
Willi de Vriese (Brugge, Belgium)

Table 3
UPPER GI ENDOSCOPY
Chris Mulder (Amsterdam, The Netherlands)
Sylvia Lahey (Arnhem, The Netherlands)
Pilar Perez-Rojo (Pamplona, Spain)

Table 4
COLONOSCOPY
Dr. Bo Pilsgaard (Copenhagen, Denmark)
Mette Olesen (Copenhagen, Denmark)
Anita Jorgensen (Norway)
WORKSHOP 2: ADVANCED TECHNOLOGIES FOR IMPROVED GI DISEASE MANAGEMENT
(WORKSHOP OF BOSTON SCIENTIFIC)

Time: 13:30 – 15:00
Room: Room 19
Language: English

Chair: Michiel de Lange, Boston Scientific Europe
Dummy Training: Dr. M.J. Bruno (Amsterdam, The Netherlands)
Theo Ponchon (Amsterdam, The Netherlands)

Aim:
To show and discuss the new advances in endoscopy and the implications it has for the nurses.

WORKSHOP 3: “ENDOSCOPY TODAY AND TOMORROW“
(WORKSHOP OF OLYMPUS)

Time: 13:30 – 15:00
Room: Room 20
Language: English

Chair: Guido Merk, Olympus

Aim:
Validation and documentation in flexible endoscope reprocessing:
The participants shall understand and appreciate the Olympus activities on reprocessing validation and documentation under the aspect of quality assurance.

A view behind the scenes - product research and development of innovative Endo-Therapy devices:
The participant should understand and appreciate the Olympus research and development flow structure based on different examples of product development statuses. A possibility for hands-on with just launched up to early stage prototype devices will be given.
WORKSHOP 4: PATIENT SAFETY – HOW TO CREATE A "CULTURE OF SAFETY"?
(WORKSHOP OF THE DANISH ENDOSCOPY NURSES SOCIETY)

Time: 13:30 – 15:00
Room: Room 26+27
Language: Danish

Chair: Louise Steen (Nordby, Denmark)
       Brita Lindeberg (Frederiksberg, Denmark)
Speakers: Lena Plough (Esbjerg, Denmark)
          Ann-Sophie Nielsen (Glostrup, Denmark)

WORKSHOP 5: DUMMY TRAINING

Time: 15:30-17:00
Room: Room 18
Language: English

Endotrainer: Dr. Martin Neumann
Co-ordinators: Christine Petersen (Amsterdam, The Netherlands)
               Eric Pflimlin (Basle, Switzerland)

INTENSIVE HANDS-ON-TRAINING ON THE FOLLOWING MODELS (PIG-DUMMIES):

See WORKSHOP 1

WORKSHOP 6: ADVANCED SYSTEMS FOR ENDOSCOPY AND ERCP
(WORKSHOP OF COOK)

Time: 15:30 – 17:00
Room: Room 19
Language: English
**WORKSHOP 7: HYGIENE AND INFECTION CONTROL “SURGERY”**

**Time:** 15:30 – 18:00  
**Room:** Room 20  
**Language:** English  

**Chair:** Ulrike Beilenhoff (Ulm, Germany)  
Christiane Neumann (Birmingham, UK)  

**Aim:**  
To enable delegates to discuss their problems regarding Infection Control, Microbiological Surveillance, Outbreak Management, etc, in an informal setting.  
- Ask the question - we may have the answers.

**WORKSHOP 8: FAST-TRACK COLONIC SURGERY**  
(Workshop of the Danish Endoscopy Nurses Society)

**Time:** 15:30 – 17:00  
**Room:** Room 26+27  
**Language:** Danish  

**Chair:** Margit Rytkønen  
**Speaker:** Kirsten Rud (Birkerød, Denmark)  
Marianne Hallin (Hvidovre, Denmark)
## ESGENA SCIENTIFIC PROGRAMME

### SUNDAY & MONDAY

<table>
<thead>
<tr>
<th>SUNDAY 16 OCTOBER 05</th>
<th>MONDAY 17 OCTOBER 05</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A1 CONGRESS HALL</strong></td>
<td><strong>A2+A3 CONGRESS HALL</strong></td>
</tr>
<tr>
<td>LANGUAGE: English</td>
<td>LANGUAGE: English</td>
</tr>
<tr>
<td>8:30-10:00</td>
<td>8:30-10:00</td>
</tr>
<tr>
<td><strong>SESSION 1</strong></td>
<td><strong>SESSION 2</strong></td>
</tr>
<tr>
<td>THERAPEUTIC ENDOSCOPIC ULTRASONOGRAPHIE</td>
<td>EDUCATION &amp; SPECIALIST TRAINING</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td>COFFEE BREAK</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td>10:00 – 10:30</td>
</tr>
<tr>
<td>10:30-12:00</td>
<td>10:30-12:00</td>
</tr>
<tr>
<td><strong>SESSION 3</strong></td>
<td><strong>SESSION 4</strong></td>
</tr>
<tr>
<td>FREE PAPER SESSION</td>
<td>LIVER DISEASE</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>LUNCH &amp; POSTER SESSION</td>
<td>LUNCH &amp; POSTER SESSION</td>
</tr>
<tr>
<td>SOCIETY INFORMATION DESKS</td>
<td>SOCIETY INFORMATION DESKS</td>
</tr>
<tr>
<td>13:30-15:00</td>
<td>13:30-15:00</td>
</tr>
<tr>
<td><strong>SESSION 5</strong></td>
<td><strong>SESSION 6</strong></td>
</tr>
<tr>
<td>FREE PAPER SESSION</td>
<td>UPDATE ON COLORECTAL CANCER SCREENING</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>COFFEE BREAK</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>15:00 – 15:30</td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>15:30-17:00</td>
</tr>
<tr>
<td><strong>SESSION 7</strong></td>
<td><strong>SESSION 8</strong></td>
</tr>
<tr>
<td>HYGIENE &amp; INFECTION CONTROL</td>
<td>BRONCHOSCOPY</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>ROOM 19, 1ST FLOOR</td>
<td></td>
</tr>
<tr>
<td>17:15-18:15</td>
<td></td>
</tr>
<tr>
<td>ESGENA GENERAL ASSEMBLY (MEMBERS ONLY)</td>
<td></td>
</tr>
<tr>
<td>UEGW WELCOME RECEPTION</td>
<td></td>
</tr>
<tr>
<td>EAST HALL 19:30</td>
<td></td>
</tr>
</tbody>
</table>
SESSION 1: THERAPEUTIC ENDOSONOGRAPHY
08:30-10:00 A1 Congress Hall
Language: English

Chair: Sylvia Lahey (The Netherlands)
Mette Oelsen (Copenhagen, Denmark)

08:30-08:40 WELCOME
Christiane Neumann (Birmingham, UK)

08:40-09:10 EUS CONTROLLED PUNCTURES
Annette Fritscher-Ravens (London, UK)

09:10-09:40 EUS CONTROLLED PAIN THERAPY
Andreas Püspök (Vienna, Austria)

09:40-10:00 EUS CONTROLLED PANCREATIC PSEUDOCYST DRAINAGE
Rainer Schöffl (Linz, Austria)

SESSION 2: EDUCATION AND SPECIALIST TRAINING
08:30-10:00 A2+A3 Congress Hall
Language: English

Chair: Pilar Perez-Rojo (Pamplona, Spain)
Brita Lindeberg (Frederiksberg, Denmark)

08:30-08:40 WELCOME
Pilar Perez-Rojo (Pamplona, Spain)

08:40-09:10 EDUCATIONAL PATHWAYS IN GASTROINTESTINAL NURSING
Christine Norton (London, UK)

09:10-09:35 EDUCATION OF ENDOSCOPY NURSES – A SURVEY UPDATE IN EUROPEAN COUNTRIES
Ulrike Beilenhoff (Ulm, Germany)

09:35-10:00 SCORE CARDS FOR ENDOSCOPY DUMMY WORKSHOPS
Martin Neumann (Erlangen, Germany)
Michael Ortmann (Basle, Switzerland)
SUNDAY, 16 OCTOBER 2005

SESSION 3: FREE PAPER SESSION (SERVICE DEVELOPMENT)
10:30-12:00  A1 Congress Hall
Language: English

Chair: Di Campbell (Torbay, UK)
Brita Lindeberg (Frederiksberg, Denmark)

10:30-10:45  NUTRITION NURSE LED GASTRO-JEJUNOSTOMY FEEDING SERVICE
Angela Abdoolla (Cardiff, UK)

10:45-11:00  QUALITY – IMPROVEMENT MODEL INCREASES CORPORATION BETWEEN HOME CARE – AND HOSPITAL NURSES REGARDING PATIENTS AT NUTRITIONAL RISK
M. Holst, I. Andersen, H. H. Rasmussen (Aalborg, Denmark)

11:00-11:15  ENDOSCOPY UNIT DESIGN: AN ESSENTIAL KEYSTONE TO PROVIDING AN EFFICIENT CARING SERVICE
Libby Thomson, Roger Leicester (London, UK)

11:15-11:30  OUR EXPERIENCE TO IMPROVE THE ENDOSCOPY SERVICE
Jayne Tillett, Judith Wilson, Barney Hawthorne, Joy Whitlock, Einir Holland, Jenny Lau-Braddick, Maureen Melling (Cardiff, UK)

11:30-11:45  IS THERE A NEED FOR NURSE ENDOCOPISTS IN THE IRISH HEALTH SERVICE?: A STUDY ON THE EVALUATION OF NURSE PROVIDED ENDOCOPY
Donna Roche (Cork, Ireland)

11:45-12:00  TRAINING TO PERFORM FLEXIBLE SIGMOIDOSCOPY: A PERSONAL EXPERIENCE FROM THE NETHERLANDS
Janette Gaarenstroom (Utrecht, The Netherlands)

SESSION 4: HEPATOLOGY
10:30-12:00  A2+A3 Congress Hall
Language: English

Chair: Helene Desirat (France)
Lotte Julin Hansen (Sundby, Denmark)

10:30-11:00  RADIO FREQUENCE THERMO APPLICATION (RFTA)
Prof. Heim (Basle, Switzerland)

11:00-11:30  GENETIC TESTS IN GE
Deidre Kelly (Birmingham, UK)

11:30-12:00  TRANSJUGULAR LIVERBIOPTSY
Simon Olliff (Birmingham, UK)
SESSION 5: FREE PAPER SESSION (CLINICAL)
13:30-15:00
A1 Congress Hall
Language: English

Chair: Dianelle Duforest-Rey (France)
Anna-Gitte Jensen (Ringsted, Denmark)

13:30-13:45 A COURSE OF INSTRUCTION FOR WOMEN WITH IRRITABLE BOWEL SYNDROME
Mariette Bengtsson, Kerstin Ulander, Elisabet Bergh Börgdal, Ann-Christine Christensson, Bodil Ohlsson (Malmoe + Lund, Sweden)

13:45-14:00 PATIENT SATISFACTION SURVEY CONCERNING THE EDUCATION AT THE „IBD-PATIENT SCHOOL“
Dorrit Jakobsen, Bodil Meyer (Aarhus, Denmark)

14:00-14:15 GROUP BASED INTERVENTION IN IBD-PATIENTS – EFFECT ON QUALITY OF LIFE ASSESSMENT?
Lena Oxelmark, Anne Magnusson, Robert Lofberg, Pernilla Hillerås (Stockholm, Sweden)

14:15-14:30 WIRELESS CAPSULE ENTEROSCOPY: BOWEL PREPARATION IS FEASIBLE AND NECESSARY
Heidi Storm, Hanne Scherfig, Lotte Dinesen, Flemming Møesgaard, Vibeke Wewer, Mette S. Kjær, Pia Munkholm, Sven Adamsen (Copenhagen, Denmark)

14:30-14:45 IMPROVING THE CARE OF PATIENTS WITH ALCOHOL RELATED HEALTH PROBLEMS
Gwenda Veenboer, Chantal Bakhuysen (Amsterdam, The Netherlands)

14:45-15:00 WHY DO CIRRHOTIC PATIENTS FALL? DESCRIPTION AND ANALYSIS OF FALLS IN A HOSPITALIZATION UNIT
López Eva, García Raquel, Hernández Josefina, Sanz Miquèl (Barcelona, Spain)

SESSION 6: UPDATE ON COLORECTAL CANCER SCREENING
13:30-15:00
A2+A3 Congress Hall
Language: English

Chair: Gerlinde Weilguny (Vienna, Austria)
Margit Rytkönen (Frederiksværk, Denmark)

13:30-14:00 CANCER SCREENING - UPDATE OF EUROPEAN SITUATION
Jean-Francois Rey (St. Laurent du Var, France)

14:00-14:30 EVALUATION OF THE NATIONAL SCREENING PROGRAMME IN GERMANY
Bernd Bokemeyer (Minden, Germany)

14:30-15:00 PUBLIC AWARENESS CAMPAIGNS DONE BY NURSES
Di Campbell (Torbay, UK)
SESSION 7: HYGIENE AND INFECTION CONTROL
15:30-17:00  A1 Congress Hall
Language: English
Chair: Stanka Popovic (Ljubljana, Slovenia)
Louise Steen (Nordby, Denmark)

15:30-16:00  NEW ESGE-ESGENA GUIDELINES ON MICROBIOLOGICAL SURVEILLANCE
Ulrike Beilenhoff (Ulm, Germany)

16:00-16:30  OUTBREAK MANAGEMENT - HOW TO REASSURE THE PUBLIC
Thierry Ponchon (Lyon, France)

16:30-17:00  HEALTH PROBLEMS WITH DISINFECTANTS – ARE THE ALTERNATIVES A SAFER SOLUTION?
Christiane Neumann (Birmingham, UK)

SESSION 8: BRONCHOSCOPY
15:30-17:00  A2+A3 Congress Hall
Language: English
Chair: Michael Ortmann (Switzerland)
Anni Stevnsborg (Denmark)

15:30-16:00  EVALUATION OF BRONCHOSCOPY STANDARDS
Janet van Zwam (Nijmegen, The Netherlands)

16:00-16:30  TRANSBRONCHIAL NEEDLE ASPIRATION
Frank Hermens (Nijmegen, The Netherlands)

16:30-17:00  EBUS
Prashant Chhajed (Basle, Switzerland)
MONDAY, 17 OCTOBER 2005

SESSION 9:  PLENARY SESSION – NEW TECHNIQUES & DEVELOPMENTS IN ENDOSCOPY
8:30-10:30  Room M1 in Hall C
Language:  English

Chair:  Christiane Neumann (Birmingham, UK)
        Ulrike Beilenhoff (Ulm, Germany)

08:30-09:30  PRESENTATION FROM THE INDUSTRY
08:40-08:50  BOSTON SCIENTIFIC
           New Stents in the G. I. Tract - Montse Agusti
08:50-09:00  COOK
           Advanced systems for ERCP and Endoscopy - Ed Brennan
09:00-09:10  FUJINON
           New processor generation for video-endoscopes - Peter Jurkowski
09:10-09:20  OLYMPUS
           EXERA II - New Endoscopy System - Dr. Mesecke von Rheinbaben
09:20-09:30  PENTAX
           “Take care of your endoscope” - Anne Bunk
09:30-09:50  NEW TECHNIQUES OF THE DETECTION OF EARLY LESIONS
           Ralf Kiesslich (Mainz, Germany)
09:50-10:10  DOUBLE BALLOON ENDOSCOPY
           Chris Mulder (Amsterdam, The Netherlands)
10:10-10:20  BEST FREE PAPER AND BEST POSTER AWARD
           Christiane Neumann, President, ESGENA
           Brita Lindeberg (Denmark)
10:20-10:25  CLOSE OF MEETING
           Christiane Neumann, President, ESGENA
10:25-10:30  INVITATION TO THE NEXT ESGENA CONFERENCE, OCTOBER 2006 IN BERLIN
           Ulrike Beilenhoff, President, DEGEA
MONDAY, 17 OCTOBER 2005

NOVEL TREATMENTS OF GORD: AN EVIDENCE BASED APPROACH
(Core programme)
11:00-12:30 A1 Congress Hall
Language: English

Chair: Jan Tack (Leuven, Belgium)
       Peter Funch-Jensen (Denmark)

STRETTA
Jan Tack (Leuven, Belgium)

ENTERYX
Horst Neuhaus (Duesseldorf, Germany)

GATEKEEPER
Paul Fockens (Amsterdam, The Netherlands)

LAPAROSCOPIC ANTI-REFLUX SURGERY
Marco Catarci (Rome, Italy)
CONGRESS VENUE

The 13th United European Gastroenterology Week will be held at the Copenhagen Congress Center – Bella Center. The Congress Center is ideally located only 5 minutes from Copenhagen Airport, Kastrup and only 10 - 15 minutes from the centre of Town. Copenhagen Congress Center is the biggest congress centre in Scandinavia with perfect facilities for international congress activities, including very modern and flexible congress halls and meeting rooms and a very large and comfortable exhibition area centrally located in between the congress halls. Catering facilities are excellent with a number of good restaurants available. The centre has one of the most advanced IT-systems installed. Transport connections to Copenhagen and Malmoe City and as well to Copenhagen Airport are excellent with the local Metro station located only 50 meters from the entrance and with several bus lines available.

BC Bella Center
Copenhagen Congress Center
Center Boulevard
DK-2300 Copenhagen S
Denmark

Tel.: +45 325 28 811
Fax: +45 325 29 636
E-mail: bc@bellacenter.dk
Website: www.bellacenter.dk

HOW TO REACH THE COPENHAGEN CONGRESS CENTER - Bella Center

On registration, all participants will receive a passport valid for all public transport in Copenhagen and suburbs. The Bella Center can be reached in 5 - 10 minutes from the Airport and the centre of Copenhagen can be reached in 10 - 15 minutes by metro or taxi. The transport time to Malmoe City is about 20 - 30 minutes by car or train.
OVERALL PLAN:

INDEX:
(1) Auditorium 15
(2) Restaurant Bel Club
(3) Press Centre
(4) Coffee Break Stations
(5) Wireless LAN Area
(6) Cloakroom
(7) Speakers Centre
(8) ESGE Endoscopy Training
(9) ESGE Learning Area
INDEX:

(1) Cloakroom
(2) ESGE Endoscopy Training
(3) ESGE Reception
(4) ESGE Lecture Theatre
(5) ESGE Ultrasound Theatre
HALL C:

INDEX:
(1) Wireless LAN Area
(2) Coffee Break Stations
INDEX:

(1) Abstract Book Distribution
(2) Bag Distribution
(3) Restaurant Bel Club
(4) Bella Center Information
(5) Danske Bank
(6) Coffee Break Stations
(7) Stairs to Meeting Rooms on 1st floor
LIST OF THE MAIN MEETING ROOMS (IN ALPHABETICAL ORDER)

A1 Congress Hall
A2+A3 Congress Hall
Auditorium 10, 11, 12
Auditorium 15
Room M1 in Hall C
Room M2 in Hall C
Room M3 in Hall C
Room M4 in Hall C
Room M5 in Hall C
Lunch Sessions L1-L8

LOCATION DIRECTORY (IN ALPHABETICAL ORDER)

Cloakroom
Congress Bags Distribution
Congress Counter
UEGW Information Counter
Internet Facility
Poster Exhibition
Press Centre
Speakers Centre / Media Check

Hall B
Entrance Foyer
Entrance Foyer
Hall E
Hall C
Hall C
Focus Room at Entrance Foyer
Hall B
GENERAL INFORMATION

ABSTRACT BOOK
Participants receive their abstract book of the UEGW 2005 in exchange for the voucher which is included in the participants documents. The abstract booth is located next to the congress counter in the entrance hall of the Bella Center.

AIRPORT
Copenhagen Airport is located 8 km from the city. Buses, trains and taxis provide transport to the Copenhagen city centre. Taxis can be hired from outside all arrival areas. Fares include VAT and tips and can normally be paid by credit card. Train tickets are available from the ticket office above the railway station in Terminal 3.

BANK
An ATM / cash machine is located in the entrance foyer (west entrance) of the Bella Center.

BUSINESS CENTRE
A business centre with copy facilities is located in the entrance foyer (west entrance) of the Bella Center. They open on weekdays between 8:00 and 16:00.

CAR PARK
Parking space is available next to the Bella Center and participants arriving by car are advised to use these facilities. The parking space (P5) in front of the west entrance of the Bella Center is reserved for buses only. Parking fees are not included in the registration fee.

CLOAKROOM
A cloakroom can be used free of charge in Hall B from Saturday, 15 October through Wednesday, 19 October 2005. Participants can also store their luggage here.

CME CREDITS
The 13th United European Gastroenterology Week has been accredited by the European Accreditation Council for Continuing Medical Education in Brussels (EACCME), an institution of the UEMS. European physicians will be granted 6 credits per day by the EACCME for the attendance at the scientific sessions from Monday, 17 October to Wednesday, 19 October 2005.
In addition, participating in a post graduate course (PGC) will be granted credit points as follows:

- **Combined EAGE, EDS, ISDS, EAES PGC**: 9 credits
- **ESGE PGC**: 6 credits
- **EASL PGC**: 6 credits
- **ESPGHAN PGC**: 3 credits

Each physician should claim only those sessions for credit that he or she has actually attended in the educational activity.

In order to maintain CME accreditation we kindly ask the delegates to complete the form of attendance included in the congress bag and return it to the congress counter on the last day of their participation. The CME certificate of EACCME will be issued at the congress counter.

**COFFEE BREAKS**

Coffee, tea and water are served during the morning and afternoon coffee breaks from Monday, 17 October to Wednesday, 19 October 2005 free of charge to all participants wearing congress name badges. The coffee stations are located in Hall C and Hall E at the Bella Center. The coffee breaks for the ESGENA Conference are embedded in the programme on Saturday, 15 October and Sunday, 16 October 2005.

**CONGRESS BAGS**

Participants receive their congress bag in exchange for the voucher which is included in the participants documents. The booth is located next to the congress counter in the entrance hall of the Bella Center.

**CONGRESS COUNTER**

All personal congress documents will be available at the congress counter located in the main entrance hall (west entrance) of the Bella Center.

Opening hours:

- **Friday, 14 October 2005**: 14:00 - 18:00
- **Saturday, 15 October 2005**: 08:00 - 18:30
- **Sunday, 16 October 2005**: 08:00 - 21:00
- **Monday, 17 October 2005**: 07:30 - 18:00
- **Tuesday, 18 October 2005**: 08:00 - 18:00
- **Wednesday, 19 October 2005**: 08:00 - 16:00

During these opening hours the congress counter can be reached at:

- **Telephone**: +45 3262 2535
- **Fax**: +45 3262 2531
- **E-mail**: uegw2005@discongress.com
CONGRESS DOCUMENTATION
The company Marathon will produce a CD containing the best of UEGW and a CD including the poster presentations. Interested participants can purchase these CDs at the booth of Marathon.

CONGRESS INFORMATION SYSTEM
www.uegw-2005.dk
Participants can benefit from the web based UEGW Congress Information System CO CONGRESS ONLINE® on-site in the exhibition Hall C: They can set up and print out a personal congress programme schedule. The UEGW Congress Information System provides information on:

- Updated scientific programme
- Programme by day
- Programme by formats with accepted abstracts of chairpersons and speakers
- Programme search

CONGRESS NEWS
UEGW 2005 congress news will be distributed to all registered participants during the UEGW 2005 free of charge.

COMMITTEE AND BUSINESS MEETINGS
During the UEGW 2005 several committee and business meetings will take place at the Bella Center. The list of meetings is published in the chapter “Business Meetings” of the final programme. The staff at the information counter in hall E will be happy to help with requests for organising further meetings during UEGW 2005.

CURRENCY
The Danish Crown is the official currency in Denmark. Exchange of foreign currency is available at the Copenhagen Airport and at most hotels, banks and exchange offices throughout the city.

ELECTRICITY
Denmark uses a 220 volt 50Hz system. Sockets have the European standard and plugs are two-prong grounded.
EXHIBITION
The technical exhibition is located in Hall C and Hall E of the Bella Center. Information on particular exhibitors and exhibition floor plans are included in the exhibition guide brochure.

Opening hours:
- Monday, 17 October 10:00 - 18:00
- Tuesday, 18 October 10:00 - 18:00
- Wednesday, 19 October 10:00 - 16:00

FIRST AID
First aid can be provided through the Bella Center Information located in the entrance foyer of the Bella Center or any staff member.

INFORMATION
An information counter is located in Hall E of the Bella Center. Staff members will be happy to help with any queries.

INSURANCE
When registering for UEGW 2005 participants agree that neither the Organising Committee nor the Congress Secretariat assumes any liability whatsoever. Participants are strongly recommended to make their own arrangements for health and travel insurance before they depart from their country. The organisers will not be responsible for a loss or damage of personal belongings.

INTERNET
As a courtesy to all participants several internet terminals are available at the exhibition booth of Novartis located in Hall C of the Bella Center. The internet lounge is accessible according to the opening hours of the exhibition.

LANGUAGE
The official congress language of the UEGW 2005 is English. Simultaneous interpretation is not provided.

LOST AND FOUND
A lost and found service is available at the Bella Center Information in the entrance foyer of the Bella Center.
LUNCHES

Lunches are served for registered delegates wearing a congress name badge from 12:30 until 14:00 from Monday, 17 October through Wednesday, 19 October 2005 in the Hall C of the Bella Center.

MOBILE PHONES

Participants are kindly requested to keep their mobile phones in the off position while attending the scientific sessions in the meeting rooms.

NAME BADGES

Participants are requested to wear their name badge at all times during the congress. Only delegates who are wearing their name badge will be admitted to the congress venue.

The colours of the name badges have the following significance:

- Dark Blue: Delegates, fellows in training
- Light Blue: ESGENA participants
- Green: Accompanying persons
- Red: Faculty
- Orange: Press
- Yellow: Exhibitors
- Purple: Congress staff
- Grey: Postgraduate Courses
- White: Guests

POSTER PRESENTATION

The poster exhibition is located in Hall C of the Bella Center from Monday, 17 October to Wednesday, 19 October 2005. The posters will change daily and access is possible according to the opening hours of the technical exhibition.

The authors of the posters are asked to hang their poster on the particular congress day between 8:00 and 9:00 and to remove the poster between 17:00 and 18:00 on the day of presentation. Posters that have not been removed by 18:00 will be discarded.

PRESS

The press centre is set up in the Focus room next to the congress counter in the entrance foyer of the Bella Center. It is open from Saturday, 15 October through Wednesday, 19 October 2005. Press conferences are organised during the UEGW 2005. The personnel of the press centre which is managed by the press agency Geelmuyden.Kiese is pleased to provide more detailed information.

PROGRAMME CHANGES

The organisers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances.
PUBLIC TRANSPORTATION

All registered UEGW delegates, fellows in training, accompanying persons as well as ESGENA Conference delegates will receive a Travel Pass together with the personal congress documents. The public transportation ticket is valid from Saturday, 15 October until Wednesday, 19 October 2005 on all buses, trains, metro and harbour boat transportation in Copenhagen. The Travel Pass covers the whole Greater Copenhagen Area and allows to visit museums and attractions in within this area.

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>On-site registration</strong></td>
<td></td>
</tr>
<tr>
<td>Delegate</td>
<td>800</td>
</tr>
<tr>
<td>Fellow in training*</td>
<td>250</td>
</tr>
<tr>
<td>Accompanying person</td>
<td>125</td>
</tr>
<tr>
<td>Lunch session</td>
<td>50</td>
</tr>
<tr>
<td>ESGENA Conference</td>
<td>250</td>
</tr>
<tr>
<td>Combined postgraduate course</td>
<td>220</td>
</tr>
<tr>
<td>ESGE postgraduate course</td>
<td>220</td>
</tr>
<tr>
<td>EASL postgraduate course</td>
<td>110</td>
</tr>
<tr>
<td>ESPGHAN postgraduate course</td>
<td>50</td>
</tr>
</tbody>
</table>

*The applicant must be under 35 years of age. A personal letter signed by the head of the relevant university or institutional department including an official stamp must be presented.

The registration fee includes the following:

- Admission to all scientific sessions and UEGW Opening Plenary Session
- Admission to all UEGW satellite symposia
- Admission to all UEGW breakfast meetings
- Admission to the ESGE Learning Area
- Admission to the technical exhibition
- Opening Ceremony and Welcome Reception on Sunday, 16 October 2005
- Travel Pass (plastic card to be signed) valid from Saturday, 15 October until Wednesday, 19 October 2005
- Congress bag with congress material
- Coffee breaks and lunches from Monday, 17 October through Wednesday, 19 October 2005
Accompanying persons

- Admission to the UEGW Opening Plenary Session
- Admission to the technical exhibition
- Opening Ceremony and Welcome Reception on Sunday, 16 October 2005
- Travel Pass (plastic card to be signed) valid from Saturday, 15 October until Wednesday, 19 October 2005
- Coffee breaks and lunches from Monday, 17 October through Wednesday, 19 October 2005
- Copenhagen sightseeing tour

ESGENA conference

- Admission to all ESGENA scientific sessions
- Admission to the ESGENA Welcome Reception on Saturday, 15 October 2005
- Admission to the UEGW Opening Plenary Session
- Admission to all UEGW satellite symposia
- Admission to all UEGW breakfast meetings
- Admission to the ESGE Learning Area
- Admission to the UEGW technical exhibition
- Travel Pass (plastic card to be signed) valid from Saturday, 15 October until Wednesday, 19 October 2005
- Congress bag with complete ESGENA conference material
- Coffee breaks and lunches from Saturday, 15 October through Monday, 17 October 2005

Postgraduate courses

- Admission to the particular postgraduate course
- Coffee breaks and lunch as per the course programme

RESTAURANTS

Beverages and snacks can be purchased at several self service restaurants of the Bella Center.

SMOKING POLICY

For the comfort and health of all participants, smoking is not permitted at the Bella Center.

SPEAKERS CENTRE / MEDIA CHECK

The speakers centre / media check is located in Hall B of the Bella Center. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their presentation but at latest 3 hours prior to the presentation. The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook.

In the speakers centre there are several PC working stations where speakers can also work on their PC charts in a quiet area. Technical staff will be glad to assist.
Opening hours:

- **Friday, 14 October 2005**
  16:00 - 20:00
- **Saturday, 15 October 2005**
  08:00 - 18:00
- **Sunday, 16 October 2005**
  08:00 - 18:00
- **Monday, 17 October 2005**
  07:00 - 18:00
- **Tuesday, 18 October 2005**
  07:00 - 18:00
- **Wednesday, 19 October 2005**
  07:00 - 17:00

**STAFF**

Members of the congress staff who can be recognised by their purple name badge can be contacted any time in case of questions.

**SUPPORTING PROGRAMME**

Detailed information is provided on information boards at the congress counter in the entrance foyer of the Bella Center.

**TAXIS**

Taxis are available upon demand in front of the west entrance of the Bella Center. Participants can also call taxis at the Bella Center Information in the entrance foyer.

**WEATHER**

Weather in Copenhagen can be rainy and windy with temperature between 10 to 18°C in October. Therefore, it is recommended to bring a light overcoat and an umbrella.

**COPENHAGEN METRO MAP**
SOCIAL PROGRAMME/
SUPPORTING PROGRAMME

OPENING CEREMONY AND WELCOME RECEPTION

Date: Sunday, 16 October 2005
Time: 19:30 – 22:30
Place: Bella Center, East Hall (Hall H)

The Opening Ceremony will be held in the East Hall, next to the east entrance of the Bella Center. The 13th United European Gastroenterology Week will be opened by:

- **Jørgen Rask-Madsen** Chairman of the Local Organizing Committee
- **Juan-R. Malagelada** Secretary General of the UEGF
- **Alberto Montori** President of the UEGF Foundation
- **Stefan Lindgren** Member of the Local Organizing Committee and Former Chairman of the Swedish Society of Gastroenterology

The Opening Ceremony will include a homage to Hans Christian Andersen, the great author of many world famous fairy tales. Hans Christian Andersen’s 200th birthday has been celebrated throughout the year and the famous violinist, Professor Kim Sjøgren, and his beautiful Mermaid String Orchestra will follow the great European travels made by the poet in the first part of the 19th century. The admired actor Asger Reher will accompany the travels by reading small parts of the poets travel journal and will recite one of the fairy tales.

Following the Opening Ceremony, all delegates and accompanying persons are invited to join the Welcome Reception. Food and beverages as well as entertainment will be provided. The Welcome Reception in the East Hall will offer the opportunity to meet with colleagues from all over the world in a casual atmosphere.
CONCERT

Date: Monday, 17 October 2005
Time: 20:00
Place: Holmens Kirke, Church of the Navy in Copenhagen

On Monday evening, October 17 at 20:00, a classical concert is arranged in the marvellous *Church of the Navy in Copenhagen Holmens Kirke*, which is an architectural masterpiece built in 1619. The evenings programme will include some of the most beautiful orchestral works of Mozart and Haydn performed by musicians from the highly estimated orchestra, Collegium Musicum, conducted by the internationally famous Musical Director of the Royal Opera House in Copenhagen, Michael Schønwandt. The church will be open already from 19:00.

Admission
EUR 30. Tickets can be purchased at the Congress Counter.

Address
Holmens Kanal, 1060 København K
The location is opposite to the Danish Government Palace, Christianborg Castle in 5 minutes walking distance from the metro station at Kongens Nytorv.

TOURS

Detailed information on the offered tours during the UEGW 2005 is displayed on the information boards at the congress counter in the main entrance foyer (west entrance) of the Bella Center.
ACKNOWLEDGEMENTS

The UEGF Council and the Local Organizing Committee express their thanks to the following companies for their support to the 13th UEGW

ALTANA Pharma
AstraZeneca
JANSSEN-CILAG
NOVARTIS
OLYMPUS
Schering-Plough
Solvay Pharmaceuticals

CONGRESS WEBSITE

www.uegw-2005.dk